arsenic has been researched along with Leukemia, Promyelocytic, Acute in 911 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 57 (6.26) | 18.2507 |
| 2000's | 394 (43.25) | 29.6817 |
| 2010's | 394 (43.25) | 24.3611 |
| 2020's | 66 (7.24) | 2.80 |
| Authors | Studies |
|---|---|
| Costa, LJ; Dhir, A; Jamy, OH; Xavier, AC | 1 |
| Alex, AA; Balasubramanian, P; Balasundaram, N; Chendamarai, E; David, S; Ganesan, S; Janet, NB; Korula, A; Krishna, S; Kulkarni, U; Kumar, SP; Mathews, V; Palani, HK; Radhakrishnan, NR; Venkatraman, A; Yasar, M | 1 |
| Allen, S; Budman, D; Calabro, A; Devoe, C; Dhingra, R; Ghiuzeli, CM; Saunders, J; Stýblo, M | 1 |
| Ammatuna, E; Diepstra, A; Hazenberg, CLE; Huls, GA; Santing, M | 1 |
| Huang, J; Tang, Z; Wang, L | 1 |
| Saitoh, Y; Serizawa, S; Shinohara, M; Shiraiwa, R; Yago, K | 1 |
| Hayakawa, A; Horibe, K; Iijima-Yamashita, Y; Kato, M; Kiyotani, C; Matsumoto, K; Osumi, T; Shioda, Y; Terashima, K; Tomizawa, D; Yamada, Y | 1 |
| Jin, J; Naranmandura, H; Wang, HF; Wang, QQ; Zhao, JZ; Zhu, HH | 1 |
| Manley, PW | 1 |
| Chen, H; Gao, Y; Huang, X; Li, Y; Xu, H; Yu, J; Yuan, H; Zhang, X | 1 |
| Chen, YQ; Huang, DP; Huang, LB; Li, Y; Liang, C; Liao, LH; Luo, JS; Luo, XQ; Mai, HR; Tang, YL; Wang, LN; Yang, LH; Ye, ZL; Zhang, XL | 1 |
| Yanada, M | 1 |
| Cheng, K; Guo, X; Li, B; Luo, R; Ma, D; Xu, W; Yun, K; Zhuo, S | 1 |
| Chen, K; Chen, W; Clode, P; Guagliardo, P; Huang, S; Jiang, H; Leung, JK; Song, W; Xu, J; Young, SG | 1 |
| Bunce, CM; Drayson, MT; Khanim, FL | 1 |
| Chen, SN; Huang, J; Jin, J; Li, L; Li, ZY; Lou, LJ; Lou, YJ; Lu, Y; Ma, YF; Mao, LP; Meng, HT; Qian, JJ; Sun, CH; Wang, HY; Wei, JY; Wu, Q; Xu, GX; Xu, JY; Yan, XY; Yang, M; Yu, WJ; Zhu, HH; Zhu, XL | 1 |
| Chen, X; Jia, Y; Liu, Y; Zhang, M | 1 |
| Wiernik, PH | 1 |
| Chen, LM; Gong, S; He, PC; Li, GH; Liu, HB; Liu, L; Lu, XH; Qin, WW; Wald, DN; Wang, HY; Wang, MC; Wei, SH; Xi, JY; Yao, YZ; Zhang, CS; Zhang, HY; Zhang, M; Zhang, XX; Zheng, YS; Zhu, HH | 1 |
| Das, C; Das, R; Jain, A; Jandial, A; Jindal, N; Karunakaran, P; Khadwal, A; Kumar, SR; Lad, D; Malhotra, P; Naseem, S; Prakash, G; Saini, N; Singh, C; Varma, N; Varma, S; Yanamandra, U | 1 |
| Cabrera, HB; Galvis, CC; Regino, CA; Sanz, MÁ; Torres, JD | 1 |
| He, J; Li, W; Lu, D; Lu, P; Shi, Y; Su, Y; Wu, S; Yang, J; Zhang, G; Zhang, M; Zhang, X | 1 |
| Duan, X; Liu, B; Yang, M | 1 |
| Dai, B; Gao, W; Hu, J; Li, J; Li, K; Li, Y; Wang, F; Wang, L; Wang, Y; Zhang, T; Zhao, L; Zhu, H; Zhu, J | 1 |
| Balajthy, Z; Botó, P; Czimmerer, Z; Fésüs, L; Jambrovics, K; Kolostyák, Z; Pap, A; Sarang, Z; Szatmari, I; Uray, IP | 1 |
| Gao, C; Hai, X; Li, J; Lin, L; Lv, J; Tian, S; Wu, M | 1 |
| Chen, C; Hu, J; Liu, YM; Wang, J | 1 |
| Hai, X; Hostetter, TH; Lu, S; Pang, C; Wu, M | 1 |
| Duan, R; Hai, X; Lv, J; Pang, C; Tian, S; Wu, M; Yang, H; Zhang, H | 1 |
| Bajel, A; Blombery, PA; Chan, KL; Dun, K; Nedumannil, R; Ng Liet Hing, M; Nguyen, T; Ninkovic, S; Ryland, GL; Tiong, IS; Westerman, DA | 1 |
| Abraham, A; Balasubramanian, P; Fouzia, NA; George, B; Kulkarni, UP; Lionel, S; Mani, T; Mathews, V; Nair, SC; Selvarajan, S | 1 |
| Balajthy, Z; Jambrovics, K; Póliska, S; Scholtz, B; Uray, IP | 1 |
| Gao, Y; Jiang, Z; Sun, Y; Tang, M; Tu, B; Wu, Z; Xu, H; Ye, A; Yi, J | 1 |
| Bachiashvili, K; Bathini, S; Bhatia, R; Choi, JK; Dunn-Valadez, S; Godby, K; Goyal, G; Jamy, O; Mehta, A; Mikhail, FM; Morlote, D; Oliver, JD; Purdy, KE; Rangaraju, S; Reddy, VB; Vachhani, P; Worth, S | 1 |
| Chen, B; Chen, LX; Dong, HB; He, J; Jiang, RR; Liu, JW; Ou-Yang, J; Yuan, CY; Zeng, H; Zhang, Q; Zhang, QG; Zhou, M | 1 |
| Fan, S; Fu, Y; Guo, D; Hou, J; Lei, R; Li, H; Liu, J; Tang, L; Wu, Y; Zhao, Y | 1 |
| Chen, GH; Chen, HQ; Chen, YQ; Fan, Z; Feng, XQ; Guo, BY; Huang, DP; Huang, LB; Lan, HK; Li, B; Li, WL; Li, Y; Liang, C; Liu, RY; Luo, JS; Luo, XQ; Mai, HR; Tang, YL; Wan, WQ; Wang, LN; Yang, LC; Yang, LH; Zhang, XL; Zhen, ZJ; Zhou, DH | 1 |
| Guan, X; Hu, X; Li, H; Sun, H; Toy, PH; Wang, H; Xu, X; Zhang, Y | 1 |
| Eskazan, AE; Yilmaz, U | 1 |
| Li, D; Que, Y; Sun, Y; Wang, L; Yang, X; Zhu, H | 1 |
| Guo, Z; Hu, Y; Jin, Z; Li, H; Ma, J; Mo, J; Wang, X; Wang, Z; Wei, W; Xu, Y; Zhang, J; Zhao, J | 1 |
| Gong, BF; Gong, XY; Li, Y; Lin, D; Liu, BC; Liu, KQ; Liu, YT; Mi, YC; Wang, JX; Wang, Y; Wei, H; Wei, SN; Zhang, GJ; Zhou, CL | 1 |
| Fan, XY; Hu, YJ; Jiang, FL; Liu, Y; Liu, YJ; Xia, YZ; Zhang, DD; Zhou, FL | 1 |
| Hirano, S | 1 |
| Fan, C; Jiang, H; Jin, J; Lou, Y; Lu, Y; Ma, Y; Wang, Y; Ye, X | 1 |
| Cangini, D; Cerchione, C; Ghelli Luserna Di Rorà, A; Giannini, MB; Gottardi, M; Martinelli, G; Padella, A; Simonetti, G; Sperotto, A | 1 |
| Ji, L; Jiang, Y | 1 |
| Baron, J; Freyer, CW; Luger, SM; Man, Y; Peterson, CE; Przespolewski, A | 1 |
| Yokoyama, Y | 1 |
| Breccia, M | 1 |
| Gang, EJ; Le, J; Li, SY; Liu, HC; Lu, Y; Pei, RZ; Qian, SY; Si, T; Tang, SH | 1 |
| Chen, H; Gao, C; Gao, Y; Guo, M; Guo, S; Hai, X; Lin, L; Wang, X; Wu, Z | 1 |
| Chen, Y; Huang, Q; Li, C; Liu, G; Liu, R; Liu, Y; Lu, C; Song, Y; Xiao, C; Yu, L; Yu, X; Zhu, D | 1 |
| Kumar, S; Tchounwou, PB | 1 |
| Baer, MR; DeZern, A; Duong, VH; Emadi, A; Gehrie, E; Ghiaur, G; Gojo, I; Hambley, B; Hickey, E; Kashanian, S; Levis, MJ; Li, A; Newman, MJ; Smith, BD; Varadhan, R; Zacholski, K | 1 |
| de Thé, H; Rérolle, D; Wu, HC | 1 |
| Kalalinia, F; Khaleghian, A; Mirjalili, S | 1 |
| Bernardi, M; Ferrara, F; Molica, M | 1 |
| Baer, MR; Benner, A; Burnett, AK; Ehninger, G; Elliott, MA; Estey, EH; Gonzales, P; Görner, M; Grimwade, D; Hills, RK; Ho, AD; Kayser, S; Krämer, A; Krzykalla, J; Levis, MJ; Mayer, J; Norsworthy, K; Novak, J; Platzbecker, U; Ráčil, Z; Röllig, C; Russell, NH; Schlenk, RF; Smith, BD; Szotkowski, T; Tallman, MS; Thiede, C; Walter, RB; Westermann, J; Žák, P | 1 |
| Chavda, SJ; Koh, M; Lindsay, S; Willis, F | 1 |
| Dunoyer-Geindre, S; Kruithof, EKO; Lecompte, T; Rivier-Cordey, AS; Tsopra, O | 1 |
| An, R; Fu, W; He, H; Hou, J | 1 |
| Angelini, DF; Battistini, L; Berardi, A; Castelli, G; Catalano, G; Cicconi, L; D'Angiò, A; Fioritoni, G; Graziani, G; Guerrera, G; Lo-Coco, F; Massai, L; Mastrangelo, D; Noguera, NI; Pasquini, L; Pelosi, E; Piras, E; Piredda, ML; Testa, U; Voso, MT | 1 |
| Guan, W; Jing, Y; Li, WJ; Yang, L; Yu, L | 1 |
| Chen, J; Dai, J; Guo, H; Liu, X; Yan, L; Yu, S; Zhang, W; Zhu, J | 1 |
| Feng, L; Li, B; Li, F; Liu, Y; Shi, Y; Wang, J; Yan, M | 1 |
| Chen, B; Fu, JY; Hou, JX; Wu, LY; Zhang, YM | 1 |
| Soloway, AH; Warner, VD | 1 |
| Guo, M; Hai, X; Wang, W; Zhou, J | 1 |
| Alonzo, TA; Feusner, JH; Fu, CH; Gamis, AS; Gerbing, RB; Gregory, JJ; Hirsch, BA; Kutny, MA; Meshinchi, S; Raimondi, SC; Wang, YC | 1 |
| Das, M | 1 |
| Cao, J; Chen, W; Liu, X; Niu, M; Qi, J; Sang, W; Shen, Y; Wu, Q; Xu, K; Yao, Y | 1 |
| Fan, D; Fu, J; Ge, F; Hou, J; Hou, W; Li, H; Li, X; Sun, J; Wang, P; Wang, S; Yang, K; Yang, Y; Zhang, Y; Zhao, H; Zhou, J | 1 |
| Federzoni, EA; Humbert, M; Tschan, MP | 1 |
| Coombs, CC; Mathews, SP | 1 |
| Brossart, P; Gembruch, U; Giovannini, G; Janzen, V; Mayer, K; Merz, WM; Nellessen, CM | 1 |
| Chen, S; Dai, H; Drexler, HG; Geffers, R; Kaufmann, M; Li, J; MacLeod, RAF; Meyer, C; Nagel, S; Pommerenke, C; Quentmeier, H; Schneider, B; Thress, KS | 1 |
| Chen, Z; de Thé, H; Pandolfi, PP | 1 |
| Ahmadian, S; Alimoghaddam, K; Alizadeh, S; Ghaffari, SH; Ghavamzadeh, A; Hassani, S; Khaleghian, A | 1 |
| Chen, C; Huang, JB; Liu, ZL; Wang, J; Xu, HG; Xue, HM; Zhang, BH | 1 |
| Chen, L; Chen, SJ; Chen, Z; Cui, W; Gao, MQ; Hu, J; Li, JM; Mi, JQ; Nie, RM; Shen, ZX; Wang, J; Wang, KK; Wang, ZY; Xi, XD; Zhao, LL; Zhu, HM | 1 |
| Asik, A; Balcı Okcanoglu, T; Biray Avci, C; Dogan Sigva, ZO; Gunduz, C; Kayabasi, C; Ozmen Yelken, B; Saydam, G; Yılmaz Susluer, S | 1 |
| Akasaka, T; Honjo, G; Minoda, S; Nakagawa, M; Ohno, H; Okanoue, Y | 1 |
| Fang, LW; Hu, NB; Li, B; Pan, LJ; Qin, TJ; Qu, SQ; Xiao, ZJ; Xu, ZF; Zhang, HL; Zhang, Y | 1 |
| Hofmann, WK; Lengfelder, E; Nolte, F | 2 |
| Balme, B; Carlioz, V; Collinge, E; Gerland, LM; Paubelle, E; Salles, G; Sujobert, P; Thomas, X; Tigaud, I | 1 |
| Bøe, SO; Eriksson, J; Lång, A; Lång, E; Rowe, AD; Øye, A | 1 |
| Cao, F; Chen, B; Le, XC; Lu, X; Shen, S; Zhou, J | 1 |
| Hou, J; Hou, W; Jin, B; Li, H; Wang, P; Yang, H; Zhang, Y; Zhao, H; Zhou, J | 1 |
| Balasubramanian, P; Goni, D; Malhotra, P; Nampoothiri, RV | 1 |
| Cai, Z; Fan, J; He, Q; Huang, W; Wang, Z | 1 |
| Chen, LM; Gong, S; Liu, X; Liu, Y; Wang, HY; Wang, MC; Xi, JY; Zhang, HY; Zhang, XX | 1 |
| Alfonso, V; Breccia, M; Cicconi, L; Diverio, D; Divona, M; Foa, R; Franceschini, L; Iaccarino, L; Latagliata, R; Lo-Coco, F; Molica, M; Ottone, T; Rizzo, M; Voso, MT | 1 |
| Chen, M; Gan, LG; Li, LW; Liu, BZ; Liu, L; Shan, ZL; Xiao, CL; Xu, T; Yao, SF; Zhao, Y; Zhong, L | 1 |
| Li, YM | 1 |
| Fan, S; Gao, C; Guo, M; Hai, X; Hu, S; Liu, S; Wang, B; Wang, W; Zhou, J | 1 |
| Hussain, L; Maimaitiyiming, Y; Naranmandura, H; Su, L; Wang, QQ | 1 |
| Atsuta, Y; Emi, N; Fujimaki, K; Fujisawa, S; Fujita, H; Kobayashi, Y; Maeda, A; Miyazaki, Y; Naoe, T; Ohtake, S; Ohwada, A; Sunami, K; Takeshita, A; Taniwaki, M; Tsuboi, K; Tsuzuki, M; Yanada, M | 1 |
| Hao, L; Wang, H; Wang, X; Xu, G; Zhao, J | 1 |
| del Rincon, SV; Diaz, Z; Garnier, N; Gupta, A; Kourelis, M; Kwan, S; Mann, KK; Miller, WH; Molina, MF; Petruccelli, LA; Schipper, HM | 1 |
| Abhilash, M; Abhilash, S; Manju, A; Mathews, VV; Nair, RH; Paul, MV | 1 |
| Bradley, TP; Budman, DR; Kritharis, A | 1 |
| Firkin, F; Iland, H | 1 |
| Aizawa, S; Hatta, Y; Horikoshi, A; Iriyama, N; Takeuchi, J; Toyoda, H; Yoshino, Y; Yuan, B | 2 |
| Liu, Z; Sun, G; Wang, F; Wang, H; Wang, Y; Xi, S; Xu, Y; Yang, Y; Zheng, Q; Zheng, Y | 1 |
| Cao, JJ; Chen, D; Chen, LG; Du, XH; Fan, Z; Li, SY; Lin, L; Liu, XH; Ma, JX; Pei, RZ; Sha, KY; Shi, XW; Tang, SH; Wu, JY; Ye, PP; Zhang, BB; Zhang, PS; Zhuang, XX | 1 |
| Belin, E; Chesnut, G; Taylor, S | 1 |
| Cavenee, WK; Cloughesy, TF; Iwanami, A; Mischel, PS | 1 |
| Dworzak, M; Lackner, H; Müller, E; Seidel, MG; Urban, C | 1 |
| Li, R; Rao, Y; Zhang, D | 1 |
| Alimoghaddam, K; Bashash, D; Ghaffari, SH; Ghavamzadeh, A; Hassani, S; Mardani, H; Mirzaee, R; Yousefi, M; Zaghal, A; Zaker, F; Zekri, A | 1 |
| Kiyoi, H; Naoe, T; Tomita, A | 1 |
| Fan, H; Li, S; Lin, J; Lu, X; Zhu, H | 1 |
| Nakamura, Y; Taguchi, A; Tanaka, M; Tanaka, Y; Tanizawa, Y; Yujiri, T | 1 |
| Arnold, LL; Cohen, SM; Dodmane, PR; Hoyt, R; Lele, SM; Maness-Harris, L; Muirhead, DE; Wedel, WR | 1 |
| Jia, XH; Liu, JQ; Wang, KK; Wang, P; Xi, WD; Yang, XW; Zhang, H | 1 |
| He, Y; Huang, S; Mao, C; Qin, X; Sun, X; Zhu, L | 1 |
| Chen, M; Liu, T; Niu, T; Wang, L; Xie, LP; Zeng, K; Zou, XL | 1 |
| Au, WY; Han, L; Ho, JC; Ip, MS; Kwong, YL | 1 |
| Asou, N; Fujita, H; Hyo, R; Inaguma, Y; Ishigatsubo, Y; Iwanaga, M; Izumi, T; Kiyoi, H; Matsuda, M; Miyawaki, S; Miyazaki, Y; Nakaseko, C; Naoe, T; Nomura, S; Ohnishi, K; Ohtake, S; Okada, M; Shinagawa, K; Takeshita, A; Yamauchi, T | 1 |
| Amadori, S; Avvisati, G; Brandts, CH; Breccia, M; Carella, AM; Cazzola, M; Cerqui, E; Cicconi, L; Ciceri, F; Di Bona, E; Divona, M; Döhner, H; Döhner, K; Ehninger, G; Fabbiano, F; Fazi, P; Ferrara, F; Fiedler, W; Finizio, O; Fioritoni, G; Ganser, A; Hänel, M; Hertenstein, B; Iacobelli, S; Kropp, MG; La Nasa, G; Levis, A; Link, H; Lo-Coco, F; Lübbert, M; Luppi, M; Mandelli, F; Melillo, L; Morra, E; Orlando, SM; Platzbecker, U; Rambaldi, A; Salih, HR; Sauer, M; Schlenk, RF; Schmitz, N; Sica, S; Specchia, G; Thiede, C; Venditti, A; Vignetti, M; von Lilienfeld-Toal, M; Wattad, M | 1 |
| Chen, SJ; Chen, Z | 2 |
| Cao, F; Li, Y; Liu, X; Shi, C; Wang, H; Yang, D; Ye, X; Zhao, H; Zhou, J | 1 |
| Chen, X; Shao, J; Yan, J | 1 |
| Kuo, TC; Tian, TF; Tseng, YJ | 1 |
| de Thé, H; Lallemand-Breitenbach, V | 1 |
| Fung, TK; So, CW | 1 |
| Chen, Z; Huang, J; Jin, J; Lou, Y; Mai, W; Meng, H; Qian, W; Suo, S; Tong, H; Tong, Y; Wang, Y; Ye, X | 1 |
| Huang, J; Jin, J; Lou, Y; Mai, W; Meng, H; Qian, W; Tong, H; Tong, Y | 2 |
| Au, WY; Fong, BM; Lang, BH; Mao, KJ; Tam, S | 1 |
| Iacoboni, G; Montesinos, P; Sanz, MA | 2 |
| Huang, XJ; Jiang, B; Lai, YY; Liu, YR; Qin, YZ; Shi, HX; Zhu, HH | 1 |
| Delaune, A; Dubus, I; Falluel-Morel, A; Goullé, JP; Petit, A; Vannier, JP; Vasse, M | 1 |
| Hoffman, E; Mielicki, WP | 1 |
| Cheng, Y; Liu, G; Lu, A; Wang, B; Wu, J; Zhang, L | 1 |
| Hofmann, WK; Lengfelder, E; Nowak, D | 2 |
| Mayor, S | 1 |
| Chen, L; Hu, X; Wang, J; Xu, X | 1 |
| Hasan, SK; Lo-Coco, F; Montesinos, P; Sanz, MA | 1 |
| Matsue, K; Nisihida, Y; Sugihara, H; Takeuchi, M; Tsuda, K; Ugai, T; Yamakura, M | 1 |
| Lo-Coco, F; Orlando, SM; Platzbecker, U | 1 |
| Miura, Y; Suyama, K; Takano, T | 1 |
| Chen, SJ; Huang, XJ; Jiang, H; Jin, J; Li, JY; Ma, J; Wang, JX; Wu, DP; Zhu, HH | 1 |
| Firkin, F | 2 |
| Chen, H; Hankins, PL; Miodragović, DU; O'Halloran, TV; Swindell, EP | 1 |
| Appelbaum, FR; Bloomfield, CD; Gallagher, RE; Gulati, K; Holowka, N; Koval, G; Larson, RA; Laumann, K; Moser, BK; Paietta, E; Poiré, X; Powell, BL; Sher, D; Stock, W; Tallman, MS; Willman, C | 1 |
| Dillon, R; Grimwade, D | 1 |
| Douer, D; Ganzel, C; Tallman, MS | 1 |
| Dos Santos, GA; Kats, L; Pandolfi, PP | 1 |
| Cui, H; Gu, Y; Guo, R; Hu, M; Li, T; Li, X; Liang, H; Liu, X; Lu, Y; Pan, Z; Shan, H; Wang, L; Xu, C; Xu, Z; Yang, B; Yu, S; Zhang, Y | 1 |
| Macheta, A; Podhorecka, M | 1 |
| Huang, J; Jin, J; Lou, Y; Mai, W; Meng, H; Qian, W; Suo, S; Tong, H; Tong, Y; Yu, W | 1 |
| Ablain, J; de Reynies, A; de Thé, H; Minucci, S; Rice, K; Soilihi, H | 1 |
| Cheng, X; He, P; Liu, F; Liu, Y; Shi, L; Wang, Y; Zhang, M; Zhao, J; Zhou, N; Zhu, H | 1 |
| Mische, SE; Seigneres, B; Zhu, G | 1 |
| Breccia, M; Cicconi, L; Lo-Coco, F | 2 |
| Cheng, X; He, P; Liu, F; Liu, Y; Shi, L; Tian, Y; Wang, Y; Zhang, M; Zhao, J; Zhou, N; Zhu, H | 1 |
| Ito, K; Nakahara, F; Weiss, CN | 1 |
| Ansari, M; Bourquin, JP; Gumy-Pause, F; Huezo-Diaz, P; Judas, C; Mattiello, V; Rock, N | 1 |
| Altman, JK; Appelbaum, FR; Attar, EC; Coutre, SE; Gore, SD; Kopecky, KJ; Larson, RA; Levitan, D; Maher, T; Othus, M; Paietta, E; Powell, B; Stock, W; Tallman, MS; Wetzler, M; Willman, CL | 1 |
| Chen, L; Gao, L; Hu, X; Lü, S; Song, X; Wang, J; Yang, J; Zhang, W | 1 |
| Montesinos, P; Sanz, MA | 1 |
| de Thé, H; Rice, KL | 1 |
| Altman, JK; Cull, EH | 1 |
| Cicconi, L; Lo-Coco, F | 4 |
| Bochtler, T; Egerer, G; Hohmann, N; Mikus, G; Siller, N | 1 |
| Guan, X; Li, C; Li, M; Shu, X; Sun, Y | 1 |
| Huang, XJ; Qin, YZ; Zhu, HH | 1 |
| Mousavizadeh, K; Noori, S; Pourfathollah, A; Safa, M; Zand, H | 1 |
| Ahmadian, S; Alimoghaddam, K; Ghaffari, SH; Ghavamzadeh, A; Khaleghian, A | 1 |
| Kumar, S; Tchounwou, PB; Yedjou, CG | 1 |
| Hasan, SK; Lo-Coco, F | 2 |
| Cull, EH; Kwaan, HC | 1 |
| Garnier, N; Miller, WH; Nichol, JN | 1 |
| Iland, HJ; Seymour, JF; Wei, A | 1 |
| Grimwade, D; Hills, RK; Jovanovic, JV | 1 |
| Douer, D; Ganzel, C | 1 |
| Feusner, JH; Gregory, J; Kutny, MA | 1 |
| Komatsu, N | 1 |
| Chen, S; Chen, Z; Hu, J; Li, J; Mi, J; Wang, Z; Zhu, H | 1 |
| Cheong, HJ; Jung, YS; Kim, KH; Kim, SJ; Lee, N; Park, HS; Won, JH | 1 |
| Breccia, M; Efficace, F; Foà, R; Latagliata, R; Lo Coco, F; Minotti, C; Molica, M | 1 |
| Cao, F; Lan, W; Li, D; Li, J; Li, L; Li, Y; Liu, X; Meng, R; Shi, C; Wang, H; Yang, B; Zhang, Y; Zhang, Z; Zhao, H; Zhou, J | 1 |
| Buc Calderon, P; Felipe, KB; Glorieux, C; Kviecinski, MR; Sandoval, JM; Sid, B; Stockis, J; Valenzuela, M; Verrax, J | 1 |
| Gill, H; Hai, JJ; Kumana, CR; Kwong, YL; Siu, CW; Tse, HF | 1 |
| Lei, H; Ma, CM; Song, LL; Tu, YY; Wang, WW; Wei, W; Wen, DH; Wu, YL; Xia, L; Xu, HZ | 1 |
| Cortes, J; Daver, N; Eghtedar, A; Ferrajoli, A; Garcia-Manero, G; Kadia, T; Kantarjian, H; O'Brien, S; Pierce, S; Ravandi, F; Rodriguez, I | 1 |
| Fang, ZG; He, Y; Hu, Y; Huang, RW; Li, XD; Lin, DJ; Liu, JJ; Liu, Q; Long, ZJ; Wang, DN; Xiao, RZ; Yan, JS | 1 |
| Chen, M; Fan, Y; Fang, K; Meng, J; Tu, Y; Wan, L; Yu, L; Zhu, W | 1 |
| Chen, RL; Huang, BT; Li, BS; Zeng, QC; Zhao, WH | 1 |
| He, Y; Hu, Y; Huang, R; Li, X; Wang, D; Wang, W; Xiao, R; Zhang, E | 1 |
| Bally, C; de Thé, H; Lehmann-Che, J | 1 |
| Ai, WZ; Andreadis, C; Caballero, L; Damon, LE; Emi, N; Gaensler, KM; Greene, CC; Gupta, NK; Hwang, J; Kaplan, LD; Leavitt, AD; Logan, AC; Mahindra, A; Mannis, GN; Martin, TG; Miyazaki, Y; Naoe, T; Ohtake, S; Olin, RL; Sayre, PH; Smith, CC; Venstrom, JM; Wolf, JL; Yanada, M | 1 |
| Amadori, S; Avvisati, G; Breccia, M; Cerqui, E; Cottone, F; Di Bona, E; Efficace, F; Ferrara, F; Finizio, O; Fioritoni, G; Kropp, MG; Levis, A; Lo-Coco, F; Mandelli, F; Platzbecker, U; Schlenk, RF; Sica, S; Specchia, G; Vignetti, M | 1 |
| Arteaga, MF; Fung, TK; Mikesch, JH; So, CW | 1 |
| Ablain, J; de Reynies, A; de Thé, H; Halftermeyer, J; Le Bras, M; Metzger, D; Peres, L; Vitaliano-Prunier, A | 1 |
| Sui, M; Zhang, Z; Zhou, J | 1 |
| Gore, SD; Zeidan, AM | 1 |
| Fujita, H | 1 |
| Anderlini, P; Borthakur, G; Brandt, M; Cortes, J; Daver, N; Dinardo, C; Ferrajoli, A; Garcia-Manero, G; Hosing, C; Kadia, T; Kantarjian, H; Marcucci, G; O'Brien, S; Pemmaraju, N; Pierce, S; Popat, U; Ravandi, F; Verstovsek, S | 1 |
| Nitto, T; Sawaki, K | 1 |
| Barakat, S; Couban, S; Lachaine, J; Mathurin, K | 1 |
| Arai, M; Hirano, T; Onda, K; Sakai, C; Sugiyama, K; Tanaka, S | 1 |
| Barakat, S; Lachaine, J; Mathurin, K; Schuh, AC | 1 |
| Hatakeyama, N; Hori, T; Igarashi, K; Inazawa, N; Noguchi, H; Sasaki, M; Somekawa, Y; Suzuki, N; Tsutsumi, H; Yamamoto, M | 1 |
| Bashey, A; Carraway, HE; Gore, SD; Holland, K; Leech, M; Morris, L; Pratz, K; Smith, BD; Solomon, S; Stewart, M; Zeidan, AM; Zhang, X | 1 |
| Firkin, F; Ho, WK; Roncolato, F | 1 |
| Ades, L; Breccia, M; Cassinat, B; Di Bona, E; Fenaux, P; González-Sanmiguel, JD; Görlich, D; Grimwade, D; Hofmann, WK; Huerta, AJ; Kishore, B; Lambert, JF; Lehmann, S; Lengfelder, E; Lo-Coco, F; Montesinos, P; Nloga, AM; Pagoni, M; Ramadan, SM; Sanz, M; Sauerland, MC; Schmidt, A | 1 |
| Fischer, T; Koehler, M | 1 |
| Cottone, F; Efficace, F; Lo-Coco, F | 1 |
| Dai, L; Li, P; Liu, Y; Song, T; Wang, L; Wang, Z; Zhang, H | 1 |
| Abraham, A; Aiyaz, M; Alex, AA; Balasubramanian, P; Chandy, M; Chendamarai, E; Chomienne, C; Ganesan, S; George, B; Janet, NB; Kamath, V; Lakshmi, KM; Mathews, V; Mugasimangalam, R; Mullapudi, N; Nair, SC; Nellickal, AJ; Padua, RA; Srivastava, A; Srivastava, V; Viswabandya, A | 1 |
| Coombs, CC; Tallman, MS; Tavakkoli, M | 1 |
| Ma, H; Yang, J | 1 |
| Bernardi, R; Coltella, N; Ponente, M; Ponzoni, M; Valsecchi, R | 1 |
| Eyler, R; Moeller, J; Patel, K; Perreault, S; Pham, T; Podoltsev, N; Russell, K | 1 |
| Jin, J; Li, F; Lu, Y; Mai, W; Meng, H; Mu, Q; Pei, R; Qian, W; Tong, H; Yu, M; Zhao, X | 1 |
| Chen, X; Guo, S; Qin, N; Zhang, X | 1 |
| Chen, SJ; Chen, Z; Mi, JQ; Yan, XJ; Zhou, GB | 1 |
| Geng, Z; Ouyang, J; Wang, S; Wang, Z; Zhou, M | 1 |
| Huang, J; Jin, J; Lou, Y; Ma, Y; Mai, W; Mao, L; Meng, H; Ni, W; Pan, H; Qian, W; Suo, S; Tong, H; Wang, Y; Wei, J; Yu, W | 1 |
| de Thé, H | 3 |
| Allen, SL; Altman, JK; Cortes, JE; Coutre, S; Di Bona, E; Kantarjian, H; Lo-Coco, F; Ravandi, F; Sanford, D; Sanz, MA; Wetzler, M | 1 |
| Bu, N; Cao, FL; Naranmandura, H; Wang, QQ; Zhang, YF; Zhou, J; Zhou, XY | 1 |
| Barnes, G; Kruse, M; Lo-Coco, F; Martin, M; Mueller, U; Pathak, A; Wildner, R | 1 |
| Chen, B; Chen, C; Chen, L; Chen, SJ; Chen, Z; Fu, YK; Gu, ZH; Hu, J; Jin, J; Li, JM; Lou, YJ; Mi, JQ; Shen, Y; Shen, ZX; Shi, JY; Wang, ZY; Zhao, WL; Zhu, HH; Zhu, HM; Zhu, YM | 1 |
| Clarke, KM; Mills, KI; Young, CS | 1 |
| He, J; Jin, J; Lou, Y; Ma, Y; Mai, W; Meng, H; Pan, H; Qian, W; Sun, J; Tong, H; Wang, Y; Ye, X | 1 |
| Aznab, M; Rezaei, M | 1 |
| Ravandi, F | 4 |
| Barnes, G; Kruse, M; Lo-Coco, F; Martin, M; Mueller, U; Tallman, M; Tang, B; Wildner, R | 1 |
| Bowen, D; Burnett, AK; Clark, RE; Friis, L; Grech, A; Grimwade, D; Hills, RK; Hunter, A; Jones, G; Kell, J; Khwaja, A; Knapper, S; Lok, J; McMullin, MF; Morgan, YG; Russell, NH | 1 |
| Kantarjian, H; Ravandi, F | 1 |
| Han, S; Huang, XJ; Jiang, H; Jiang, Q; Liang, GW; Shi, LW; Zhu, HH | 1 |
| Cottone, F; Efficace, F; Lo Coco, F; Mandelli, F; Platzbecker, U | 1 |
| Aviram, A; Klein, A; Muchtar, E; Oniashvili, N; Parnes, D; Raanani, P; Rabizadeh, E; Shepshelovich, D; Yeshaya, J | 1 |
| Cheng, X; He, P; Liu, Y; Qi, J; Wang, C; Wang, Y; Zhang, M; Zhao, J; Zhu, H | 1 |
| Cantú-Rodríguez, OG; Gómez-Almaguer, D; Gómez-De León, A; González-Leal, XJ; Gutiérrez-Aguirre, H; Jaime-Pérez, JC; Pinzón-Uresti, MA | 1 |
| Ren, YQ; Wang, LL | 1 |
| Matsushita, H | 1 |
| Huang, XJ; Jiang, H; Jiang, Q; Liu, J; Zhu, HH | 1 |
| Chen, Z; Hu, R; Li, W; Lu, H; Zhang, T | 1 |
| Ablain, J; de Thé, H; Esnault, C; Lehmann-Che, J; Poirot, B | 1 |
| Kolb, EA; Meshinchi, S | 1 |
| Adès, L; Alex, AA; Chomienne, C; Fenaux, P; Ganesan, S; Gorombei, P; Guerenne, L; Krief, P; Mathews, V; Omidvar, N; Padua, RA; Patel, S; Pla, M; Schlageter, MH; West, R | 1 |
| Černelč, P; Falnoga, I; Podgornik, H; Šlejkovec, Z | 1 |
| Bashford, J; Bradstock, K; Browett, P; Campbell, LJ; Catalano, A; Collins, M; Di Iulio, J; Filshie, R; Firkin, F; Grigg, A; Hertzberg, M; Hugman, A; Iland, HJ; Moore, J; Reynolds, J; Seldon, M; Seymour, JF; Supple, SG; Szer, J; Taper, J; Taylor, K; Tiley, C | 1 |
| Al Ustwani, O; Griffiths, EA; Torka, P; Wang, ES; Wetzler, M | 1 |
| Falchi, L; Kantarjian, HM; Ravandi-Kashani, F; Verstovsek, S | 1 |
| Cairoli, R; Cicconi, L; Divona, M; Iaccarino, L; Lo-Coco, F; Ottone, T; Voso, MT | 1 |
| Degos, L | 2 |
| Khadwal, A; Malhotra, P; Saikia, UN; Yanamandra, U | 1 |
| Adachi, K; Honma, Y; Kawakami, K; Miyake, T; Suzumiya, J; Takahashi, T | 1 |
| Gerber, JM; Grunwald, MR; Lipford, EH; McDonnell, MH; Smith, ET | 1 |
| Li, D; Luo, D; Wu, S; Zhang, Y; Zhou, J | 1 |
| Hu, L; Huang, L; Li, C; Meng, F; Tang, Y; Wan, K; Wang, Y; Xu, D; Zhou, J | 1 |
| Altman, JK; Norsworthy, KJ | 1 |
| Chi, X; Gao, J; Liu, H; Shan, H; Zhang, Z; Zhao, Z; Zhou, H; Zhu, X | 1 |
| Cao, F; Ge, F; Hou, J; Li, H; Li, J; Li, L; Li, X; Liu, S; Lv, C; Su, Y; Wang, P; Wang, S; Xu, M; Zhang, Y; Zhou, J | 1 |
| Lo-Coco, F; Testa, U | 1 |
| Hao, L; Lu-Qun, W; Ran, W; Xiang-Xin, L; Xiao-Ning, Y | 1 |
| Di Donato, L; Lo-Coco, F; Schlenk, RF | 1 |
| Li, L; Liu, Y; Pan, C; Wang, D; Zen, K; Zhang, CY; Zhu, D; Zhuo, J | 1 |
| Blondeau, S; Bouyer, S; Colin, O; Houeto, JL; Julian, A; Meurin, E; Neau, JP; Puyade, M | 1 |
| Chung, H; Jo, S; Kim, S; Lee, H; Lee, YL | 1 |
| Alimoghaddam, K; Devlin, S; Douer, D; Esteve, J; Ganzel, C; Ghavamzadeh, A; Kuk, D; Mathews, V; Mohty, M; Nagler, A; Polge, E; Rowe, JM; Tallman, MS; Wang, H; Weisdorf, D; Zhang, MJ | 1 |
| Albano, F; Alfonso, V; Amadori, S; Avvisati, G; Breccia, M; Cerqui, E; Ciardi, C; Cicconi, L; Di Bona, E; Divona, M; Ferrantini, A; Ferrara, F; Kropp, MG; Lavorgna, S; Levis, A; Lo-Coco, F; Mandelli, F; Ottone, T; Paoloni, F; Piciocchi, A; Santoro, A; Sborgia, M; Sica, S; Voso, MT | 1 |
| Afroze, D; Azad, NA; Aziz, SA; Baba, SM; Dar, FA; Jan, A; Pandith, AA; Shah, ZA | 1 |
| Koike, S; Nishimoto, S; Ogasawara, Y; Suzuki, T; Takagi, N; Yuan, B | 1 |
| Atashrazm, F; Dickinson, JL; Holloway, AF; Lowenthal, RM; Woods, GM | 1 |
| Jin, J; Liu, L; Lou, Y; Ma, Y | 1 |
| Albano, F; Amadori, S; Avvisati, G; Borlenghi, E; Brandts, CH; Breccia, M; Brossart, P; Cairoli, R; Cicconi, L; Cortelezzi, A; D'Arco, AM; Di Bona, E; Di Renzo, N; Divona, M; Döhner, H; Döhner, K; Efficace, F; Ehninger, G; Fabbiano, F; Fazi, P; Ferrara, F; Fiedler, W; Fozza, C; Frairia, C; Ganser, A; Hänel, M; Hertenstein, B; La Nasa, G; Link, H; Lo-Coco, F; Lübbert, M; Mandelli, F; Melillo, L; Paoloni, F; Platzbecker, U; Pogliani, EM; Rambaldi, A; Röllig, C; Salih, HR; Sborgia, M; Schlenk, RF; Schmitz, N; Thiede, C; Vignetti, M; Wattad, M | 1 |
| Chen, L; Chen, Q; Chen, S; Chen, Y; Chen, Z; Hu, J; Li, J; Li, X; Mi, J; Shen, Z; Sun, H; Wang, A; Wang, L; Wang, Z; Zhang, Y; Zhao, H; Zhao, W; Zhao, X; Zhou, W; Zhu, H | 1 |
| Chen, XY; Fan, XY; Jiang, FL; Liu, Y; Liu, YJ; Zhong, HM | 1 |
| Béné, MC; Bonnet, A; Chevallier, P; Garandeau, C; Garnier, A; Guillaume, T; Houreau-Langlard, D; Hourmant, M; Le Gouill, S; Moreau, P; Peterlin, P; Tissot, A; Vantyghem, S | 1 |
| Bonora, M; Gafà, R; Giorgi, C; Kroemer, G; Lanza, G; Magri, E; Missiroli, S; Pandolfi, PP; Patergnani, S; Perrone, M; Pinton, P; Poletti, F; Raimondi, A; Tacchetti, C | 1 |
| Abraham, A; Aiyaz, M; Alex, AA; Balasubramanian, P; Balasundaram, N; Chendamarai, E; Chomienne, C; David, S; Ganesan, S; George, B; Korula, A; Kulkarni, U; Mathews, V; Mugasimangalam, R; Padua, RA; Palani, HK; Srivastava, A | 1 |
| Atsuta, Y; Emi, N; Gotoh, M; Hashimoto, H; Henzan, H; Ichinohe, T; Kanamori, H; Kanda, Y; Kohno, A; Kurokawa, M; Mori, T; Murata, M; Nishikawa, A; Sawa, M; Takami, A; Tomita, N; Watakabe, K; Yanada, M; Yano, S | 1 |
| Cai, Y; Chen, W; Du, X; Huang, J; Lou, J; Sun, M; Wang, Z; Zhang, Q | 1 |
| Alimoghaddam, K; Alizadeh, N; Ghaffari, SH; Ghavamzadeh, A; Hosseini, E; Momeny, M; Rostami, S; Zaki Dizaji, M | 1 |
| Abedin, S; Altman, JK | 1 |
| Angelopoulou, MK; Asimakopoulos, JV; Kelepesis, G; Konstantopoulos, K; Koutsi, C; Meletis, J; Papageorgiou, L; Petevi, K; Plata, E; Tsaftaridis, P; Vassilakopoulos, TP | 1 |
| Cao, H; Li, C; Li, D; Li, J; Qi, Y; Sun, J; Tian, R; Yang, W | 1 |
| Jiang, YH; Khairul, I; Naranmandura, H; Wang, C; Wang, QQ | 1 |
| Bochennek, K; Creutzig, U; Dworzak, MN; Faber, J; Flotho, C; Graf, N; Kontny, U; Mueller, JE; Reinhardt, D; Rossig, C; Schmid, I; von Neuhoff, C; von Neuhoff, N; von Stackelberg, A | 1 |
| Gnadler, M; Hecht, A; Lengfelder, E; Mezger, J | 1 |
| Huang, F; Ling, X; Ren, G; Su, Y; Xie, P; Xu, L; Zeng, Z; Zhang, W; Zhang, XK; Zhou, H | 1 |
| Pan, J; Zhang, X | 1 |
| Gao, N; Li, XZ; Sun, JR; Wang, XX; Yu, WZ | 1 |
| Akiyama, H; Hiruma, K; Jinta, M; Ohashi, K; Okuyama, Y; Sakamaki, H; Ueki, T | 1 |
| Alimoghaddam, K; Ghaffari, SH; Ghavamzadeh, A; Jamialahmadi, AH; Shayan-Asl, N | 1 |
| Litzow, MR | 1 |
| Nelson, R; Self, WT; Talbot, S | 1 |
| Jin, H; Li, L; Shi, G; Tang, X; Wang, J; Ye, RD; Yi, J | 1 |
| Ammatuna, E; Lo-Coco, F; Montesinos, P; Sanz, MA | 1 |
| Au, WY; Fong, BM; Kwong, YL; Tam, S | 4 |
| Dohmen, RJ; Göttsche, K; Horst, C; Keusekotten, K; Krause, A; Praefcke, GJ; Springer, HM; Weisshaar, SR | 1 |
| Tallman, MS | 8 |
| Gou, BD; Wang, K; Wang, LW; Wang, N; Zhang, TL | 1 |
| Creus, A; Marcos, R; Soriano, C | 1 |
| Allen-Bard, S; Carlin, R; Christos, PJ; Curcio, T; Feldman, EJ; Mathew, S; Mazumdar, M; Provenzano, J; Ritchie, EK; Roboz, GJ; Samuel, M; Wittenberg, B | 1 |
| Carney, DA | 1 |
| Coe, E; Schimmer, AD | 1 |
| Dalley, CD; Ezaydi, Y; Goepel, JR; Kirkbride, P; Krishna, R; Smith, DJ; Snowden, JA; Sorour, Y | 1 |
| Horikoshi, A; Iriyama, N; Kaise, T; Miyashita, SI; Shikino, O; Toyoda, H; Yoshino, Y; Yuan, B | 1 |
| Abreu e Lima, RS; Falcão, RP; Freitas, RA; Garcia, AB; Gimenes Teixeira, HL; Jordão, AA; Lima, AS; Lucena-Araujo, AR; Rego, EM; Scheucher, PS; Silva dos Santos, GA; Vannucchi, H | 1 |
| Cheng, YF; Liu, CF; Liu, GL; Lu, AD; Wang, B; Zhang, LP | 1 |
| Arai, S; Hangaishi, A; Koike, Y; Kurokawa, M; Masamoto, Y; Nannya, Y; Yatomi, Y | 1 |
| Bobé, P; Chelbi-Alix, MK | 1 |
| Altman, JK; Tallman, MS | 2 |
| Blamble, D; Cortes, J; Estey, E; Estrov, Z; Faderl, S; Ferrajoli, A; Fiorentino, J; Garcia-Manero, G; Jones, D; Kantarjian, H; O'Brien, S; Pierce, S; Ravandi, F; Verstovsek, S; Wierda, W | 1 |
| Fang, H; Wang, K; Zhang, J | 1 |
| Bao, L; Huang, XJ; Jiang, B; Jiang, H; Jiang, Q; Lin, W; Liu, YR; Lu, J; Lu, XJ; Zhang, Y | 1 |
| Dou, AX; Jia, PM; Lou, YJ; Pan, XR; Tong, JH; Zhang, CL | 1 |
| Kogan, SC | 2 |
| Cherian, OL; Raghu, KG | 1 |
| Chen, B; Chen, QS; Chen, SJ; Chen, Z; Hu, J; Li, JM; Liu, YF; Shen, ZX; Sun, HP; Tang, W; Wang, ZY; Waxman, S; Wu, CF; Wu, W; Xu, F; Zelent, A; Zhao, WL; Zhou, GB; Zhu, YM | 1 |
| Cao, YX; Dai, CW; Li, RJ; Pei, MF; Peng, HL; Shen, JK; Xu, YX; Yang, JJ; Yi, Y; Zhang, GS; Zheng, WL; Zhong, HY | 1 |
| Antoine, F; Binet, F; Girard, D | 1 |
| Li, Y; Lu, XL; Wang, BX; Wang, L; Wang, PP | 1 |
| Aubry, M; Chelbi-Alix, MK; Dianoux, L; Estephan, P; Galisson, F; Germain-Desprez, D; Mascle, XH; Percherancier, Y | 1 |
| Tang, DZ; Tao, S; Zhou, K | 1 |
| Chen, X; Lopez-Berestein, G; Ozpolat, B; Vivas-Mejía, PE | 1 |
| Hou, K; Hu, X; Li, Y; Liu, J; Liu, Y; Qu, J; Qu, X; Teng, Y; Zhang, Y | 1 |
| Di, C; Gu, S; Tan, X; Wu, Q; Xian, L; Yang, L | 1 |
| Charoensuk, V; Gati, WP; Le, XC; Weinfeld, M | 1 |
| Ammatuna, E; Ardiri, D; Centonze, D; Divona, M; Lo-Coco, F; Montefusco, E; Pacilli, M | 1 |
| Angell, R; Aslett, H; Batson, E; Burnett, AK; Clark, RE; Diverio, D; Flora, R; Grimwade, D; Hills, RK; Jones, K; Jovanovic, JV; Lo-Coco, F; Nugent, EA; Patel, Y; Rennie, K; Solomon, E; Wheatley, K | 1 |
| Duggan, J; Siderov, J | 1 |
| Amadori, S; Ammatuna, E; Cavaliere, A; Divona, M; Lo-Coco, F; Scambia, G | 1 |
| Chen, Y; He, PC; Lu, R; Lü, XH; Ni, ZF; Wang, HY; Zhang, M | 1 |
| Dai, L; Liu, YH; Ruan, CG; Shen, WH; Wang, ZY; Zhang, W | 1 |
| Kurokawa, M; Nagai, S; Takahashi, T | 2 |
| Au, WY; Fong, BM; Hon, C; Kwong, YL; Lai, WW; Tam, S; Yau, K | 1 |
| Akahane, D; Gotoh, M; Kaise, T; Kiguchi, T; Kitahara, T; Ohyashiki, K; Toyoda, H; Yoshino, Y; Yoshizawa, S; Yuan, B | 1 |
| Chen, JP; Liu, JP; Xia, Y; Xu, SN | 2 |
| Hangaishi, A; Ichikawa, M; Kaise, T; Kumano, K; Kurokawa, M; Miyashita, SI; Nagai, S; Nannya, Y; Ueda, K | 1 |
| Bao, L; Guo, T; Hong, M; Hu, Y; Jiang, Q; Lu, XJ; Shen, GX; Song, SJ; Xia, LH; Yang, LH; Zhang, XH; Zhao, T; Zhu, HH | 1 |
| Bajorin, DF; Halabi, S; Small, E | 1 |
| Bornhäuser, M; Platzbecker, U; Röllig, C; Stölzel, F; Thiede, C; Wermke, M | 1 |
| Oshimi, K; Sasaki, M; Sugimoto, K; Yamamoto, Y | 1 |
| Balasubramanian, P; Chandy, M; Chendamarai, E; George, B; Lakshmi, KM; Mathews, V; Srivastava, A; Thirugnanam, R; Viswabandya, A | 1 |
| de Witte, TJ; Jansen, JH; Linssen, PC; Luesink, M; Muus, P; Pennings, JL; Pfundt, R; van der Reijden, BA; Wissink, WM | 1 |
| Feusner, J; Gregory, J | 1 |
| Leu, L; Mohassel, L | 1 |
| Bhadauria, S; Prathapan, A; Raghu, KG; Sharma, S; Singh, R; Yadav, GK | 1 |
| Li, L; Zhang, ZH; Zhao, WD | 1 |
| Duan, MH; Han, B; Jiao, L; Shen, T; Wang, SJ; Xu, Y; Zhang, W; Zhao, YQ; Zhou, DB; Zhu, TN; Zhuang, JL; Zou, N | 1 |
| Gou, BD; Shi, YL; Wang, K; Wang, LW; Wang, N; Zhang, TL | 1 |
| Chhabra, S; Kaufman, KR; Levitt, M; Sood, R | 1 |
| Chen, XJ; Chen, YM; Wang, JX; Wang, SC; Yang, WY; Zhang, L; Zhu, XF; Zou, Y | 1 |
| Fan, S; Han, X; Hou, J; Hu, L; Li, J; Li, L; Li, X; Liu, X; Lv, C; Wang, S; Zhang, Y; Zhao, Y; Zhou, J; Zhu, L | 1 |
| Hatta, Y; Hirabayashi, Y; Ishizuka, H; Kobayashi, Y; Takei, K; Takeuchi, J; Tanaka, T | 1 |
| Fukushima, N; Hisatomi, T; Ide, M; Itamura, H; Kimura, S; Sueoka, E; Tanaka, M; Tomimasu, R; Urata, C; Yokoo, M | 1 |
| Asghari, F; Mozdarani, H | 1 |
| Arceci, R; Dauses, T; Devetten, M; Gallagher, RE; Gojo, I; Gore, SD; Jamieson, K; Morris, L; Owoeye, I; Redner, RL; Schachter-Tokarz, E; Sekeres, MA | 1 |
| Cao, F; Gilbert, GE; Heegaard, CW; Hou, J; Rasmussen, JT; Shi, J; Zhang, Y; Zhou, J | 1 |
| Chai, L; Cheng, M; Ren, Y; Wang, S; Xie, Y | 1 |
| Chang, YF; Chou, DS; Fan, CY; Hsiao, G; Jayakumar, T; Lee, JJ; Lin, KH; Sheu, JR | 1 |
| Berthou, C; Charles, F; Eveillard, JR; Ianotto, JC; Tempescul, A | 1 |
| Ferrara, F | 1 |
| Alimoghaddam, K; Ghaffari, SH; Ghahremani, MH; Ghavamzadeh, A; Hosseini, R; Mandegary, A; Rostami, S | 1 |
| Brûlé, AO; Coser, PL; Coser, VM; Lafayette, TC; Pereira, WV | 1 |
| Kumagai, Y; Shinkai, Y; Sumi, D | 1 |
| Baek, JH; Cha, SJ; Kim, H; Min, YJ; Noh, EK; Park, JH; Park, MJ; Won, JH | 1 |
| Grimwade, D; Guidez, F; Mistry, AR; Solomon, E | 1 |
| Arora, N; Das, R; Malhotra, P; Nath, A; Patel, FD; Varma, N; Varma, S | 1 |
| Meng, WT; Yang, YM; Zhang, G; Zhou, J | 1 |
| Chen, SJ; Chen, Z; de Thé, H; Hu, HY; Huang, QH; Jeanne, M; Lallemand-Breitenbach, V; Liang, WX; Song, AX; Sun, HB; Tong, JH; Wu, JH; Wu, ZY; Yan, XJ; Yang, FF; Yang, HY; Zhang, QY; Zhang, XW; Zhang, Y; Zhou, GB; Zhou, ZR | 1 |
| Chen, W; He, P; Qi, J; Wang, H; Wang, X; Zhang, M | 1 |
| Chen, Y; Gao, J; Gu, L; Jia, C; Li, Q; Ma, Z; Wu, X; Zhou, C; Zhu, Y | 1 |
| Sekeres, MA | 3 |
| de Thé, H; Nasr, R | 1 |
| Bian, S; Hao, L; Li, J; Wang, H; Wang, X; Wu, Q | 1 |
| Liu, D | 1 |
| Blinder, R; Chang, P; Galinsky, I; Ho, VT; Housman, E; Kesari, S; Lane, SW; Mullally, A; Stone, RM | 1 |
| Bjørås, M; Bøe, SO; Isakson, P; Simonsen, A | 1 |
| Feng, G; Li, Z; Meng, R; Sui, M; Yang, B; Zhou, J | 1 |
| García Salido, A; Lassaletta Atienza, A; Madero López, L; Moreno Tejero, ML; Sevilla Navarro, J | 1 |
| Berthier, C; de Thé, H; Duffort, S; Ferhi, O; Jeanne, M; Koken, M; Lallemand-Breitenbach, V; Le Bras, M; Peres, L; Raught, B; Soilihi, H | 1 |
| Bloom, SE; Bunaciu, RP; Nayak, S; Shen, M; Varner, JD; Yen, A | 1 |
| Abraham, A; Balasubramanian, P; Chandy, M; Chendamarai, E; Desire, S; George, B; Lakshmi, KM; Mathews, V; Shaji, RV; Srivastava, A; Thirugnanam, R; Viswabandya, A | 1 |
| Appelbaum, FR; Couban, S; Coutre, S; Feusner, JH; Gallagher, RE; Gregory, J; Larson, RA; Moser, B; Powell, BL; Rowe, JM; Stock, W; Stone, RM; Tallman, MS; Willman, CL | 1 |
| Fry, RC; Jaspers, I; Kesic, M; Liu, Q; Pi, J; Smeester, L; Zhang, H; Zou, F | 1 |
| Ambaglio, I; Bernasconi, P; Castagnola, C; Corso, A; Lazzarino, M; Rossi, M; Zappasodi, P | 1 |
| Bøe, SO; Simonsen, A | 1 |
| Cortes, J; Dayyani, F; Faderl, S; Garcia-Manero, G; Jones, D; Kantarjian, H; O'Brien, S; Pierce, S; Ravandi, F | 1 |
| Baĭdil'dina, DD; Dubrovina, ME; Maschan, AA; Maschan, MA; Rumiantsev, AG; Rumiantseva, IuV; Samochatova, EV; Skorobogatova, EV | 1 |
| Chen, C; Gao, SM; Jiang, L; Tan, Y; Wu, J; Xing, CY; Ye, A; Yin, L; Yu, K | 1 |
| Fu, CC; Jin, ZM; Liang, JY; Liu, YJ; Ma, X; Qiu, HY; Tang, XW; Wu, DP | 1 |
| Douer, D; Gore, S; Powell, BL; Ranganathan, A; Ravandi, F; Rowe, J; Sanz, MA; Tallman, M | 1 |
| Dai, L; Jiang, M; Liu, Y; Ruan, C; Wang, Z; Wu, D; Zhang, W | 1 |
| Lo-Coco, F; Sanz, MA | 1 |
| Manji, GA; Tallman, MS | 1 |
| Gong, YP; Luo, S; Yang, L; Yang, YM | 1 |
| Chen, X; Chen, Y; Zhang, L; Zhu, X; Zou, Y | 1 |
| Chang, XH; Cheng, YB; Xiang, Y | 1 |
| Ebinger, M; Feuchtinger, T; Gessler, P; Handgretinger, R; Hildenbrand, S; Lang, P; Scheel-Walter, HG; Schwarze, CP | 1 |
| Rogers, JE; Yang, D | 1 |
| Gore, SD; Prebet, T | 1 |
| Chen, Z; Jin, J; Li, K; Mei, C; Tong, H; Wang, H | 1 |
| Anderson, LD; Collins, RH; Kirk, A; Levitt, D; Naina, HV; Scaglioni, PP; Vusirikala, M | 1 |
| He, PC; Qi, J; Zhang, M | 1 |
| Alimoghaddam, K; Ghaffari, H; Ghavamzadeh, A; Hosseini, R; Iravani, M; Jahani, M; Jalili, M; Mousavi, A; Rostami, S | 1 |
| Alimoghaddam, K; Ghaffari, SH; Ghavamzadeh, A; Hajhashemi, M; Mozdarani, H; Yaghmaie, M | 1 |
| Chen, XW; Xia, HL; Xia, RX | 1 |
| Atsumi, A; Goto, E; Hayakawa, F; Kiyoi, H; Naoe, T; Tomita, A | 1 |
| Estey, EH; Hutchinson, F | 1 |
| Alimoghaddam, K; Bahar, B; Ghaffari, SH; Ghavamzadeh, A; Iravani, M; Jahani, M; Jalili, M; Mousavi, SA; Rostami, S | 1 |
| Jeong, KH; Park, TS; Yoon, HS | 1 |
| Breccia, M; Cicconi, L; Giannì, L; Latagliata, R; Lo-Coco, F; Minotti, C | 1 |
| Ducas, J; Ducas, RA; Seftel, MD; Seifer, C | 1 |
| Chen, JP; Qin, DB; Wang, SQ | 1 |
| Chen, HZ; Chen, XY; Qi, H; Rong, ZX; Wang, BS; Wang, H | 1 |
| Akashi, K; Harada, M; Kamimura, T; Miyamoto, T | 1 |
| Shinagawa, K | 1 |
| Abreu e Lima, RS; Curti, C; de Thé, H; dos Santos, GA; Falcão, RP; Gimenes-Teixeira, HL; Lima, AS; Lucena-Araujo, AR; Nasr, R; Pandolfi, PP; Pestana, CR; Rego, EM; Rodrigues, FP; Santana-Lemos, BA; Scheucher, PS; Thomé, CH; Uyemura, SA | 1 |
| Park, JH; Tallman, MS | 1 |
| Sanz, MA | 2 |
| Au, WY; Chan, GC; Ha, SY; Kwong, YL; Lee, V; Li, CK; Yau, J; Yuen, HL | 1 |
| Powell, BL | 2 |
| Block, GJ; Chadwick, RW; Flemington, EK; Lasky, JA; Shan, B; Sides, MD | 1 |
| Au, WY; Kumana, CR; Kwong, YL; Lau, JS; Lee, HK; Lin, SY; Liu, H; Yeung, DY | 1 |
| Gurung, A; Huang, BT; Li, BS; Xiao, Z; Zeng, QC; Zhao, WH | 1 |
| Chen, Z; de Thé, H; Lallemand-Breitenbach, V; Zhu, J | 2 |
| Alimoghaddam, K; Bashash, D; Dizaji, MZ; Ghaffari, SH; Ghavamzadeh, A | 1 |
| Mahmoudi, N | 1 |
| Keyhani, M | 1 |
| Chen, S; Fang, Y; Li, X; Liu, S; Ma, L | 1 |
| Mi, J | 1 |
| Brenneman, MA; Chen, JD; Denissova, NG; Hakhverdyan, Z; Nasello, C; Yeung, PL | 1 |
| Hatta, Y; Hirabayashi, Y; Horikoshi, A; Iriyama, N; Takeuchi, J; Toyoda, H; Yoshino, Y; Yuan, B | 1 |
| Inoue, A; Kawakami, C; Takitani, K; Tamai, H | 1 |
| Kwong, YL | 1 |
| Abraham, A; Ahmed, R; Alex, AA; Balasubramanian, P; Chandy, M; Chendamarai, E; Ganesan, S; George, B; Janet, NB; Lakshmi, KM; Mathews, V; Nair, SC; Sitaram, U; Srivastava, A; Srivastava, VM; Viswabandya, A | 1 |
| Chen, Y; Li, Z; Lu, Q | 1 |
| Chen, P; Chen, YZ; Huang, HF; Lin, ZX; Lu, R; Wu, Y | 1 |
| Beauchamp, EM; Uren, A | 1 |
| Cao, Z; Li, Q; Ruan, M; Wang, J; Zhang, L; Zhu, X; Zou, Y | 1 |
| Chen, SJ; Chen, Z; Li, JM; Mi, JQ; Shen, ZX | 1 |
| Benoilid, A; Broly, F; Echaniz-Laguna, A; Fornecker, LM; Goullé, JP; Lannes, B; Mousson de Camaret, B; Vinzio, S | 1 |
| Bagel, B; Gujral, S; Gupta, S; Khattry, N; Menon, H; Nair, R; Subramanian, PG | 1 |
| Breccia, M; Lo-Coco, F | 1 |
| Stein, EM; Tallman, MS | 3 |
| Huang, H; Liu, H; Qin, Y; Teng, R; Xu, M; Xu, R; Yang, L; You, X | 1 |
| Choudhry, A; DeLoughery, TG | 1 |
| Angaran, P; Gula, LJ; Kathirgamanathan, K; Lazo-Langner, A | 1 |
| Arcese, W; Aversa, F; Bacigalupo, A; Breccia, M; Camboni, A; Cupelli, L; Di Veroli, A; Iori, AP; Lo-Coco, F; Papayannidis, C; Ramadan, SM | 1 |
| Bjerkvig, R; Bjørås, M; Bruserud, O; Bøe, SO; Grudic, A; Lång, E; Pankiv, S; Simonsen, A | 1 |
| Chen, Y; Cortes, J; Kantarjian, H; Ravandi, F; Wang, H | 1 |
| Chen, SJ; Zhou, GB | 1 |
| Bashford, J; Bradstock, K; Browett, P; Catalano, A; Collins, M; Di Iulio, J; Filshie, R; Firkin, F; Grigg, A; Hertzberg, M; Hugman, A; Iland, HJ; Moore, J; Reynolds, J; Seldon, M; Seymour, JF; Supple, SG; Szer, J; Taper, J; Taylor, K; Tiley, C | 1 |
| Andreeff, M; Cheng, X; Freireich, EJ; Gao, MZ; Golemovic, M; Kantarjian, HM; Quintás-Cardama, A; Verstovsek, S; Zingaro, R | 1 |
| Cao, FL; Gao, CY; Hou, JX; Li, JM; Li, JN; Liu, SC; Liu, Y; Ma, RS; Shi, JL; Tan, XY; Wang, J; Yang, X; Zhou, J | 1 |
| Chun, HJ; Chung, BH; Kim, JI; Kim, SJ; Min, WS; Moon, IS; Sun, IO; Yang, CW | 1 |
| Chang, MC; Chang, YF; Chen, CG; Chiang, YH; Hsieh, RK; Lim, KH; Lin, HC; Lin, J | 1 |
| Park, JH | 1 |
| Fan, S; Han, L; Han, X; Hu, L; Li, J; Li, L; Li, X; Li, Y; Lv, C; Su, Y; Wang, S; Zhang, X; Zhang, Y; Zhang, Z; Zhao, H; Zhao, Y; Zhou, J | 1 |
| Alimoghaddam, K; Bashash, D; Ghaffari, SH; Ghavamzadeh, A; Mirzaei, R; Momeny, M | 1 |
| Chen, YZ; Li, XF; Liao, XY; Wu, Y; Yang, JH | 1 |
| Zhou, J | 1 |
| Aul, C; Berdel, WE; Braess, J; Büchner, T; Erben, P; Haferlach, C; Haferlach, T; Hanfstein, B; Hehlmann, R; Heinecke, A; Hiddemann, W; Hofmann, WK; Horst, HA; Kreuzer, KA; Krug, U; Lengfelder, E; Müller-Tidow, C; Sauerland, C; Schneider, S; Schnittger, S; Schultheis, B; Serve, H; Spiekermann, K; Wörmann, B | 1 |
| Chen, P; Chen, YZ; Huang, HF; Lu, R; Wu, Y | 1 |
| Emi, N | 2 |
| Cao, J; Chen, D; Chen, L; Du, X; Fan, Z; Li, S; Lin, L; Liu, X; Ma, J; Pei, R; Sha, K; Tang, S; Wu, J; Ye, P; Zhang, B; Zhang, P | 1 |
| Shih, HM; Yang, WC | 1 |
| Chen, MH; Liu, M; Liu, TB; Xle, JM; Yang, AQ; Yang, P | 1 |
| Attarbaschi, A; Boztug, H; Chen, HY; Cooper, BW; Dworzak, MN; König, M; Strehl, S; Suzukawa, K; Zhang, SJ | 1 |
| Alimoghaddam, K; Bashash, D; Ghaffari, SH; Ghavamzadeh, A; Hassani, S; Hezave, K; Kazerani, M; Rostami, M; Zaker, F | 1 |
| Gagat, M; Grzanka, A; Grzanka, D; Izdebska, M | 1 |
| Cao, F; Chen, B; Le, XC; Lu, X; Shen, S; Yuan, C; Zhou, J | 1 |
| Iland, HJ; Seymour, JF | 1 |
| Chen, Y; Han, L; Meng, H; Shi, C; Sui, M; Wang, H; Zhang, Z; Zhou, J; Zhou, Q | 1 |
| Lee, JS; Miller, WH; Schipper, HM; Singer, J; Waxman, S | 1 |
| Jing, Y; Waxman, S; Xia, L | 1 |
| Cai, X; Chen, G; Huang, Y; Jia, P; Yu, Y | 1 |
| Lopez-Berestein, G; Ozpolat, B | 1 |
| Nabhan, C; Tallman, MS | 1 |
| Guo, P; Hu, Y; Qiao, Z; Shen, G; Song, S; Wang, J; Yang, L; Zhang, X; Zhou, H | 1 |
| Chim, CS; Kam, S; Kwong, YL; Lam, CC; Man, C; Wong, KF | 1 |
| Balasubramanian, P; Chandy, M; George, B; Mathews, V; Shaji, RV; Srivastava, A | 2 |
| Au, WY; Chim, CS; Kwong, YL; Pang, A; Wai Lie, AK | 1 |
| Barnes, J; Chen, P; Chrest, FJ; Gorospe, M; Li, J; Liu, Y; Sinogeeva, N; Wersto, RP | 1 |
| Bachleitner-Hofmann, T; Gisslinger, H; Kees, M | 1 |
| Lu, DP; Wang, Q | 1 |
| Daniel, MT; De Thé, H; Degos, L; Dombret, H; Gourmel, B; Guillemin, MC; Janin, A; Kogan, S; Lallemand-Breitenbach, V; Lanotte, M; Raffoux, E; Soilihi, H; Vitoux, D; Zhu, J | 1 |
| Chen, GQ; Chen, SJ; Chen, Z; Jia, PM; Tong, JH; Wang, ZY; Yu, Y; Zhu, Q | 1 |
| Au, WY; Chim, CS; Chung, LP; Kwong, YL; Ma, SK | 1 |
| Cairoli, R; Di Bona, E; Marenco, P; Montillo, M; Morra, E; Nosari, A; Tedeschi, A; Tresoldi, E | 1 |
| Li, J; Shen, T; Zhang, ZN; Zuo, L | 1 |
| Chen, SY; Li, XM; Liu, SX | 2 |
| Feng, CQ; Ma, WL; Zheng, WL | 1 |
| Horii, T; Kitamura, K; Maekawa, M; Matsui, H; Naito, K; Nakamura, S; Naoe, T; Ohnishi, K; Ohno, R; Shigeno, K; Shinjo, K; Takeshita, A | 1 |
| Chen, F; Han, J; Ouyang, R; Shao, N; Zhong, L | 1 |
| Hirayama, Y; Matsunaga, T; Niitsu, Y; Sagawa, T; Sakamaki, S; Takayanagi, N; Tsuji, Y | 1 |
| Cai, X; Chen, SJ; Chen, Z; Jia, PM; Tong, JH; Wang, ZY; Yu, Y; Zhu, Q | 1 |
| Cao, Q; Chen, SJ; Chen, X; Chen, Z; Liu, YF; Shen, ZX; Wang, AH; Wang, ZY; Zhu, YM | 1 |
| Li, DP; Li, HQ; Li, R; Qi, JY; Qian, LS; Wan, CC; Wang, ZQ; Zhao, YZ; Zhou, CL | 1 |
| Baccarani, M; Malagola, M; Martinelli, G; Piccaluga, PP; Rossi, M; Visani, G | 1 |
| DiPersio, J; Douer, D; Giralt, S; Hu, W; Lill, M | 1 |
| Au, WY; Chan, CH; Chan, JC; Chen, YT; Chim, CS; Kwong, YL; Liang, R; Lie, AK; Liu, SY; Ma, SK; Mak, YK; So, CC; Wong, LG; Yeung, YM; Yip, SF | 1 |
| Chen, GQ; Chen, Z; Jing, Y; Styblo, M; Walton, F; Waxman, S; Weinberg, R; Zhou, L | 1 |
| Cortes, J; Estey, E; Kantarjian, H; Lazo, G; O'Brien, S; Thomas, D | 1 |
| Côté, S; Davison, K; Mader, S; Miller, WH | 1 |
| Liu, SX; Wang, HY | 1 |
| Dang, H; He, Q; Hong, B; Liu, H; Lu, DP; Qiu, JY; Shi, HL; Shi, Y | 1 |
| Buzyn, A; Cassinat, B; Chomienne, C; Cimerman, P; Daniel, MT; de Thé, H; Degos, L; Delarue, R; Dombret, H; Fermand, JP; Hermine, O; Lebbé, G; Poupon, J; Raffoux, E; Réa, D; Rousselot, P; Taksin, AL; Tibi, A | 1 |
| Au, WY; Chan, GC; Kou, M; Kumana, CR; Kwong, YL; Lam, CW; Mak, R | 1 |
| Cai, X; Chen, GQ; Chen, Z; Dai, W; Huang, Y; Jia, PM; Tong, JH; Yu, Y; Zhang, L; Zhao, Q | 1 |
| Liu, SX; Wang, HY; Zhang, M | 1 |
| Chen, S; Li, X; Liu, S; Lu, X; Wang, H; Zhao, X | 1 |
| Han, ZC; Liu, P | 1 |
| Grigg, A; Kimber, R; Szer, J | 1 |
| Song, J; Zhang, DS | 1 |
| Barbey, JT; Pezzullo, JC; Soignet, SL | 1 |
| Beissert, T; Güller, S; Hoelzer, D; Li, JE; Ottmann, OG; Puccetti, E; Ruthardt, M | 1 |
| Bao, L; Jiang, H; Liu, YR; Lu, DP; Qin, YZ; Wang, FR; Wang, JZ | 1 |
| Udvardy, M | 1 |
| Aguilar, TM; Bahlis, NJ; Boise, LH; Krett, N; Lee, KP; McCafferty-Grad, J; Reis, I | 1 |
| Peng, L; Xu, X | 1 |
| Lü, CF; Meng, R; Wang, W; Yang, BF; Zhou, J | 1 |
| Huang, X | 1 |
| Bi, K; Guo, G; Jiang, F; Jiang, G; Liu, C; Liu, X; Peng, J; Ren, H; Ren, Q; Tang, T; Tian, Z; Zhang, Y; Zhen, G | 1 |
| Fan, S; Li, X; Lu, C; Meng, R; Yang, B; Zhou, J | 1 |
| Benoit, G; Bobé, P; Canova, A; Chelbi-alix, MK; Pine, R | 1 |
| Hayashi, H; Kamikawa, T; Katoh, H; Maekawa, M; Naito, K; Ohnishi, K; Ohno, R; Sahara, N; Shinjo, K; Takeshita, A; Uehara, A; Yamazaki, K | 1 |
| Davison, K; Mann, KK; Miller, WH; Waxman, S | 1 |
| Gong, Z; Le, XC; Lu, X; Wang, Z; Zhou, J | 1 |
| Li, BX; Liu, Y; Meng, R; Wang, W; Yang, BF; Zhou, J | 1 |
| Aisa, Y; Iguchi, T; Ikeda, Y; Miyamoto, K; Mori, T; Okamoto, S; Shimizu, T; Yokoyama, K | 1 |
| Liu, SX; Zhao, XA | 1 |
| Lanska, DJ | 1 |
| Chen, SJ; Chen, Y; Chen, Z; De Thé, H; Fang, J; Gu, BW; Li, JM; Liu, YF; Shen, Y; Shen, ZX; Shi, JY; Shi, ZZ; Tang, W; Wang, ZY; Waxman, S; Wu, W; Yan, H; Zheng, PZ; Zhu, YM | 1 |
| Meng, R; Wang, Y; Yang, BF; Zhou, J | 1 |
| Nand, S; Tanvetyanon, T | 1 |
| Bradley, D | 1 |
| Hong, WD; Li, J; Li, QH; Luo, SK; Peng, AH; Tan, EX; Tong, XZ; Zhang, GC; Zheng, D | 1 |
| Hara, S; Ishitsuka, K; Iwao, Y; Shirahashi, A; Shishime, M; Suzumiya, J; Takamatsu, Y; Takatsuka, Y; Tamura, K; Utsunomiya, A | 1 |
| Mann, KK; Miller, WH | 1 |
| Hayakawa, F; Privalsky, ML | 1 |
| Cannizzaro, L; Ding, W; Gallagher, RE; Guidez, F; Kim, SH; Paietta, E; Ramesh, KH; Sun, Y; Warrell, RP; Zelent, A; Zhou, DC | 1 |
| Avvisati, G; Breccia, M; Carmosino, I; Finolezzi, E; Latagliata, R; Lo Coco, F; Petti, MC | 1 |
| Jing, Y | 1 |
| Jiang, B; Li, GX; Lu, DP; Qin, XY | 2 |
| Dryden, MJ; Estey, E; Faderl, S; Garcia-Manero, G; Giles, F; Kantarjian, HM; Pierce, S; Ratnam, S; Tsimberidou, AM; Whitman, GJ | 1 |
| Khan, MA; Oubrahim, H; Stadtman, ER | 1 |
| Hayash, H; Horii, T; Kitamura, K; Kobayashi, M; Maekawa, M; Naito, K; Nakamura, S; Naoe, T; Ohnishi, K; Ohno, R; Sahara, N; Shigeno, K; Shinjo, K; Takeshita, A | 1 |
| Jiang, B; Liu, KY; Lu, DP; Lu, XJ; Shen, JC | 1 |
| Pan, B; Xu, L; Yang, X | 1 |
| Feusner, J; Gregory, J; Ravindranath, Y | 1 |
| Chandy, M; George, B; Mathews, V; Poonkuzhali, B; Shaji, RV; Srivastava, A | 1 |
| Meng, R; Yang, BF; Zhou, J | 2 |
| Cai, L; Cui, J; Gao, S; Jiang, Z; Li, W; Liu, Z; Song, Y; Wang, G; Yang, Y; Yao, C; Yuan, CJ | 1 |
| Balasubramanian, P; Chandy, M; George, B; Mathews, L; Shaji, RV; Srivastava, A | 1 |
| Li, J; Shen, T; Wang, X; Xu, CM; Yang, Y; Zhang, ZN; Zuo, L | 1 |
| Bonati, A; Lo-Coco, F; Lunghi, P; Pelicci, P; Pelicci, PG; Tabilio, A | 1 |
| Chandy, M; George, B; Poonkuzhali, B; Srivastava, A; Srivastava, VM | 1 |
| Chou, WC; Dang, CV | 1 |
| Körper, S; Rojewski, MT; Schrezenmeier, H | 1 |
| Chen, G; Chen, L; Chen, S; Fang, Z; Huang, Y; Li, X; Liu, H; Ni, J; Shen, Z; Wang, Z | 1 |
| Chen, G; Chen, L; Chen, S; Jia, P; Ni, J; Shen, Z; Shi, G; Shi, X; Tang, W; Wang, Z | 1 |
| Du, J; Liu, BR; Qian, XP; Wang, LF; Yin, HT; Zou, ZY | 1 |
| Lu, M; Meng, R; Sui, XH; Wang, DS; Yang, BF; Zhou, J | 1 |
| Benecke, A; Cayre, YE; Denis, FM; Di Gioia, Y; Lutz, PG; Touw, IP | 1 |
| Meng, R; Sui, XH; Yang, BF; Zhou, J | 1 |
| Daniel, PT; Dörken, B; Essmann, F; Scholz, C; Schulze-Osthoff, K; Stärck, L; Wieder, T | 1 |
| Jena, RK; Sahu, GR | 1 |
| Emi, N; Kajiguchi, T; Naoe, T; Sawa, M; Yamamoto, K | 1 |
| Fung, Y; Lin, B; Liu, D; Ma, X; Qin, J; Wang, W; Ye, N; Yu, L | 1 |
| Ikeda, T; Kimura, F; Kufe, D; Motoyoshi, K; Nakata, Y; Ogura, K; Sato, K; Sporn, M | 1 |
| Beal, N; Diehl, LF; Huff, CA; Jones, RJ; Matsui, W; Smith, BD; Vala, M | 1 |
| Chen, SJ; Zhao, WW | 1 |
| Au, WY; Cheung, GT; Kumana, CR; Kwong, YL; Yuen, TW | 1 |
| Auffray, C; Chen, SJ; Chen, YL; Chen, Z; Du, YZ; Eveno, E; Fan, HY; Huang, QH; Imbeaud, S; Jin, G; Shen, SH; Wang, KK; Waxman, S; Xiao, DK; Zhang, J; Zhang, QH; Zhang, QY; Zhao, CJ; Zheng, PZ | 1 |
| Horii, T; Maekawa, M; Matsui, H; Naito, K; Naoe, T; Ohnishi, K; Ohno, R; Sahara, N; Shigeno, K; Shinjo, K; Shirai, N; Takeshita, A | 1 |
| Arai, A; Kitano, A; Kurosu, T; Miki, T; Miura, O; Murakami, N; Yamamoto, K | 1 |
| Akay, C; Gazitt, Y | 1 |
| Cui, JW; Gao, SJ; Jiang, ZY; Li, W; Liu, ZL; Song, YQ; Wang, GJ; Yang, Y; Yao, C; Yuan, CJ | 1 |
| Bai, SZ; Chen, GQ; Fu, GH; Guo, ZW; Liu, XB; Wang, Y; Xi, YH; Yang, BF | 1 |
| Tajima, M | 1 |
| Hao, LC; Wang, H; Zhang, LZ | 1 |
| Aradi, J; Dudognon, C; Hillion, J; Lanotte, M; Pendino, F; Ségal-Bendirdjian, E; Tarkanyi, I | 1 |
| Baccarani, M; Billi, AM; Bortul, R; Evangelisti, C; Grafone, T; Martelli, AM; Martinelli, G; Tabellini, G; Tazzari, PL | 1 |
| Fenaux, P; Lo Coco, F; Sanz, MA | 1 |
| Jia, J; Meng, L; Meng, R; Sui, X; Yang, B; Zhou, J | 1 |
| Asou, N | 1 |
| Kobayashi, M; Maekawa, M; Naito, K; Nakamura, S; Ohnishi, K; Ohno, R; Sahara, N; Shigeno, K; Shinjo, K; Takeshita, A | 1 |
| Estey, E; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Kantarjian, H; Patel, SP; Verstovek, S | 1 |
| Colosimo, AL; Guo, Q; Kurie, JM; Lee, HY; Mann, KK; Miller, WH; Padovani, AM | 1 |
| Chen, SJ; Chen, Z; Zhou, GB | 1 |
| Hu, Y; Qiao, Z; Song, S; Yang, L; Zhang, X; Zhou, H | 1 |
| Fujisawa, S; Kobayashi, M; Naito, K; Nakamura, S; Ohnishi, K; Ohno, R; Sahara, N; Shigeno, K; Shinjo, K; Takeshita, A | 1 |
| Aghdami, N; Alimoghaddam, K; Bahar, B; Baybordi, E; Ghaffari, SH; Ghavamzadeh, A; Hosseini, R; Iravani, M; Jahani, M; Khodabadeh, A; Mortazavi, Y; Mossavi, A; Rostami, S; Totonchi, M | 1 |
| Büchner, T; Hehlmann, R; Lengfelder, E; Saussele, S; Weisser, A | 1 |
| Lou, YQ; Lu, DP; Wang, FR | 1 |
| Alimoghaddam, K; Ghavamzadeh, A; Jahani, M; Rostami, S; Sanaat, Z; Shariftabrizi, A; Tavangar, M; Tavangar, SM | 1 |
| Tamm, I | 1 |
| Chen, GQ; Huang, Y; Jiang, Y; Peng, ZG; Wu, YL; Yan, H; Yu, Y; Zhao, Q; Zhu, YS | 1 |
| Au, WY; Chan, CH; Chim, CS; Fung, AT; Kwong, YL; Liang, RH; Ma, ES; Wong, KF | 1 |
| Bajel, A; Balasubramanian, P; Chandy, M; George, B; Lakshmi, KM; Mathews, V; Shaji, RV; Srivastava, A; Srivastava, VM; Viswabandya, A | 1 |
| Estey, E; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Jones, D; Kantarjian, H; Verstovsek, S | 1 |
| Frankfurt, O; Tallman, MS | 1 |
| Fukuda, M | 1 |
| Akioka, T; Hanafusa, T; Hara, S; Oka, T; Tsuji, M; Yamano, T; Yokote, T | 1 |
| Chen, GQ; Huang, Y; Jiang, Y; Liu, W; Peng, ZG; Song, LP; Zhao, Q | 1 |
| Au, WY; Kumana, CR; Kwong, YL; Lau, CP; Siu, CW; Tse, HF; Yung, C | 1 |
| Bajel, A; Chandy, M; Desire, S; George, B; Lakshmi, KM; Mathews, V; Rao, JG; Srivastava, A; Srivastava, VM; Viswabandya, A | 1 |
| Ades, L; Bordessoule, D; Castaigne, S; Chevret, S; de Botton, S; Degos, L; Dombret, H; Fegueux, N; Fenaux, P; Guerci, A; Kelaidi, C; Link, H; Meyer-Monard, S; Raffoux, E; Rayon, C; Rigal-Huguet, F; Sanz, M; Stoppa, A; Thomas, X; Vekhoff, A | 1 |
| Ammatuna, E; Lo Coco, F; Noguera, N | 1 |
| Gou, BD; Huang, J; Luo, LY; Wang, K; Zhang, TL | 1 |
| Fukai, Y; Hirata, M; Ichikawa, N; Kaise, T; Kinoshita, K; Kobayashi, H; Ohta, S; Saitoh, H; Sakurai, T; Ueno, M | 1 |
| Au, WY; Chan, EY; Cheng, VC; Kumana, CR; Kwong, YL; Lam, CW; Liu, R; Shek, TW | 1 |
| Bellincampi, L; Bernardini, S; Bonati, A; Federici, G; Lo Coco, F; Lunghi, P; Mann, K; Miller, WH; Noguera, NI; Nuccetelli, M | 1 |
| Caillot, D; Fenaux, P; Huguet, F; Pigneux, A; Raffoux, E; Thomas, X | 1 |
| Kobayashi, M; Naito, K; Nakamura, S; Ohnishi, K; Ohno, R; Sahara, N; Shigeno, K; Shinjo, K; Takeshita, A; Tobita, T | 1 |
| Kai, T; Kimura, H; Maruyama, Y; Ogawa, K; Sato, H; Shiga, Y | 1 |
| Hao, HY; Hao, L; Lu, DP; Qin, XY; Teng, ZP; Xu, H; Zhang, P; Zhu, HH | 1 |
| Fan, SJ; Han, XY; Hu, LH; Wang, Y; Wu, N; Zhou, J | 1 |
| Beran, M; Freireich, E; Giles, F; Kantarjian, H; Perez, N; Quintás-Cardama, A; Ravandi-Kashani, F; Verstovsek, S | 1 |
| Deng, SH; Han, MZ; Li, QC; Li, X; Li, Y; Li, YT; Li, ZJ; Qiu, LG; Wan, CC; Yang, RC; Zhao, YZ | 1 |
| Alimoghaddam, K; Ghavamzadeh, A; Jahani, M | 1 |
| Davis, RJ; Giafis, N; Higgins, LS; Katsoulidis, E; Nebreda, AR; Platanias, LC; Sassano, A; Tallman, MS | 1 |
| Alimoghaddam, K; Bashash, D; Ghaffari, SH; Ghavamzadeh, A; Rostami, S | 1 |
| Meng, L; Meng, R; Sui, XH; Yang, BF; Zhou, J | 1 |
| Ehninger, G; Helwig, A; Illmer, T; Klemm, M; Röllig, C; Schüttig, R; Wassilew, N | 1 |
| Duan, LN; Guo, ZK; Ji, SQ; Wang, HX | 1 |
| Fujisawa, S; Hashimoto, H; Kaise, T; Kinoshita, K; Kobayashi, M; Naito, K; Nakamura, S; Ohnishi, K; Ohno, R; Sahara, N; Shigeno, K; Shimoya, M; Shinjo, K; Suzuki, Y; Takeshita, A | 1 |
| Kwong, YL; Leung, J; Pang, A; Tse, EW; Yuen, WH | 1 |
| Aller, P; Amrán, D; de Blas, E; Esteban, D; Fernandez, C; Palacios, MA; Ramos, AM | 1 |
| Ohnishi, K | 2 |
| Chang-chun, W; Jian-xiang, W; Lu-gui, Q; Ming-zhe, H; Qiao-chuan, L; Ren-chi, Y; Wan-jun, S; Xin, L; Yan, L; Yao-zhong, Z; Yun-tao, L; Zeng-jun, L | 1 |
| Buscemi, S; Cai, L; Chen, GQ; Fu, GH; Pan, XY | 1 |
| Hayashi, H; Katoh, H; Naito, K; Ohnishi, K; Satoh, H; Takeshita, A; Terada, H; Uehara, A; Yamazaki, K | 1 |
| Agrawal, N; Kumar, A; Kumar, R; Mahapatra, M; Naithani, R | 1 |
| Emi, N; Kajiguchi, T; Kinoshita, T; Naoe, T; Ninomiya, M; Yamamoto, K | 1 |
| Hou, KZ; Jin, B; Liu, YP; Yu, P | 1 |
| Estey, E; Kantarjian, H; Keating, MJ; Tsimberidou, AM | 1 |
| Avvisati, G; Breccia, M; Buffolino, S; Cimino, G; De Angelis, G; Lo-Coco, F; Mariella, M; Martini, V; Minotti, C | 1 |
| Baysan, A; Gollapudi, S; Gupta, S; Su, H; Yel, L | 1 |
| Chen, SJ; Chen, Z; de Thé, H; Guillemin, MC; Lallemand-Breittenbach, V; Li, JM; Shen, ZX; Vitoux, D; Zhao, WL; Zhou, J; Zhu, J | 1 |
| Jing, Y; Waxman, S | 1 |
| Bi, KH; Jiang, GS | 1 |
| Büchner, T; Hehlmann, R; Lengfelder, E; Schultheis, B | 1 |
| Chen, SJ; Chen, Z; Wang, ZY; Zhang, J; Zhou, GB | 1 |
| Aribi, A; Cortes, JE; Estey, EH; Faderl, SH; Garcia-Manero, G; Kantarjian, HM; Koller, CA; Kornblau, SM; Laddie, NM; Thomas, DA | 1 |
| Akay, C; Gazitt, Y; Kircelli, F | 1 |
| Ammatuna, E; Lo Coco, F; Sanz, MA | 1 |
| Beissert, T; Bug, G; Henschler, R; Hoelzer, D; Puccetti, E; Rüster, B; Ruthardt, M; Seshire, A; Zheng, X | 1 |
| Besançon, F; Mathieu, J | 1 |
| Gattermann, N; Germing, U; Käferstein, H; Knipp, S; Schapira, M | 1 |
| de The, H; Nasr, R; Vitoux, D | 1 |
| Hede, K | 1 |
| Guo, T; Hong, M; Hu, Y; Shen, GX; Song, SJ; Wei, WN; Xia, LH; Zhang, XH | 1 |
| Karlsson, J; Påhlman, S; Pettersson, HM; Pietras, A; Øra, I | 1 |
| Abdallah, M; Bazarbachi, A; Darwiche, N; Dbaibo, GS; de Thé, H; El-Sabban, M; Hermine, O; Kfoury, Y; Kozhaya, L; Nasr, R; Panjarian, S | 1 |
| Emi, N; Kajiguchi, T; Naoe, T; Ono, Y; Yamamori, S; Yamamoto, K | 1 |
| Au, WY; Fong, BM; Hui, CK; Kwong, YL; Liu, CL; Shek, TW; Tam, S | 1 |
| Berridge, MV; Herst, PM; Hesketh, EL; Ritchie, DS | 1 |
| Chandy, M; George, B; Mathews, V; Srivastava, A; Srivastava, VM; Thomas, M | 1 |
| Ma, J | 1 |
| Ahn, HS; Kang, HJ; Park, JA; Shin, HY; Yun, JH | 1 |
| Du, JW; Fang, BJ; Gao, QL; Hu, JY; Jiang, DX; Li, YF; Lin, QD; Liu, YY; Song, YP; Wang, P; Wei, XD; Yue, H; Zhang, LN; Zhang, YL; Zhu, XH | 1 |
| Au, WY; Kwong, YL; Tam, S | 1 |
| Campbell, LJ; Catalano, A; Dawson, MA; Iland, H; Opat, S; Schwarer, A; Somana, K | 1 |
| Chen, GQ; Wang, LS; Wu, YL; Yu, Y | 1 |
| Jin, Z; Man, Z; Ran, M | 1 |
| Cang, H; Li, L; Shi, G; Wang, J; Yi, J | 1 |
| Au, WY; Fong, BM; Ho, KL; Kwong, YL; Tam, PC; Tam, S | 1 |
| Adamson, PC; Balis, FM; Blaney, SM; Fox, E; Goodspeed, W; Murgo, AJ; O'Brien, M; Razzouk, BI; Reaman, GH; Widemann, BC; Xiao, S | 1 |
| Warrell, RP | 2 |
| Cunha De Santis, G; Cunha, FQ; Faccioli, LH; Falcão, RP; Garcia, AB; Lima, AS; Moreno, SE; Rego, EM; Secco, D; Sousa, RB; Tamarozzi, MB | 1 |
| Antonioli, E; Cas, LD; D'Aloia, A; Raddino, R; Vizzardi, E; Zanini, G | 1 |
| Hu, Y; Shen, GX; Song, SJ; Wei, WN; Zhang, XH | 1 |
| Cernelc, P; Falnoga, I; Goessler, W; Podgornik, H; Raml, R; Slejkovec, Z; van Elteren, JT | 1 |
| Dawes, IW; Dilda, PJ; Hogg, PJ; Lock, RB; Perrone, GG; Philp, A | 1 |
| Jardin, F; Massy, J; Massy, N; Stamatoullas, A; Thery, JC; Tilly, H | 1 |
| Abe, Y; Muta, K; Nakashima, Y; Ohtsuka, R; Sada, E; Tachikawa, Y; Takayanagi, R | 1 |
| Aoki, S; Asai, T; Chiba, S; Hangaishi, A; Kanda, Y; Kurokawa, M; Motokura, T; Nagai, S; Ohtomo, K; Oshima, K; Watanabe, T | 1 |
| Li, D; Wei, F; Zhang, W; Zhang, X | 1 |
| Estey, E; Kopp, L; Quezada, G; Wells, RJ | 1 |
| Altman, JK; Carayol, N; Dolniak, B; Fukunaga, R; Katsoulidis, E; Platanias, LC; Redig, AJ; Tallman, MS; Ueda, T; Watanabe-Fukunaga, R | 1 |
| Chen, Z; Wang, ZY | 2 |
| Levy, M; McLean, TW; Powell, BL; Wofford, MM | 1 |
| Chen, SJ; Chen, Z; Liang, Y; Liu, P; Mao, JH; Shen, ZX; Song, JH; Wang, BS; Wang, L; Xu, F; Yan, XJ; Zhou, GB | 1 |
| Bazarbachi, A; de Thé, H; Habib, A; Hamade, E; Mahfouz, R; Nasrallah, MS | 1 |
| Isobe, Y; Oshimi, K; Sasaki, M; Sugimoto, K | 1 |
| Chen, X; Chen, Y; Zhang, L; Zhao, H; Zhu, X; Zou, Y | 1 |
| Burry, L; Cashin, R; Peckham, K; Reynolds, S; Seki, JT | 1 |
| Hazaka, Y; Kondo, T; Minami, Y; Onishi, N; Tanaka, Y; Toyoshima, K; Tsukada, J; Tsukuda, Y; Watanabe, Y; Yoda, A | 1 |
| Acevedo-Alvarez, M; Akar, U; Lopez-Berestein, G; Ozpolat, B; Vivas-Mejia, P; Zorrilla-Calancha, I | 1 |
| Mervis, J | 1 |
| Chen, GQ; Chen, SJ; Chen, Z; Gazin, C; Jin, XL; Li, XS; Ma, J; Naoe, T; Ni, JH; Shen, ZX; Shi, XG; Si, GY; Sun, GL; Tang, W; Wang, ZY; Xong, SM; Zhang, P; Zhang, TD; Zhong, HJ; Zhu, J | 1 |
| Andre, C; Chelbi-Alix, MK; Chen, Z; de The, H; Degos, L; Dhumeaux, D; Guillemin, MC; Herve, L; Koken, MH; Quignon, F; Wang, ZY; Zhu, J | 1 |
| Cai, X; Chen, GQ; Chen, SJ; Chen, Z; de The, H; Han, ZG; He, KL; Jia, PM; Kitamura, K; Liu, MM; Ma, J; Miller, W; Naoe, T; Ni, JH; Niu, C; Paul, P; Shi, GY; Shi, XG; Tang, W; Wang, ZY; Waxman, S; Xiong, SM; Zhang, P; Zhang, TD; Zhu, J | 1 |
| Chen, GQ; Chen, SJ; Chen, Y; Chen, Z; Fang, ZW; Li, XS; Ma, J; Ni, JH; Qiu, QY; Shen, ZX; Sun, GL; Tang, W; Wang, YT; Wang, ZY; Xiong, SM; Yang, KQ; Zhang, P; Zhang, TD; Zhou, L; Zhu, J | 1 |
| Kitamura, K; Kiyoi, H; Naoe, T; Ohno, R; Takeshita, A; Tobita, T; Yoshida, H | 1 |
| Look, AT | 1 |
| Avvisati, G; Davison, K; Fanelli, M; Ferrara, FF; Gambacorti-Passerini, C; Lamph, WW; Lo Coco, F; Miller, WH; Nervi, C; Pelicci, PG; Peschle, C; Riccioni, R; Rosenauer, A; Shao, W; Testa, U; Waxman, S | 1 |
| Benoit, G; Chelbi-Alix, MK; Chen, Z; de Thé, H; Giannì, M; Koken, MH; Lanotte, M | 1 |
| Delva, L; Gabrilove, JL; Gambacorti-Passerini, C; König, A; Pandolfi, PP; Rivi, R; Scheinberg, DA; Wang, ZG; Warrell, RP | 1 |
| Chen, G; Shi, G; Tang, W | 1 |
| Zhang, Z | 1 |
| Calleja, E; Corso, D; Dardashti, LJ; DeBlasio, A; Gabrilove, J; Jhanwar, S; Maslak, P; Pandolfi, PP; Scheinberg, DA; Soignet, SL; Wang, ZG; Warrell, RP | 1 |
| Gallagher, RE | 2 |
| Avvisati, G; Lo Coco, F; Mandelli, F; Nervi, C | 1 |
| Miller, M | 1 |
| Ikeda, Y; Kinjo, K; Kizaki, M; Muto, A; Ueno, H | 1 |
| Chang, CS; Chen, YC; Chou, WC; Chung, CY; Huang, SF; Huang, SY; Kuo, TL; Shen, MC; Tang, JL; Tien, HF; Wang, CH; Yao, YT | 1 |
| Harada, M; Kibata, M; Ohno, R; Omoto, E; Shudo, K; Takahashi, K; Takeuchi, M; Ueda, R; Yano, T | 1 |
| Buzyn, A; Daniel, MT; de Thé, H; Degos, L; Gianni, M; Koken, MH; Licht, J; Minard, P; Varet, B; Zelent, A | 1 |
| Paternostro, G; Tamm, I; Zapata, JM | 1 |
| Conrad, ME | 1 |
| Hoelzer, D; Jensen, K; Ottmann, OG; Puccetti, E; Ruthardt, M; Sternsdorf, T; Will, H | 1 |
| de Thé, H; Giannì, M | 1 |
| Chen, WJ; Chen, YC; Huang, CH; Lee, YT; Wu, CC | 1 |
| Vincent, PC | 1 |
| Caen, J; Cai, X; Chen, GQ; Chen, SJ; Chen, Z; Guo, WM; Ju, B; Pan, L; Sun, GL; Wang, HL; Wang, ZY; Yao, YY; Zhao, WL; Zhu, J | 1 |
| Carmignani, A; Fazzi, R; Galimberti, S; Papineschi, F; Petrini, M; Testi, R | 1 |
| Agis, H; Edelhäuser, M; Fonatsch, C; Geissler, K; Lechner, K; Mitterbauer, G; Seewann, HL; Thalhammer, R; Valent, P; Weltermann, A | 1 |
| Chalmers-Redman, RM; Dai, J; Jing, Y; Tatton, WG; Waxman, S | 1 |
| Haanen, C; Vermes, I | 1 |
| Chan, P; Huff, J; Nyska, A; Waalkes, M | 1 |
| Cao, Q; Chen, GQ; Chen, SJ; Chen, Y; Chen, Z; Gu, BW; Gu, FY; Hu, J; Li, JM; Li, XS; Liu, JX; Niu, C; Ren, MY; Shen, ZX; Su, XY; Sun, HP; Wang, ZY; Waxman, S; Wu, W; Xiong, SM; Yan, H; Yang, RR; Yu, T; Yuan, MM; Zeng, XY; Zhang, FQ; Zhang, TD; Zhou, L | 1 |
| Donelli, A; Galimberti, S; Leonardi, G; Luppi, M; Marasca, R; Petrini, M; Torelli, G; Vaccari, P; Zucchini, P | 1 |
| Chen, SJ; Chen, Z; Hu, J; Shen, ZX; Sun, GL; Wang, ZY | 1 |
| Lehmann, S; Paul, C | 1 |
| Cai, X; Chen, GQ; Chen, SJ; Chen, Z; Huang, Y; Jia, PM; Shen, YL; Wang, ZY; Xiong, SM; Yu, Y; Zhang, JW; Zhou, L; Zhu, Q | 1 |
| Fabry, U; Galm, O; Osieka, R | 1 |
| Annunziata, M; Boccuni, P; Cimino, R; Copia, C; Costantini, S; Del Vecchio, L; Dello Russo, A; Di Noto, R; Ferrara, F; Lo Pardo, C | 1 |
| Fukuchi, Y; Hata, J; Ikeda, Y; Ito, M; Kinjo, K; Kizaki, M; Muto, A; Nishihara, T; Ueyama, Y; Umezawa, A; Yamato, K | 1 |
| Akao, Y; Nakagawa, Y; Yamada, H | 1 |
| Kizaki, M | 1 |
| Hoshi, S; Kitamura, K; Kiyoi, H; Koike, M; Naoe, T; Saito, H | 1 |
| Hirosawa, S; Kamei, S; Koyama, T; Ohsawa, M; Shibakura, M | 1 |
| Chang, IY; Huang, MJ; Lin, CP; Lin, WY | 1 |
| Chang, IY; Huang, MJ; Lin, WY; Sheu, YT | 1 |
| Chen, YC; Huan, SY; Yang, CH | 1 |
| Hayashi, T; Imanaka, T; Ishii, K; Komatsu, H; Nakamura, F; Ono, Y; Sawada, H; Tanaka, Y | 1 |
| Firkin, F; Spencer, A | 1 |
| Camacho, LH; Chanel, S; Ellison, R; Heller, G; Ho, R; Scheinberg, DA; Soignet, SL; Warrell, RP | 1 |
| He, LZ; Pandolfi, PP; Rego, EM; Wang, ZG; Warrell, RP | 1 |
| Hess, JL; Westervelt, P; Zhang, T | 1 |
| Au, WY; Kwong, YL; Liang, R; Ma, SK; Ooi, C | 1 |
| Akao, Y; Kitamura, K; Kiyoi, H; Minami, Y; Naoe, T; Saito, H; Yamamoto, K | 1 |
| Novick, SC; Warrell, RP | 1 |
| Henney, JE | 1 |
| Miller, JL | 1 |
| Fujisawa, S; Fujita, Y; Matsui, H; Naito, K; Nakamura, S; Ohnishi, K; Ohno, R; Satoh, H; Shigeno, K; Shinjo, K; Sugiyama, S; Takeshita, A; Terada, H; Yoshida, H | 1 |
| Scheinberg, DA | 1 |
| Calleja, EM; Warrell, RP | 1 |
| Chen, GQ; Chen, Z; Jing, Y; Miller, WH; Wang, L; Waxman, S; Xia, L | 1 |
| Cohen, MH; Flamm Honig, S; Hirschfeld, S; Ibrahim, A; Johnson, JR; O'Leary, JJ; Pazdur, R; White, RM; Williams, GA | 1 |
| Cobcroft, R; Gill, D; Kennedy, GA; Marlton, P | 1 |
| Chen, GQ; Chen, SJ; Chen, Z; Shen, ZX; Wang, ZY | 1 |
| Miller, KB; Relias, V; Roberts, TF; Schenkein, D; Sprague, K | 1 |
| Bai, Y; Huang, S | 1 |
| Guo, W; Wang, H; Zhao, W | 2 |
| Cai, X; Jia, P; Shi, X | 1 |
| Api, M; Chiaramida, S; Dutcher, JP; Garl, S; Lucariello, R; Unnikrishnan, D; Varshneya, N; Wiernik, PH | 1 |
| Dejean, A; Lehembre, F; Müller, S; Pandolfi, PP | 1 |
| Chen, G; Chen, S; Chen, Z; Fang, Z; Huang, Y; Li, X; Liu, H; Ni, J; Shen, Z; Wang, Z | 1 |
| Au, WY; Chim, CS; Kwong, YL; Liang, R; Pang, A; Suen, C | 1 |
| Soignet, SL | 1 |
| Rust, DM; Soignet, SL | 1 |
| Chen, J; Chen, SJ; Chen, Z; Li, JM; Li, XS; Liu, YF; Niu, C; Shen, Y; Shen, ZX; Tang, W; Wang, ZY; Wu, F; Wu, W; Xiong, SM; Yan, H; Zeng, XY; Zhao, WL | 1 |
| Guo, W; Qu, B; Shen, Z; Wang, H; Wang, X; Wang, Z; Wu, F; Zhao, W | 1 |
| Zelent, A | 1 |
| Altucci, L; Chomienne, C; Gronemeyer, H; Raffelsberger, W; Reitmair, A; Rossin, A | 1 |
| Adkins, DR; Brown, RA; Curtin, P; DiPersio, JF; Hurd, D; Khoury, H; Ley, TJ; Luger, SM; Ma, MK; Westervelt, P | 1 |
| Chen, G; Zhang, T; Zhou, A | 1 |
| Fukuchi, Y; Hata, J; Hozumi, N; Ikeda, Y; Ito, M; Kawamura, C; Kizaki, M; Matsushita, H; Muto, A; Ueyama, Y; Umezawa, A; Yamada, T; Yamato, K | 1 |
| Acar, V; Bénazeth, S; Chaumeil, JC; Corriol, O; Curis, E; Deschamps, P; Guyon, F; Nicolis, I; Zerrouk, N | 1 |
| Baek, SH; Choi, YJ; Jang, MA; Kwon, TK; Lim, JH; Park, JW; Passaniti, T | 1 |
| Calleja, E; Coutré, S; Dahlberg, S; Douer, D; Ellison, R; Frankel, SR; Kalaycio, M; Kantarjian, H; Scheinberg, DA; Sievers, EL; Soignet, SL; Steinherz, P; Stone, RM; Tallman, MS; Warrell, RP | 1 |
| Au, WY; Chan, GC; Chim, CS; Ho, WK; Kwong, YL; Ooi, GC; Shek, TW | 1 |
| Hong, SH; Privalsky, ML; Yang, Z | 1 |
| Pandolfi, PP | 1 |
| Wang, ZY | 2 |
| Barbey, JT; Soignet, S | 1 |
| Chelbi-Alix, MK; de Thé, H | 1 |
| Chen, GQ; Chen, SJ; Chen, Z; Wang, ZG; Wang, ZY; Zhang, TD | 1 |
| de Thé, H; Lallemand-Breitenbach, V; Zhu, J | 1 |
| Lanotte, M; Roussel, MJ | 1 |
| Cai, X; Chen, G; Jia, P | 1 |
| Guo, W; Wang, H; Zhu, J | 1 |
| De Santis, S; Diverio, D; Lo Coco, F; Mandelli, F; Meloni, G; Petrucci, MT; Petti, MC; Pinazzi, MB; Romano, A; Tafuri, A | 1 |
| Hirayama, Y; Ishikawa, K; Ishitani, K; Kondo, A; Koyama, R; Matsunaga, T; Nagai, T; Niitsu, Y; Ohta, H; Sakamaki, S | 1 |
| Chen, Z; Guo, W; Qu, B; Shen, Z; Wang, H; Wang, X; Wang, Z; Zhao, W | 1 |
| Hu, J; Li, X; Shen, Z; Sun, G; Sun, H; Wang, Z; Wu, W | 1 |
| Bi, K; Jiang, G; Tang, T | 1 |
| Guo, W; Ju, B; Wang, H; Wang, X; Zhao, W; Zhu, J | 1 |
| Hu, N; Hu, X; Ma, L | 1 |
| Zhang, T | 1 |
| Shen, Z; Wang, H; Wang, X; Wu, F; Zhao, W | 1 |
| Qiao, Z; Yang, L; Zhang, X | 1 |
| Chen, G; Pan, L; Zhou, L | 1 |
| Feusner, JH; Nabhan, C; Rowe, JM; Tallman, MS | 1 |
| Cai, X; Chen, SJ; Chen, Z; Flexor, M; Jia, PM; Lanotte, M; Shen, YL; Tong, JH; Waxman, S; Yu, Y; Zhang, JW; Zhu, HQ; Zhu, Q | 1 |
| Kuriyama, K | 1 |
| Douer, D | 1 |
| Akiyama, H; Fukuhara, O; Hiruma, K; Maeda, Y; Mikoshiba, M; Ohashi, K; Okuyama, Y; Sakamaki, H; Takei, N; Takeshita, A | 1 |
| Han, X; Hu, L; Li, X; Liu, P; Qiu, F; Wang, S; Xiao, Y; Yang, H; Zhang, P; Zhou, J | 1 |
| Chu, H; Guo, W; Pan, L; Qu, B; Wang, H; Wang, X; Zhao, W; Zhu, J | 1 |
| Au, WY; Chim, CS; Kwong, YL; Liang, R; Lie, AK | 1 |
| Fujisawa, S; Fujita, Y; Matsui, H; Naito, K; Nakamura, S; Ohnishi, K; Ohno, R; Sahara, N; Satoh, H; Shigeno, K; Shinjo, K; Takeshita, A; Terada, H; Yoshida, H | 1 |
| Bloomfield, CD; Slack, JL; Tallman, MS; Tricot, G; Waxman, S | 1 |
| Miller, WH | 1 |
| Chen, SS; Jiang, B; Liu, KY; Liu, YR; Lu, DP; Qiu, JY; Wang, Q | 1 |
| Lo Coco, F | 1 |
| Annunziata, M; Ciolli, S; Fanci, R; Ferrara, F; Gianfaldoni, G; Leoni, F; Nozzoli, C | 1 |
| Davison, K; Mann, KK; Miller, WH | 1 |
| Dombret, H; Fenaux, P; Soignet, SL; Tallman, MS | 1 |
| Chen, GQ; Chen, SJ; Chen, Z; Shen, ZX; Sun, GL; Tong, JH; Wang, ZY | 1 |
| Garnier-Suillerot, A; Petroutsa, M; Salerno, M | 1 |
| Miller, WH; Waxman, S | 1 |
| DiPersio, JF; Ley, TJ; Ma, MK; Oldfather, KM; Pollock, JL; Walter, MJ; Westervelt, P; Williams, A | 1 |
| Chen, S; Gong, S; Wang, HY; Wei, SH; Zhang, XJ; Zhang, XX; Zhao, CY | 1 |
| Hirano, S; Udagawa, O | 1 |
| Korsos, V; Miller, WH | 1 |
| Ball, G; Hay, RT; Jaffray, EG; Liczmanska, M; Mojsa, B; Rojas-Fernandez, A; Tatham, MH; Yin, Y | 1 |
| Carrall, JA; Dillon, CT; Harris, HH; Lai, B; Lambert, JM; Lie, W | 1 |
| Chen, H; Fan, S; Gao, Y; Guo, M; Hai, X; Lin, L; Wu, Z; Zhao, Q | 1 |
| Pemmaraju, N | 1 |
| de Thé, H; Esnault, C; Rahmé, R | 1 |
| Levis, M | 2 |
| Jia, JS; Lai, YY; Liu, YR; Qin, YZ; Zhao, XS; Zhu, HH | 1 |
| Chen, QY; Costa, M | 1 |
| Chen, YJ; Islam, K; Maimaitiyiming, Y; Naranmandura, H; Wang, C; Wang, QQ; Xu, S; Yang, C | 1 |
| Hu, J; Jin, J; Lo-Coco, F; Zhu, HH | 1 |
| Jin, J; Lou, Y; Mao, L; Tong, H; Wei, J; Xu, W; Yu, W | 1 |
| Ding, X; Guo, Z; Khan, A; Li, H; Sun, Y; Wang, X; Wu, T; Wu, Z; Xie, Q; Yang, J; Yu, L; Zhao, L; Zhi, D | 1 |
| Ablain, J; Anthony, E; de Thé, H; Fonsart, J; Leiva, M; Peres, L | 1 |
| Wilcox, DE | 1 |
| Huang, XJ; Zhu, HH | 2 |
| Chen, SJ; Huang, XJ; Jin, J; Li, JY; Ma, J; Wang, JX; Wu, DP; Zhu, HH | 1 |
| Arar, K; Barbry, P; Bouttier, M; Cassinat, B; Chomienne, C; Friederich, E; Lecellier, CH; Mari, B; Maurin, T; Portales-Casamar, E; Saumet, A; Vallar, L; Vetter, G; Wasserman, WW | 1 |
| Licht, JD | 1 |
| Lis, P; Litwin, I; Maciaszczyk-Dziubińska, E | 1 |
| Hu, J | 1 |
| de Thé, H; Lallemand-Breitenbach, V; Le Bras, M | 1 |
| Wiśniewska, E; Wysocki, R | 1 |
| Jing, Y; Lu, M; Waxman, S; Xia, L | 1 |
| Mumford, JL; Schmitt, MT; Zhang, TC | 1 |
| Bohle, DS; Colombo, M; Diaz, Z; Mann, KK; Miller, WH; Schipper, HM; Smith, KN; Su, H | 1 |
| Chen, SJ; Chen, Z; Wang, ZY; Zhao, WL; Zhou, GB | 1 |
| Chen, HY; Cheng, L; Chou, WC; Dang, CV; Yang, PC; Yu, SL | 1 |
| Himeno, S; Kojima, C; Qu, W; Sakurai, T; Waalkes, MP | 1 |
| Cyranoski, D | 1 |
| Geoffroy, MC; Hattersley, N; Hay, RT; Jaffray, EG; Palvimo, JJ; Plechanovova, A; Shen, L; Tatham, MH | 1 |
| Petrie, K; Zelent, A | 1 |
| Kitamura, K; Naoe, T; Ohno, R; Yoshida, H | 1 |
| Chelbi-Alix, MK; Chen, Z; de Thé, H; Degos, L; Koken, MH; Quignon, F; Wang, ZY; Zhu, J | 1 |
| Chen, Z; de Thé, H; Quignon, F | 1 |
| Bishop, JM; Daniel, MT; de Thé, H; Degos, L; Guillemin, MC; Janin, A; Kogan, SC; Lallemand-Breitenbach, V | 1 |
| Lane, AA; Ley, TJ; Pollock, JL; Walter, MJ; Westervelt, P | 1 |
| Tsui, EY; Yeung, YM; Yip, SF | 1 |
184 review(s) available for arsenic and Leukemia, Promyelocytic, Acute
| Article | Year |
|---|---|
Chemotherapeutics-induced osteonecrosis of the jaw in a patient with acute promyelocytic leukemia: A rare case report.
Topics: Arsenicals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Humans; Leukemia, Promyelocytic, Acute | 2022 |
Treatment for relapsed acute promyelocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Treatment Outcome; Tretinoin | 2022 |
Does the pursuit of scientific excellence serve or hamper translational medical research: an historical perspective from hematological malignancies.
Topics: Arsenic Trioxide; Arsenicals; Hematologic Neoplasms; Humans; Leukemia, Promyelocytic, Acute; Oxides; Thalidomide; Translational Research, Biomedical; Tretinoin | 2022 |
Glomerulonephritis Secondary to Acute Promyelocytic Leukemia that Resolved after Induction Therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenicals; Glomerulonephritis; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin | 2023 |
Refractory acute promyelocytic leukemia with PLZF/RARa rearrangement: a case report and literature review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin | 2023 |
Potential of natural products in combination with arsenic trioxide: Investigating cardioprotective effects and mechanisms.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Biological Products; Cardiotonic Agents; Heart; Humans; Leukemia, Promyelocytic, Acute; Oxides | 2023 |
Biotransformation of arsenic and toxicological implication of arsenic metabolites.
Topics: Animals; Antineoplastic Agents; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Biotransformation; Humans; Leukemia, Promyelocytic, Acute; Risk Assessment; Toxicity Tests | 2020 |
Gemtuzumab ozogamicin in acute myeloid leukemia: past, present and future.
Topics: Aged; Animals; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Arsenicals; Calicheamicins; Chlorides; Clinical Trials as Topic; Cytarabine; Daunorubicin; Drug Approval; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Mice; Middle Aged; Multicenter Studies as Topic; Recurrence; Sialic Acid Binding Ig-like Lectin 3; Tretinoin | 2020 |
Arsenic compounds: The wide application and mechanisms applied in acute promyelocytic leukemia and carcinogenic toxicology.
Topics: Antineoplastic Agents; Arsenicals; Humans; Leukemia, Promyelocytic, Acute | 2021 |
Successful treatment of acute promyelocytic leukemia in pregnancy with single-agent all-trans retinoic acid.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Gestational Age; Humans; Leukemia, Promyelocytic, Acute; Neoadjuvant Therapy; Pregnancy; Pregnancy Complications, Neoplastic; Treatment Outcome; Tretinoin | 2018 |
Acute Promyelocytic Leukemia: A Paradigm for Oncoprotein-Targeted Cure.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins; Oncogene Proteins, Fusion; Tretinoin; Tumor Suppressor Proteins | 2017 |
The evolving use of arsenic in pharmacotherapy of malignant disease.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Biotransformation; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Gastrointestinal Diseases; Gene Expression Regulation; Heart Diseases; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Metabolic Networks and Pathways; Methyltransferases; Neoplasms; Oxides; Reactive Oxygen Species; Signal Transduction; Treatment Outcome | 2013 |
A drug from poison: how the therapeutic effect of arsenic trioxide on acute promyelocytic leukemia was discovered.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Asian People; China; Drug Discovery; Humans; Leukemia, Promyelocytic, Acute; Medicine, Chinese Traditional; Oxides; Remission Induction; Treatment Outcome | 2013 |
Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O 3) in acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Molecular Targeted Therapy; Oxides; Tretinoin | 2013 |
Management of elderly patients with acute promyelocytic leukemia: progress and problems.
Topics: Aged; Aged, 80 and over; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Disease Management; Humans; Leukemia, Promyelocytic, Acute; Oxides; Treatment Outcome; Tretinoin | 2013 |
Acute promyelocytic leukemia: do we have a new front-line standard of treatment?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Consolidation Chemotherapy; Humans; Leukemia, Promyelocytic, Acute; Molecular Targeted Therapy; Oxides; Remission Induction; Tretinoin | 2013 |
[Arsenic trioxide: impact on the growth and differentiation of cancer cells and possible use in cancer therapy].
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Caspases; Cell Differentiation; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; MAP Kinase Kinase 4; Mitochondria; Neoplasms; NF-kappa B; Oxides | 2013 |
Treatment of acute promyelocytic leukemia with arsenic trioxide: clinical results and open questions.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Recurrence, Local; Oxides; Remission Induction | 2013 |
Meta-analysis of all-trans retinoic acid-linked arsenic trioxide treatment for acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Remission Induction; Treatment Outcome; Tretinoin | 2014 |
Biology and management of therapy-related acute promyelocytic leukemia.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Early Diagnosis; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasms, Second Primary; Oxides; Retrospective Studies; Risk Factors; Tretinoin | 2013 |
Anticancer activity of small-molecule and nanoparticulate arsenic(III) complexes.
Topics: Antineoplastic Agents; Arsenic; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Drug Carriers; Humans; Inactivation, Metabolic; Leukemia, Promyelocytic, Acute; Nanoparticles; Oxides; Sulfhydryl Compounds; Thermodynamics | 2013 |
Postconsolidation maintenance and monitoring in patients with acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Consolidation Chemotherapy; Humans; In Situ Hybridization, Fluorescence; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Monitoring, Physiologic; Oncogene Proteins, Fusion; Oxides; Polymerase Chain Reaction; Tretinoin | 2013 |
Synergy against PML-RARa: targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia.
Topics: Animals; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Cell Transformation, Neoplastic; Gene Expression Regulation, Leukemic; Humans; Leukemia, Promyelocytic, Acute; Mice; Oncogene Proteins, Fusion; Oxides; Remission Induction; Signal Transduction; Transcriptional Activation; Tretinoin | 2013 |
[Acute promyelocytic leukemia--modern approach to disease pathogenesis and differentiation treatment].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Oxides; Secondary Prevention; Survival Rate; Tretinoin | 2013 |
Novel treatment of acute promyelocytic leukemia: As₂O₃, retinoic acid and retinoid pharmacology.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Receptors, Retinoic Acid; Retinoids; Transcription Factors; Tumor Suppressor Proteins | 2013 |
ATRA + ATO: has a new standard of care been established in low-risk acute promyelocytic leukaemia?
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Randomized Controlled Trials as Topic; Standard of Care; Treatment Outcome; Tretinoin | 2014 |
The role of PML in hematopoietic and leukemic stem cell maintenance.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Fatty Acids; Hematopoietic Stem Cells; Humans; Leukemia, Promyelocytic, Acute; Nuclear Proteins; Oncogene Proteins, Fusion; Oxides; Promyelocytic Leukemia Protein; Signal Transduction; Transcription Factors; Tumor Suppressor Proteins | 2014 |
How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia.
Topics: Adult; Arsenic Trioxide; Arsenicals; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Premedication; Syndrome; Tretinoin | 2014 |
Contemporary treatment of APL.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Tretinoin | 2014 |
What is the standard regimen for patients with acute promyelocytic leukemia?
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Humans; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Oxides; Practice Guidelines as Topic; Tretinoin | 2014 |
Advanced progress on the relationship between RA and its receptors and malignant tumors.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Proliferation; Drug Resistance, Neoplasm; Drug Therapy, Combination; Gene Expression Regulation, Leukemic; Humans; Leukemia, Promyelocytic, Acute; Neoplastic Cells, Circulating; Oxides; Receptors, Retinoic Acid; Signal Transduction; Tretinoin | 2014 |
Understanding the molecular pathogenesis of acute promyelocytic leukemia.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Transformation, Neoplastic; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Clinical Trials as Topic; Disease Models, Animal; DNA End-Joining Repair; Drug Synergism; Granulocyte Precursor Cells; Humans; Leukemia, Promyelocytic, Acute; Mice; Molecular Targeted Therapy; Neoplasm Proteins; Neoplasms, Second Primary; Neoplastic Stem Cells; Oncogene Proteins, Fusion; Oxides; Signal Transduction; Topoisomerase II Inhibitors; Translocation, Genetic; Tretinoin | 2014 |
The coagulopathy in acute promyelocytic leukaemia--what have we learned in the past twenty years.
Topics: Annexin A2; Anticoagulants; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blood Coagulation Disorders; Blood Coagulation Tests; Carboxypeptidase B2; Disseminated Intravascular Coagulation; Fibrinolysis; Forecasting; Granulocyte Precursor Cells; Hemorrhagic Disorders; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recombinant Proteins; Risk Factors; S100 Proteins; Thrombomodulin; Thrombophilia; Thromboplastin; Tretinoin; Urokinase-Type Plasminogen Activator | 2014 |
Triple A therapy: the molecular underpinnings of the unique sensitivity of leukemic promyelocytes to anthracyclines, all-trans-retinoic acid and arsenic trioxide.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Granulocyte Precursor Cells; Humans; Leukemia, Promyelocytic, Acute; Molecular Targeted Therapy; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Topoisomerase II Inhibitors; Transcription, Genetic; Tretinoin | 2014 |
Conventional induction and post-remission therapy in APL: have we arrived?
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Consolidation Chemotherapy; Daunorubicin; Harringtonines; Homoharringtonine; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Mercaptopurine; Methotrexate; Mitoxantrone; Multicenter Studies as Topic; Oxides; Remission Induction; Tretinoin | 2014 |
Have all-trans retinoic acid and arsenic trioxide replaced all-trans retinoic acid and anthracyclines in APL as standard of care.
Topics: Adult; Age Factors; Aged; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Blood Coagulation Factors; Clinical Trials as Topic; Combined Modality Therapy; Cytarabine; Etoposide; Humans; Hydroxyurea; Idarubicin; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Middle Aged; Mitoxantrone; Multicenter Studies as Topic; Oxides; Platelet Transfusion; Practice Guidelines as Topic; Remission Induction; Risk Assessment; Thioguanine; Treatment Outcome; Tretinoin | 2014 |
Can we say farewell to monitoring minimal residual disease in acute promyelocytic leukaemia?
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Cell Differentiation; Clinical Trials as Topic; Disease Management; Drug Monitoring; Drug Resistance, Neoplasm; Historically Controlled Study; Humans; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Leukocytosis; Neoplasm, Residual; Oncogene Proteins, Fusion; Oxides; Real-Time Polymerase Chain Reaction; Remission Induction; Salvage Therapy; Tretinoin | 2014 |
Extramedullary disease in APL: a real phenomenon to contend with or not?
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzoates; Cerebral Hemorrhage; Humans; Incidence; Leukemia, Promyelocytic, Acute; Leukemic Infiltration; Models, Biological; Multicenter Studies as Topic; Organ Specificity; Oxides; Prognosis; Randomized Controlled Trials as Topic; Remission Induction; Risk Factors; Tetrahydronaphthalenes; Tretinoin | 2014 |
Treatment of paediatric APL: how does the therapeutic approach differ from adults?
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Age Factors; Age of Onset; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Blood Coagulation Disorders; Bone Marrow Examination; Cell Differentiation; Child; Child, Preschool; Heart Diseases; Humans; Infant; Leukemia, Promyelocytic, Acute; Multicenter Studies as Topic; Neoplasm, Residual; Neoplasms, Second Primary; Oncogene Proteins, Fusion; Oxides; Prognosis; Pseudotumor Cerebri; Randomized Controlled Trials as Topic; Remission Induction; Risk Factors; Salvage Therapy; Tretinoin | 2014 |
Progress in the treatment of acute promyelocytic leukemia: optimization and obstruction.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Drug Synergism; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Recurrence, Local; Oxides; Salvage Therapy; Tretinoin | 2014 |
Epigenetics in acute promyelocytic leukaemia pathogenesis and treatment response: a TRAnsition to targeted therapies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; DNA Methylation; Epigenesis, Genetic; Humans; Leukemia, Promyelocytic, Acute; Molecular Targeted Therapy; Oxides; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Treatment Outcome; Tretinoin | 2015 |
Inhibition factors of arsenic trioxide therapeutic effects in patients with acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Mutation; Oxides | 2014 |
New strategies in acute promyelocytic leukemia: moving to an entirely oral, chemotherapy-free upfront management approach.
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Disease Management; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Neoplasm, Residual; Oxides; Tretinoin | 2014 |
[Treatment for acute promyelocytic leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzoates; Clinical Trials, Phase III as Topic; Consolidation Chemotherapy; Disseminated Intravascular Coagulation; Gene Fusion; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Molecular Targeted Therapy; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Receptors, Retinoic Acid; Recurrence; Remission Induction; Retinoic Acid Receptor alpha; Tetrahydronaphthalenes; Transcription Factors; Tretinoin; Tumor Suppressor Proteins | 2014 |
Molecular mechanisms of the antileukemia activities of retinoid and arsenic.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Drug Synergism; Epigenesis, Genetic; Gene Expression Regulation, Leukemic; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Oxides; Treatment Outcome; Tretinoin | 2014 |
Acute promyelocytic leukemia: where did we start, where are we now, and the future.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Drug-Related Side Effects and Adverse Reactions; Humans; Leukemia, Promyelocytic, Acute; Oxides; Treatment Failure; Tretinoin | 2015 |
Insights into the All-trans-Retinoic Acid and Arsenic Trioxide Combination Treatment for Acute Promyelocytic Leukemia: A Meta-Analysis.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Chemical and Drug Induced Liver Injury; Controlled Clinical Trials as Topic; Humans; Leukemia, Promyelocytic, Acute; Oxides; Randomized Controlled Trials as Topic; Remission Induction; Risk; Tretinoin | 2015 |
Synergistic targeted therapy for acute promyelocytic leukaemia: a model of translational research in human cancer.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Molecular Targeted Therapy; Oncogene Proteins, Fusion; Oxides; Translational Research, Biomedical; Tretinoin | 2015 |
[Pathogenesis of Acute Promyelocytic Leukemia].
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Disease Models, Animal; Epigenomics; Humans; Leukemia, Promyelocytic, Acute; Medicine, Chinese Traditional; Mice; Molecular Targeted Therapy; Oncogene Proteins, Fusion; Oxides; Transcription, Genetic; Tretinoin | 2015 |
p53 as an Effector or Inhibitor of Therapy Response.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Breast Neoplasms; Female; Humans; Leukemia, Promyelocytic, Acute; Molecular Targeted Therapy; Oncogene Proteins, Fusion; Oxides; Treatment Outcome; Tretinoin; Tumor Suppressor Protein p53 | 2015 |
Acute myeloid leukemia in children and adolescents: identification of new molecular targets brings promise of new therapies.
Topics: Adolescent; Adult; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Clinical Trials as Topic; Down Syndrome; Epigenesis, Genetic; GATA1 Transcription Factor; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Medical Oncology; Molecular Medicine; Mutation; Oxides; ras Proteins; Receptor Protein-Tyrosine Kinases; Treatment Outcome; Tretinoin | 2015 |
Current standard treatment of adult acute promyelocytic leukaemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Early Diagnosis; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Stem Cell Transplantation; Tretinoin | 2016 |
Swallowing a bitter pill-oral arsenic trioxide for acute promyelocytic leukemia.
Topics: Administration, Intravenous; Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Hematologic Neoplasms; Humans; Leukemia, Promyelocytic, Acute; Oxides; Remission Induction; Treatment Outcome | 2016 |
The evolution of arsenic in the treatment of acute promyelocytic leukemia and other myeloid neoplasms: Moving toward an effective oral, outpatient therapy.
Topics: Administration, Oral; Ambulatory Care; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials, Phase III as Topic; Female; Follow-Up Studies; Forecasting; Hematologic Neoplasms; Humans; Infusions, Intravenous; Leukemia, Promyelocytic, Acute; Male; Oxides; Randomized Controlled Trials as Topic; Risk Assessment; Treatment Outcome | 2016 |
Acute promyelocytic leukemia with cryptic t(15;17) on isochromosome 17: a case report and review of literature.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Examination; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Disease Progression; Fatal Outcome; Genetic Predisposition to Disease; Humans; In Situ Hybridization, Fluorescence; Isochromosomes; Karyotype; Leukemia, Promyelocytic, Acute; Male; Molecular Diagnostic Techniques; Mutation; Oncogene Proteins, Fusion; Oxides; Phenotype; Predictive Value of Tests; Time Factors; Translocation, Genetic; Treatment Outcome; Tretinoin; Young Adult | 2015 |
Optimal treatment strategies for high-risk acute promyelocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Blood Coagulation Disorders; Disease Management; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Remission Induction; Treatment Outcome; Tretinoin | 2016 |
Prognostic factors in acute promyelocytic leukemia: strategies to define high-risk patients.
Topics: Antigens, CD; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Chromosome Aberrations; Disseminated Intravascular Coagulation; DNA-Binding Proteins; fms-Like Tyrosine Kinase 3; Hemorrhagic Disorders; Humans; Immunophenotyping; Leukemia, Promyelocytic, Acute; Leukocyte Count; Nuclear Proteins; Oncogene Proteins, Fusion; Oxides; Prognosis; Risk Factors; Tandem Repeat Sequences; Treatment Outcome; Tretinoin; Tumor Protein p73; Tumor Suppressor Proteins | 2016 |
Current management of newly diagnosed acute promyelocytic leukemia.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Drug-Related Side Effects and Adverse Reactions; Humans; Leukemia, Promyelocytic, Acute; Oxides; Randomized Controlled Trials as Topic; Tretinoin | 2016 |
All-Trans Retinoic Acid plus Arsenic Trioxide versus All-Trans Retinoic Acid plus Chemotherapy for Newly Diagnosed Acute Promyelocytic Leukemia: A Meta-Analysis.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Treatment Outcome; Tretinoin | 2016 |
Acute promyelocytic leukemia: preventing early complications and late toxicities.
Topics: Adult; Age Factors; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Humans; Leukemia, Promyelocytic, Acute; Oxides; Survival Rate | 2016 |
Metabolism, toxicity and anticancer activities of arsenic compounds.
Topics: Animals; Antineoplastic Agents; Arsenic Poisoning; Arsenicals; Humans; Leukemia, Promyelocytic, Acute | 2017 |
Arsenic trioxide.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence | 2008 |
The expanding role of arsenic in acute promyelocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Cytarabine; Humans; Leukemia, Promyelocytic, Acute; Oxides; Treatment Outcome; Tretinoin | 2008 |
Arsenic trioxide mechanisms of action--looking beyond acute promyelocytic leukemia.
Topics: Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Proliferation; Humans; Leukemia, Promyelocytic, Acute; Oxides; Reactive Oxygen Species | 2008 |
What is the role of arsenic in newly diagnosed APL?
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Treatment Outcome; Tretinoin | 2008 |
Transcriptome and proteome analyses of drug interactions with natural products.
Topics: Animals; Arsenic Trioxide; Arsenicals; Benzamides; Drug Discovery; Drug Synergism; Gene Expression Profiling; Herb-Drug Interactions; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Promyelocytic, Acute; Oxides; Piperazines; Proteome; Pyrimidines; Tretinoin | 2008 |
Interaction between arsenic trioxide and human primary cells: emphasis on human cells of myeloid origin.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Degranulation; Cell Differentiation; Gene Expression Regulation; Humans; Inflammation; Leukemia, Promyelocytic, Acute; MAP Kinase Signaling System; Myeloid Cells; NADPH Oxidases; Oxidative Stress; Oxides; Reactive Oxygen Species | 2009 |
Beneficial and adverse effects of molecularly targeted therapies for acute promyelocytic leukemia in central nervous system.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Central Nervous System Neoplasms; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Tretinoin | 2009 |
[Efficacy of arsenic trioxide for acute promyelocytic leukemia: a systematic review and meta-analysis].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides | 2009 |
Acute promyelocytic leukemia in childhood.
Topics: Anthracyclines; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Humans; Leukemia, Promyelocytic, Acute; Oxides; Prognosis; Translocation, Genetic; Tretinoin | 2009 |
[Arsenic trioxide in combination with all-trans retinoic acid for acute promyelocytic leukemia: a systematic review and meta-analysis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome; Tretinoin | 2009 |
Acute promyelocytic leukemia: what are the treatment options?
Topics: Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Promyelocytic, Acute; Oxides; Remission Induction; Secondary Prevention; Tretinoin | 2010 |
Signal transduction pathways and transcription factors triggered by arsenic trioxide in leukemia cells.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Reactive Oxygen Species; Signal Transduction; Transcription Factors | 2010 |
Acute promyelocytic leukemia: a paradigm for differentiation therapy.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Dyspnea; Fever; Gene Expression Regulation, Leukemic; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Models, Biological; Neoplasm, Residual; Oncogene Proteins, Fusion; Oxides; Transcription, Genetic; Treatment Outcome; Tretinoin | 2010 |
Arsenic trioxide as a treatment for myelodysplastic syndrome.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; DNA-Binding Proteins; Drug Therapy, Combination; Humans; Leukemia, Promyelocytic, Acute; MDS1 and EVI1 Complex Locus Protein; Multicenter Studies as Topic; Myelodysplastic Syndromes; Oxides; Proto-Oncogenes; Salvage Therapy; Thalidomide; Transcription Factors | 2006 |
The impact of molecularly targeted therapies upon the understanding of leukemogenesis and the role of hematopoietic stem cell transplantation in acute promyelocytic leukemia.
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Survival; Cell Transformation, Neoplastic; Glutamates; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Promyelocytic, Acute; Myeloid Progenitor Cells; Neoplastic Stem Cells; Nuclear Proteins; Oxides; Prodrugs; Promyelocytic Leukemia Protein; Transcription Factors; Tretinoin; Tumor Suppressor Proteins | 2010 |
Modern approaches to treating acute promyelocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Tretinoin | 2011 |
Differentiation syndrome in patients with acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Glucocorticoids; Humans; Leukemia, Promyelocytic, Acute; Leukocyte Count; Oxides; Risk Factors; Syndrome; Time Factors; Tretinoin | 2012 |
The efficacy and safety of arsenic trioxide with or without all-trans retinoic acid for the treatment of acute promyelocytic leukemia: a meta-analysis.
Topics: Adolescent; Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Clinical Trials as Topic; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome; Tretinoin; Young Adult | 2011 |
Advances in therapies for acute promyelocytic leukemia.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cell Differentiation; Clinical Trials as Topic; Consolidation Chemotherapy; Cytarabine; Disease-Free Survival; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Multicenter Studies as Topic; Oncogene Proteins, Fusion; Oxides; Risk; Salvage Therapy; Tretinoin | 2011 |
[All-trans retinoic acid and arsenic trioxide: their molecular mechanisms of action and updated clinical progress in APL therapy].
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Molecular Targeted Therapy; Oxides; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Tretinoin | 2011 |
Treatment of acute promyelocytic leukemia without cytotoxic chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Treatment Outcome; Tretinoin | 2011 |
Acute promyelocytic leukemia can be treated successfully without cytotoxic chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Treatment Outcome; Tretinoin | 2011 |
Impact of arsenic trioxide in the treatment of acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Remission Induction; Treatment Outcome | 2012 |
Arsenic trioxide in acute promyelocytic leukemia: potion not poison.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides | 2011 |
Curing APL through PML/RARA degradation by As2O3.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Oxides; Sumoylation; Treatment Outcome | 2012 |
Current treatment strategy of acute promyelocytic leukemia.
Topics: Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cytarabine; Humans; Leukemia, Promyelocytic, Acute; Oxides; Prognosis; Secondary Prevention; Survival Rate; Tretinoin | 2011 |
Pathogenesis and treatment of leukemia: an Asian perspective.
Topics: Arsenic Trioxide; Arsenicals; Asian People; Cell Proliferation; Humans; Leukemia; Leukemia, Large Granular Lymphocytic; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Tretinoin | 2012 |
A new era for an ancient drug: arsenic trioxide and Hedgehog signaling.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Neoplasms; Cerebellar Neoplasms; Hedgehog Proteins; Humans; Leukemia, Promyelocytic, Acute; Medulloblastoma; Oncogene Proteins; Oxides; Sarcoma, Ewing | 2012 |
How to manage acute promyelocytic leukemia.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cell Transformation, Neoplastic; Central Nervous System Neoplasms; Consolidation Chemotherapy; Drug Synergism; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Oxides; Recurrence; Tretinoin | 2012 |
Arsenic trioxide for management of acute promyelocytic leukemia: current evidence on its role in front-line therapy and recurrent disease.
Topics: Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Tretinoin | 2012 |
Bleeding and thrombosis in acute promyelocytic leukemia.
Topics: Antifibrinolytic Agents; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blood Coagulation Tests; Clinical Trials as Topic; Combined Modality Therapy; Cysteine Endopeptidases; Disseminated Intravascular Coagulation; Factor VIIa; Factor VIII; Fibrinogen; Fibrinolysis; Hemorrhage; Heparin; Humans; Leukemia, Promyelocytic, Acute; Multicenter Studies as Topic; Neoplasm Proteins; Oxides; Plasma; Platelet Count; Platelet Transfusion; Recombinant Proteins; Thromboplastin; Thrombosis; Treatment Failure; Tretinoin | 2012 |
Targeted therapy: The new lease on life for acute promyelocytic leukemia, and beyond.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Core Binding Factor Alpha 2 Subunit; Fusion Proteins, bcr-abl; Hematopoietic Stem Cells; Humans; Leukemia, Promyelocytic, Acute; Molecular Targeted Therapy; Oncogene Proteins, Fusion; Oxides; RUNX1 Translocation Partner 1 Protein; Translocation, Genetic; Tretinoin; Tumor Cells, Cultured | 2012 |
Provocative pearls in diagnosing and treating acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Arsenic Trioxide; Arsenicals; Biopsy, Fine-Needle; Bone Marrow; Clinical Trials as Topic; Dexamethasone; Granulocyte Precursor Cells; Humans; Leukemia, Promyelocytic, Acute; Oxides; Practice Guidelines as Topic; Prognosis; Pulmonary Edema; Remission Induction; Respiratory Insufficiency; Tretinoin | 2012 |
Arsenic trioxide: an ancient drug revived.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Myeloid; Leukemia, Promyelocytic, Acute; Multiple Myeloma; Oxides; Reactive Oxygen Species | 2012 |
Mechanisms of action of arsenic trioxide.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides | 2002 |
Liposomal-all-trans-retinoic acid in treatment of acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Clinical Trials as Topic; Drug Carriers; Histone Deacetylase Inhibitors; Humans; Leukemia, Promyelocytic, Acute; Liposomes; Oxides; Tretinoin | 2002 |
Management of acute promyelocytic leukemia.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Daunorubicin; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Promyelocytic, Acute; Oxides; Remission Induction; Tretinoin | 2002 |
How acute promyelocytic leukaemia revived arsenic.
Topics: Animals; Arsenic Trioxide; Arsenicals; Cell Differentiation; China; Europe; Gene Expression Regulation, Neoplastic; History, 15th Century; History, 16th Century; History, 18th Century; History, 20th Century; History, 21st Century; History, Ancient; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Receptors, Retinoic Acid; Transcription Factors; Tumor Suppressor Proteins | 2002 |
Arsenic trioxide: acute promyelocytic leukemia and beyond.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Cell Differentiation; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species | 2002 |
Current study of APL treatment in China.
Topics: Animals; Antineoplastic Agents; Arsenicals; China; Humans; Leukemia, Promyelocytic, Acute; Remission Induction; Treatment Outcome | 2002 |
[A review of the research on malignant hemopathies treated with arsenium-containing Chinese drugs].
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Humans; Leukemia; Leukemia, Promyelocytic, Acute; Materia Medica; Oxides; Sulfides; Tumor Cells, Cultured | 2000 |
[Research advances on effect of arsenic trioxide on tumor].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Gene Expression; Gene Expression Profiling; Humans; Leukemia, Promyelocytic, Acute; Oxides | 2002 |
Arsenic trioxide (trisenox) therapy for acute promyelocytic leukemia in the setting of hematopoietic stem cell transplantation.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Combined Modality Therapy; Europe; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Regression, Spontaneous; Oxides; Practice Guidelines as Topic; Risk Factors; Tretinoin; United States | 2003 |
Treatment of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide: review of clinical and basic studies.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Hematologic Neoplasms; Humans; Leukemia, Promyelocytic, Acute; Oxides | 2003 |
[Relationship of arsenic trioxide and tumor cell apoptosis].
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; HeLa Cells; Humans; Leukemia, Promyelocytic, Acute; Oxides | 2003 |
[Expanding possibilities, strategic considerations, and novel methods in the diagnosis and chemotherapy of adult acute myeloid leukemia].
Topics: Adult; Anthracyclines; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cytarabine; Drug Resistance, Neoplasm; Gene Expression Profiling; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Oligonucleotide Array Sequence Analysis; Oxides; Palliative Care; Prognosis; Remission Induction; Tretinoin | 2003 |
The PML-RARalpha fusion protein and targeted therapy for acute promyelocytic leukemia.
Topics: Arsenic Trioxide; Arsenicals; Cell Differentiation; Drug Delivery Systems; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Tretinoin | 2004 |
Acute promyelocytic leukemia as a paradigm for targeted therapy.
Topics: Arsenic Trioxide; Arsenicals; Drug Delivery Systems; Humans; Leukemia, Promyelocytic, Acute; Oxides; Treatment Outcome; Tretinoin | 2004 |
[Advances in the study on antineoplastic action of realgar].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Humans; K562 Cells; Leukemia; Leukemia, Promyelocytic, Acute; Materia Medica; Oxides; Tumor Cells, Cultured | 2004 |
An efficient therapeutic approach to patients with acute promyelocytic leukemia using a combination of arsenic trioxide with low-dose all-trans retinoic acid.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Recurrence; Remission Induction; Treatment Outcome; Tretinoin | 2004 |
Acute promyelocytic leukemia: recent advances in therapy and molecular basis of response to arsenic therapies.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Humans; Leukemia, Promyelocytic, Acute; Models, Biological; Oncogene Proteins, Fusion; Oxides; Reactive Oxygen Species | 2005 |
Arsenic trioxide as a treatment for myelodysplastic syndrome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Cell Division; Clinical Trials as Topic; Dexamethasone; DNA-Binding Proteins; Drug Therapy, Combination; Glutathione; Hematologic Neoplasms; Humans; Leukemia, Promyelocytic, Acute; MDS1 and EVI1 Complex Locus Protein; Multicenter Studies as Topic; Myelodysplastic Syndromes; Neovascularization, Pathologic; Oxides; Proto-Oncogenes; Transcription Factors | 2005 |
Arsenic trioxide therapy in acute promyelocytic leukemia and beyond: from bench to bedside.
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle; Humans; Leukemia, Promyelocytic, Acute; Oxides | 2004 |
Arsenic trioxide: an anti cancer missile with multiple warheads.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Inducing Factor; Arsenic Trioxide; Arsenicals; Chromatin Assembly and Disassembly; DNA Fragmentation; Flavoproteins; Humans; Leukemia, Promyelocytic, Acute; Membrane Proteins; Mitosis; Oxides; Tumor Suppressor Protein p53 | 2005 |
[Pharmacological and clinical properties of arsenic trioxide (Trisenox) for relapse or refractory acute promyelocytic leukemia therapy].
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Mice; Oxides | 2005 |
Arsenic trioxide in the treatment of acute promyelocytic leukemia. A review of current evidence.
Topics: Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides | 2005 |
Acute promyelocytic leukemia: a model of molecular target based therapy.
Topics: Arsenic Trioxide; Arsenicals; Cell Differentiation; Drug Delivery Systems; Drug Synergism; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin | 2005 |
Treatment concepts of acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Hemorrhage; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Neoplasm, Residual; Oncogene Proteins, Fusion; Oxides; Prognosis; Recurrence; Risk Factors; Stem Cell Transplantation; Thrombosis; Translocation, Genetic; Transplantation, Homologous; Tretinoin | 2005 |
Strategies for the treatment of acute promyelocytic leukemia.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Treatment Outcome; Tretinoin | 2006 |
Hypoxia inducible factor-1alpha and leukemic cell differentiation.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Transformation, Neoplastic; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Leukemia; Leukemia, Promyelocytic, Acute; Oxides | 2006 |
Treatment of acute promyelocytic leukemia with gemtuzumab ozogamicin.
Topics: Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Gemtuzumab; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides | 2006 |
Arsenic derivatives in hematologic malignancies: a role beyond acute promyelocytic leukemia?
Topics: Administration, Oral; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Hematologic Neoplasms; Humans; Leukemia, Promyelocytic, Acute; Oxides; Remission Induction; Treatment Outcome | 2006 |
[Therapeutic strategies for patients with relapsed acute promyelocytic leukemia].
Topics: Aminoglycosides; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzoates; Clinical Trials as Topic; Combined Modality Therapy; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Hydroxamic Acids; Leukemia, Promyelocytic, Acute; Oxides; Practice Guidelines as Topic; Recurrence; Remission Induction; Tetrahydronaphthalenes; Tretinoin | 2006 |
Recent advances in the treatment of APL.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Diagnosis, Differential; History, 20th Century; History, 21st Century; Humans; Leukemia, Promyelocytic, Acute; Oxides; Translocation, Genetic | 2006 |
Optimizing treatment for elderly patients with acute promyelocytic leukemia: is it time to replace chemotherapy with all-trans retinoic acid and arsenic trioxide?
Topics: Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Drug Therapy, Combination; Humans; Leukemia, Promyelocytic, Acute; Oxides; Prognosis; Tretinoin | 2006 |
Arsenic trioxide and acute promyelocytic leukemia: clinical and biological.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Humans; Leukemia, Promyelocytic, Acute; Oxides; Treatment Outcome | 2007 |
The design of selective and non-selective combination therapy for acute promyelocytic leukemia.
Topics: Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Drug Administration Schedule; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin | 2007 |
Relationship between cytokines and leukocytosis in patients with APL induced by all-trans retinoic acid or arsenic trioxide.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cytokines; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Oxides; Tretinoin | 2006 |
[Arsenic trioxide: "a successful poison" in patients with acute promyelocytic leukemia].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Drug Synergism; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Remission Induction; Risk Factors; Time Factors | 2007 |
Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin | 2007 |
Treatment of relapsed or refractory acute promyelocytic leukemia.
Topics: Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; fms-Like Tyrosine Kinase 3; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Promyelocytic, Acute; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Oxides; Transplantation, Autologous; Transplantation, Homologous | 2007 |
Acute promyelocytic leukemia: new issues on pathogenesis and treatment response.
Topics: Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Models, Biological; Oncogene Proteins, Fusion; Oxides; Tretinoin | 2007 |
[Arsenic trioxide as a therapeutic agent in APL].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides | 2007 |
Arsenic trioxide and neuroblastoma cytotoxicity.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Brain Neoplasms; Cell Death; Cell Differentiation; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Neuroblastoma; Oxides | 2007 |
Leukemia, an effective model for chemical biology and target therapy.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Benzamides; Dasatinib; Growth Inhibitors; Humans; Imatinib Mesylate; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Promyelocytic, Acute; Oxides; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Tretinoin | 2007 |
PML-RARalpha inhibitors (ATRA, tamibaroten, arsenic troxide) for acute promyelocytic leukemia.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzoates; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Oxides; Tetrahydronaphthalenes; Tretinoin | 2007 |
New data with arsenic trioxide in leukemias and myelodysplastic syndromes.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Humans; Leukemia, Promyelocytic, Acute; Myelodysplastic Syndromes; Oxides | 2007 |
Acute promyelocytic leukemia: from highly fatal to highly curable.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; History, 20th Century; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin | 2008 |
[Progresses in the study of hematology in China, 1997].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Myelomonocytic, Acute; Leukemia, Promyelocytic, Acute; Oxides; Thrombophlebitis | 1997 |
Relapsed acute promyelocytic leukemia previously treated with all-trans retinoic acid: clinical experience with a new synthetic retinoid, Am-80.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenicals; Benzoates; Biomarkers, Tumor; Cheilitis; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Hypercholesterolemia; Hypertriglyceridemia; Leukemia, Promyelocytic, Acute; Leukocytosis; Male; Middle Aged; Neoplasm Proteins; Oncogene Proteins, Fusion; Pilot Projects; Recurrence; Remission Induction; Salvage Therapy; Tetrahydronaphthalenes; Treatment Outcome; Tretinoin; Tumor Cells, Cultured | 1998 |
[Arsenic trioxide, a new drug for the treatment of acute promyelocytic leukemia resistant to tretinoine].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin | 1999 |
[Arsenic efficient in acute promyelocytic leukemia].
Topics: Antineoplastic Agents; Arsenicals; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Tretinoin | 1999 |
Arsenic-induced apoptosis in malignant cells in vitro.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspases; Down-Regulation; Glutathione; Growth Inhibitors; Hematopoietic Stem Cells; Humans; Leukemia; Leukemia, B-Cell; Leukemia, Promyelocytic, Acute; Leukocytes, Mononuclear; Neuroblastoma; Oxides; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured | 2000 |
[Recent advances of differentiation-inducing therapy for leukemia].
Topics: Animals; Arsenic Trioxide; Arsenicals; Cell Differentiation; Histone Deacetylase Inhibitors; Leukemia, Promyelocytic, Acute; Oxides; Remission Induction; Transcription, Genetic; Tretinoin | 2000 |
Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: an useful salvage therapy.
Topics: Acute Kidney Injury; Antineoplastic Agents; Apoptosis; Arrhythmias, Cardiac; Arsenic Trioxide; Arsenicals; Cell Differentiation; Chemical and Drug Induced Liver Injury; Drug Evaluation; Drug Screening Assays, Antitumor; Gastrointestinal Neoplasms; Humans; Leukemia, Promyelocytic, Acute; Life Tables; Medicine, Chinese Traditional; Mitochondria; Models, Biological; Neoplasm Proteins; Neoplastic Stem Cells; Neuromuscular Diseases; Oncogene Proteins, Fusion; Oxides; Remission Induction; Salvage Therapy; Survival Analysis; Treatment Outcome; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2000 |
Arsenicals and inhibitors of histone deacetylase as anticancer therapy.
Topics: Acetylation; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; China; Chromatin; Drug Evaluation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gastrointestinal Diseases; Histone Deacetylase Inhibitors; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Melarsoprol; Neoplasm Proteins; Neoplasms; Nervous System Diseases; Oxides; Phenylbutyrates; Protein Processing, Post-Translational; Salvage Therapy; Tretinoin | 1999 |
Arsenicals in hematologic cancers.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Drug Evaluation, Preclinical; Hematologic Neoplasms; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tumor Cells, Cultured | 2000 |
Old, new drugs and new, new drugs for the new millennium.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzamides; Clinical Trials as Topic; Female; Forecasting; Humans; Imatinib Mesylate; Leukemia, Promyelocytic, Acute; Male; Oxides; Piperazines; Prognosis; Pyrimidines; Sensitivity and Specificity; Treatment Outcome | 2000 |
Differentiating agents in pediatric malignancies: all-trans-retinoic acid and arsenic in acute promyelocytic leukemia.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Child; Disease Models, Animal; Drug Therapy, Combination; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin | 2000 |
Acute progranulocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Clinical Trials as Topic; Cytarabine; Humans; Leukemia, Promyelocytic, Acute; Neoplasm, Residual; Oxides; Prognosis; Salvage Therapy; Survival Analysis; Tretinoin | 2001 |
Treatment of acute promyelocytic leukemia with arsenic compounds: in vitro and in vivo studies.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides | 2001 |
Clinical experience of arsenic trioxide in relapsed acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Recurrence, Local; Oxides | 2001 |
Risk/benefit profile of arsenic trioxide.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Recurrence, Local; Oxides; Risk Assessment | 2001 |
Histone deacetylases and transcriptional therapy with their inhibitors.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Histone Deacetylase Inhibitors; Humans; Leukemia, Promyelocytic, Acute; Mice; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Transcription, Genetic; Tretinoin | 2001 |
Arsenic compounds as anticancer agents.
Topics: Antineoplastic Agents; Apoptosis; Arsenicals; Cell Differentiation; Chlorides; Humans; Leukemia, Promyelocytic, Acute; Neoplasms; Tumor Cells, Cultured | 2001 |
APL, a model disease for cancer therapies?
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Nucleus; Cellular Senescence; Humans; Inclusion Bodies; Leukemia, Promyelocytic, Acute; Multigene Family; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Tretinoin | 2001 |
Arsenic trioxide, a therapeutic agent for APL.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Disease Models, Animal; Drug Synergism; Humans; Leukemia, Promyelocytic, Acute; Mice; Mitochondria; Neoplasm Proteins; Nuclear Proteins; Oncogene Proteins, Fusion; Oxides; Promyelocytic Leukemia Protein; Remission Induction; Survival Rate; Transcription Factors; Tretinoin; Tumor Suppressor Proteins | 2001 |
Pathways of retinoic acid- or arsenic trioxide-induced PML/RARalpha catabolism, role of oncogene degradation in disease remission.
Topics: Animals; Arsenic Trioxide; Arsenicals; Binding Sites; Caspases; Cell Differentiation; Cysteine Endopeptidases; Humans; Leukemia, Promyelocytic, Acute; Multienzyme Complexes; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Proteasome Endopeptidase Complex; Protein Structure, Tertiary; Remission Induction; Tretinoin | 2001 |
Maturation sensitive and resistant t(15;17) NB4 cell lines as tools for APL physiopathology: nomenclature of cells and repertory of their known genetic alterations and phenotypes.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Oxides; Phenotype; Retinoids; Terminology as Topic; Transgenes; Tumor Cells, Cultured | 2001 |
Arsenic trioxide: its role in acute promyelocytic leukemia and potential in other hematologic malignancies.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Hematologic Neoplasms; Humans; Leukemia, Promyelocytic, Acute; Oxides; Survival Analysis | 2001 |
Acute promyelocytic leukemia: evolving therapeutic strategies.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Remission Induction; Tretinoin | 2002 |
Advances in the treatment of relapsed acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Transplantation; Combined Modality Therapy; Humans; Leukemia, Promyelocytic, Acute; Neoplasm, Residual; Oxides; Recurrence; Tretinoin | 2002 |
Differentiation and apoptosis induction therapy in acute promyelocytic leukaemia.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenicals; Cell Differentiation; Hemorrhagic Disorders; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Neoplasm, Residual; Oncogene Proteins, Fusion; Tretinoin | 2000 |
Advances in the management of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Hematologic Neoplasms; Humans; Leukemia, Promyelocytic, Acute; Multiple Myeloma; Myelodysplastic Syndromes; Oxides; Recurrence; Remission Induction; Survival Analysis; Treatment Outcome; Tretinoin | 2002 |
Molecular targets of arsenic trioxide in malignant cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Glutathione; Growth Inhibitors; Humans; Leukemia, Promyelocytic, Acute; Multiple Myeloma; Myelodysplastic Syndromes; Oxides | 2002 |
Introduction.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Remission Induction; Tretinoin | 2002 |
Arsenic trioxide: mechanisms of action.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Division; Glutathione; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Neovascularization, Pathologic; Oncogene Proteins, Fusion; Oxides; Recurrence | 2002 |
Established practice in the treatment of patients with acute promyleocytic leukemia and the introduction of arsenic trioxide as a novel therapy.
Topics: Antineoplastic Agents; Antineoplastic Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Prognosis; Randomized Controlled Trials as Topic; Recurrence | 2002 |
Expanding the use of arsenic trioxide: leukemias and beyond.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Humans; Leukemia; Leukemia, Promyelocytic, Acute; Multiple Myeloma; Neoplasms; Oxides | 2002 |
How retinoic acid and arsenic transformed acute promyelocytic leukemia therapy.
Topics: Arsenic; Arsenic Trioxide; Humans; In Situ Hybridization, Fluorescence; Leukemia, Promyelocytic, Acute; Nuclear Proteins; Promyelocytic Leukemia Protein; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Transcription Factors; Translocation, Genetic; Tretinoin; Tumor Suppressor Proteins | 2022 |
PI3K/Akt/mTOR Signaling Pathway and the Biphasic Effect of Arsenic in Carcinogenesis.
Topics: Animals; Arsenic; Carcinogenesis; Humans; Leukemia, Promyelocytic, Acute; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; TOR Serine-Threonine Kinases | 2018 |
The simpler, the better: oral arsenic for acute promyelocytic leukemia.
Topics: Administration, Oral; Antineoplastic Agents; Arsenic; Arsenic Trioxide; Chemical and Drug Induced Liver Injury; China; Diarrhea; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis | 2019 |
Arsenic. Can this toxic metalloid sustain life?
Topics: Animals; Arsenic; Humans; Leukemia, Promyelocytic, Acute | 2013 |
Acute promyelocytic leukemia in children and adolescents.
Topics: Antineoplastic Agents; Arsenic; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Leukemia, Promyelocytic, Acute; Survival Rate; Translocation, Genetic; Tretinoin | 2014 |
[Pathways of arsenic uptake in prokaryotic and eukaryotic cells].
Topics: Animals; Aquaporins; Arsenic; Biological Transport; Environmental Restoration and Remediation; Escherichia coli; Eukaryotic Cells; Humans; Leukemia, Promyelocytic, Acute; Parasitic Diseases; Plants; Prokaryotic Cells; Saccharomyces cerevisiae; Soil Pollutants | 2010 |
Arsenic in the treatment of newly diagnosed acute promyelocytic leukemia: current status and future research direction.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic; Humans; Leukemia, Promyelocytic, Acute; Survival Analysis; Tretinoin | 2011 |
The cell biology of disease: Acute promyelocytic leukemia, arsenic, and PML bodies.
Topics: Animals; Antineoplastic Agents; Arsenic; Humans; Leukemia, Promyelocytic, Acute; Mice; Oncogene Proteins, Fusion; Oxidative Stress; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Small Ubiquitin-Related Modifier Proteins; Tretinoin | 2012 |
[Molecular basis of arsenic action in promyelocytic leukemia cells].
Topics: Animals; Apoptosis; Arsenic; Cell Cycle; Humans; Leukemia, Promyelocytic, Acute; Mutation; Neoplasm Proteins; Neutrophils; Nuclear Proteins; Promyelocytic Leukemia Protein; Receptors, Retinoic Acid; Transcription Factors; Tretinoin; Tumor Suppressor Proteins | 2002 |
Retinoic acid and arsenic for treating acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Arsenic; Drug Therapy, Combination; Humans; Leukemia, Promyelocytic, Acute; Tretinoin | 2005 |
Retinoic acid and arsenic: towards oncogene-targeted treatments of acute promyelocytic leukaemia.
Topics: Animals; Arsenic; Artificial Gene Fusion; Cell Transformation, Neoplastic; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Nuclear Proteins; Promyelocytic Leukemia Protein; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Transcription Factors; Translocation, Genetic; Tretinoin; Tumor Suppressor Proteins | 1997 |
[Arsenic and retinoic acid, towards targeted treatments of acute promyelocytic leukemia?].
Topics: Antineoplastic Agents; Arsenic; Humans; Leukemia, Promyelocytic, Acute; Tretinoin | 1998 |
[Arsenic and retinoic acid, toward targeted treatments of acute promyelocytic anemia?].
Topics: Antineoplastic Agents; Arsenic; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Nuclear Proteins; Promyelocytic Leukemia Protein; Receptors, Retinoic Acid; Recombinant Fusion Proteins; Retinoic Acid Receptor alpha; Transcription Factors; Translocation, Genetic; Tretinoin; Tumor Suppressor Proteins | 1998 |
Mouse models of acute promyelocytic leukemia.
Topics: Animals; Antineoplastic Agents; Arsenic; Chromosome Deletion; Disease Models, Animal; Leukemia, Promyelocytic, Acute; Mice; Models, Biological; Mutation; Neoplasm Proteins; Oncogene Proteins, Fusion; Tretinoin | 2001 |
76 trial(s) available for arsenic and Leukemia, Promyelocytic, Acute
| Article | Year |
|---|---|
The comparison of plasma arsenic concentration and urinary arsenic excretion during treatment with Realgar-Indigo naturalis formula and arsenic trioxide in children with acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Arsenic; Arsenic Trioxide; Arsenicals; Child; Drugs, Chinese Herbal; Humans; Leukemia, Promyelocytic, Acute; Tretinoin | 2022 |
An effective and chemotherapy-free strategy of all-trans retinoic acid and arsenic trioxide for acute promyelocytic leukemia in all risk groups (APL15 trial).
Topics: Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Treatment Outcome; Tretinoin | 2022 |
Long-term outcome of children with acute promyelocytic leukemia: a randomized study of oral versus intravenous arsenic by SCCLG-APL group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic; Arsenic Trioxide; Arsenicals; Child; Humans; Leukemia, Promyelocytic, Acute; Oxides; Treatment Outcome; Tretinoin | 2023 |
PML-RARA monitoring in newly diagnosed acute promyelocytic leukemia treated with an entirely oral chemotherapy-free postremission approach: A multiple institution experience.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenicals; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oncogene Proteins, Fusion; Retrospective Studies; Tretinoin | 2020 |
[Therapies for newly diagnosed acute promyelocytic leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Japan; Leukemia, Promyelocytic, Acute; Oxides; Prospective Studies; Treatment Outcome; Tretinoin | 2020 |
Arsenic Trioxide Consolidation Allows Anthracycline Dose Reduction for Pediatric Patients With Acute Promyelocytic Leukemia: Report From the Children's Oncology Group Phase III Historically Controlled Trial AAML0631.
Topics: Adolescent; Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Consolidation Chemotherapy; Cytarabine; Disease-Free Survival; Female; Historically Controlled Study; Humans; Leukemia, Promyelocytic, Acute; Male; Mercaptopurine; Methotrexate; Oxides; Young Adult | 2017 |
Causes and prognostic factors for early death in patients with acute promyelocytic leukemia treated with single-agent arsenic trioxide.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arsenic Trioxide; Arsenicals; Child; Creatinine; Female; Fibrin Fibrinogen Degradation Products; Hemorrhage; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides | 2017 |
Characteristics of fibrinolytic disorders in acute promyelocytic leukemia.
Topics: Adult; Aged; Arsenic Trioxide; Arsenicals; Blood Coagulation Disorders; Blood Proteins; Female; Fibrinolysis; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Proteins; Oxides | 2018 |
Phase 2 study of arsenic trioxide followed by autologous hematopoietic cell transplantation for relapsed acute promyelocytic leukemia.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cytarabine; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Oncogene Proteins, Fusion; Oxides; Remission Induction; Transcription, Genetic; Transplantation, Autologous; Young Adult | 2013 |
[Clinical investigation of homoharringtonine in combination with all-transretinoic acid and arsenic trioxide for acute promyelocytic leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Harringtonines; Homoharringtonine; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Retrospective Studies; Treatment Outcome; Tretinoin | 2013 |
Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Consolidation Chemotherapy; Disease-Free Survival; Female; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Male; Middle Aged; Neutropenia; Oxides; Thrombocytopenia; Tretinoin; Young Adult | 2013 |
Characteristics and prognosis analysis of additional chromosome abnormalities in newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide as the front-line therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Chromosome Aberrations; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxides; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Translocation, Genetic; Tretinoin; Young Adult | 2013 |
Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial.
Topics: Administration, Intravenous; Administration, Oral; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Drugs, Chinese Herbal; Female; Fever; Follow-Up Studies; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Liver; Maintenance Chemotherapy; Male; Middle Aged; Oxides; Remission Induction; Sulfides; Treatment Outcome; Tretinoin; Young Adult | 2013 |
Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow; Female; fms-Like Tyrosine Kinase 3; Humans; Karyotype; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Mutation; Oncogene Proteins, Fusion; Oxides; Prognosis; Treatment Outcome; Young Adult | 2014 |
Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy.
Topics: Adult; Aged; Aminoglycosides; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Disease-Free Survival; Dogs; Female; Gemtuzumab; Humans; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Male; Mercaptopurine; Methotrexate; Middle Aged; Oncogene Proteins, Fusion; Oxides; Platelet Count; Remission Induction; Risk; Treatment Outcome; Tretinoin; Young Adult | 2014 |
Arsenic trioxide and mannitol for the treatment of acute promyelocytic leukemia relapse in the central nervous system.
Topics: Adolescent; Adult; Arsenic Trioxide; Arsenicals; Blood-Brain Barrier; Central Nervous System Neoplasms; Child; Female; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Male; Mannitol; Middle Aged; Oxides; Recurrence; Remission Induction; Young Adult | 2014 |
Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis.
Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Autografts; Female; Graft Survival; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Peripheral Blood Stem Cell Transplantation | 2015 |
Randomized phase III trial of retinoic acid and arsenic trioxide versus retinoic acid and chemotherapy in patients with acute promyelocytic leukemia: health-related quality-of-life outcomes.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Prospective Studies; Quality of Life; Tretinoin | 2014 |
Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukapheresis; Leukemia, Promyelocytic, Acute; Leukocyte Count; Leukocytosis; Male; Middle Aged; Oxides; Retrospective Studies; Survival Rate; Tretinoin | 2015 |
Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzoates; Biomarkers, Tumor; Cardiovascular Diseases; Cell Differentiation; Combined Modality Therapy; Consolidation Chemotherapy; Disease-Free Survival; Drug Resistance, Neoplasm; Febrile Neutropenia; Female; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oncogene Proteins, Fusion; Oxides; Recurrence; Remission Induction; Salvage Therapy; Tetrahydronaphthalenes; Tretinoin | 2015 |
Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Denmark; Female; Humans; Idarubicin; Intention to Treat Analysis; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Leukocyte Count; Male; Middle Aged; New Zealand; Oncogene Proteins, Fusion; Oxides; Quality of Life; Real-Time Polymerase Chain Reaction; Time Factors; Treatment Outcome; Tretinoin; United Kingdom; Young Adult | 2015 |
[Efficacy Analysis of Arsenic Trioxide Combined with All Trans Retinoic Acid for Acute Promyelocytic Leukemia].
Topics: Arsenic Trioxide; Arsenicals; Drug Therapy, Combination; Humans; Leukemia, Promyelocytic, Acute; Oxides; Remission Induction; Tretinoin | 2015 |
Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Australia; Consolidation Chemotherapy; Female; Humans; Leukemia, Promyelocytic, Acute; Lymphoma; Male; Middle Aged; Neoplasm Recurrence, Local; Oxides; Remission Induction; Treatment Outcome; Young Adult | 2015 |
Arsenic trioxide-based therapy is suitable for patients with psoriasis-associated acute promyelocytic leukemia - A retrospective clinical study.
Topics: Adolescent; Adult; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Psoriasis; Retrospective Studies; Survival Rate | 2016 |
PML-RARα kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy.
Topics: Adolescent; Adult; Aged; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Female; fms-Like Tyrosine Kinase 3; Humans; Induction Chemotherapy; Italy; Kinetics; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Mutation; Oncogene Proteins, Fusion; Oxides; Prognosis; Tretinoin; Young Adult | 2016 |
Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Prospective Studies; Risk Factors; Treatment Outcome; Tretinoin; Young Adult | 2017 |
Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Prognosis; Remission Induction; Survival Rate | 2008 |
Use of all-trans retinoic acid in combination with arsenic trioxide for remission induction in patients with newly diagnosed acute promyelocytic leukemia and for consolidation/maintenance in CR patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Remission Induction; Survival Rate; Time Factors; Tretinoin | 2009 |
Arsenic trioxide in recurrent urothelial cancer: a cancer and leukemia group B phase II trial (CALGB 99903).
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Recurrence; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms; Urologic Neoplasms; Urothelium | 2009 |
Single-agent arsenic trioxide in the treatment of children with newly diagnosed acute promyelocytic leukemia.
Topics: Adolescent; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Disease-Free Survival; Female; Humans; Karyotyping; Leukemia, Promyelocytic, Acute; Male; Neutropenia; Oxides; Remission Induction; Time Factors | 2010 |
Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxides; Prognosis; Remission Induction; Survival Rate; Treatment Outcome; Tretinoin; Young Adult | 2010 |
Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data.
Topics: Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Female; Follow-Up Studies; Hair; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Nails; Oxides; Recurrence; Remission Induction; Time Factors; Treatment Outcome | 2010 |
Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Mercaptopurine; Methotrexate; Middle Aged; North America; Oxides; Survival Analysis; Treatment Outcome; Tretinoin; Young Adult | 2010 |
[Recurrences of acute promyelocytic leukemia in children: experience with arsenic trioxide therapy and autologous hematopoietic cell transplantation].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Combined Modality Therapy; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia, Promyelocytic, Acute; Oxides; Remission Induction; Secondary Prevention; Transplantation Conditioning; Transplantation, Autologous | 2010 |
Effect of arsenic trioxide on the treatment of children with newly diagnosed acute promyelocytic leukemia in China.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; China; Cohort Studies; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Remission Induction; Survival Analysis; Tretinoin | 2011 |
Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Disease-Free Survival; Female; Follow-Up Studies; Humans; Iran; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Remission Induction; Survival Analysis | 2011 |
Oral arsenic trioxide-based maintenance regimens for first complete remission of acute promyelocytic leukemia: a 10-year follow-up study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Cytarabine; Daunorubicin; Disease-Free Survival; Dyspepsia; Female; Follow-Up Studies; Headache; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Recurrence; Remission Induction; Time Factors; Treatment Outcome; Tretinoin | 2011 |
The early addition of arsenic trioxide versus high-dose arabinoside is more effective and safe as consolidation chemotherapy for risk-tailored patients with acute promyelocytic leukemia: multicenter experience.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Tretinoin; Young Adult | 2012 |
Allogeneic stem cell transplantation for advanced acute promyelocytic leukemia in the ATRA and ATO era.
Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oncogene Proteins, Fusion; Oxides; Retrospective Studies; Stem Cell Transplantation; Survival Rate; Transplantation, Homologous; Tretinoin | 2012 |
All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4).
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Female; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Treatment Outcome; Tretinoin; Young Adult | 2012 |
Arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: a single center experience.
Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cause of Death; Child; Disease-Free Survival; Drug Monitoring; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Male; Middle Aged; Oxides; Remission Induction; Treatment Outcome | 2002 |
Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experience.
Topics: Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Proteins; Neoplasm Recurrence, Local; Oncogene Proteins, Fusion; Oxides; Polymerase Chain Reaction; Remission Induction; Safety; Salvage Therapy; Survival Rate; Treatment Outcome | 2003 |
Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Recurrence; Statistics, Nonparametric; Survival Rate; Treatment Outcome; Tretinoin | 2003 |
Oral arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Remission Induction; Salvage Therapy; Treatment Outcome; Tretinoin | 2003 |
Arsenic speciation in urine from acute promyelocytic leukemia patients undergoing arsenic trioxide treatment.
Topics: Adult; Antineoplastic Agents; Arsenic; Arsenic Trioxide; Arsenicals; Arsenites; Cacodylic Acid; Chromatography, High Pressure Liquid; Humans; Injections, Intravenous; Leukemia, Promyelocytic, Acute; Male; Methylation; Middle Aged; Oxidation-Reduction; Oxides | 2004 |
All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; In Situ Nick-End Labeling; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Prospective Studies; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome; Tretinoin; Tumor Cells, Cultured | 2004 |
[Clinical observation and following up of two administration methods of arsenic trioxide in treatment of acute promyelocytic leukemia].
Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Case-Control Studies; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Leukemia, Promyelocytic, Acute; Male; Oxides; Remission Induction; Treatment Outcome | 2004 |
Comparing two arsenic trioxide administration methods in APL therapy.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Oxides | 2004 |
[Pharmacokinetics of intravenous arsenic trioxide in the treatment of acute promyelocytic leukemia].
Topics: Adolescent; Adult; Arsenic Trioxide; Arsenicals; Female; Hair; Humans; Infusions, Intravenous; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Nails; Oxides; Treatment Outcome; Young Adult | 1997 |
Increased erythropoietin level and reticulocyte count during arsenic trioxide therapy.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Erythropoietin; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Reticulocyte Count | 2005 |
Effects of administration styles of arsenic trioxide on intracellular arsenic concentration, cell differentiation and apoptosis.
Topics: Apoptosis; Arsenic; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line; Drug Administration Schedule; Humans; Intracellular Fluid; Leukemia, Promyelocytic, Acute; Oxides | 2005 |
Arsenic trioxide therapy in relapsed or refractory Japanese patients with acute promyelocytic leukemia: updated outcomes of the phase II study and postremission therapies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow; Female; Humans; Japan; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Recurrence; Remission Induction; Treatment Outcome | 2005 |
Anti-leukemic and anti-angiogenesis efficacy of arsenic trioxide in new cases of acute promyelocytic leukemia.
Topics: Adolescent; Adult; Angiogenesis Inhibitors; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow; Disease Progression; Female; Follow-Up Studies; Humans; Immunohistochemistry; Leukemia, Promyelocytic, Acute; Leukocytosis; Male; Middle Aged; Neovascularization, Pathologic; Oxides; Recurrence; Remission Induction; Survival Rate; Time Factors; Treatment Outcome | 2006 |
Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Partial Thromboplastin Time; Platelet Count; Remission Induction; Survival Analysis; Treatment Outcome | 2006 |
Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia.
Topics: Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Gemtuzumab; Humans; Leukemia, Promyelocytic, Acute; Leukocyte Count; Male; Middle Aged; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Polymerase Chain Reaction; Remission Induction; Tretinoin | 2006 |
Effects of oral arsenic trioxide therapy on QT intervals in patients with acute promyelocytic leukemia: implications for long-term cardiac safety.
Topics: Administration, Oral; Adult; Aged; Arsenic Trioxide; Arsenicals; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Electrocardiography; Electrocardiography, Ambulatory; Female; Heart Conduction System; Heart Rate; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Treatment Outcome | 2006 |
Hepatotoxicity profile of single agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia, its impact on clinical outcome and the effect of genetic polymorphisms on the incidence of hepatotoxicity.
Topics: Adult; Arsenic Trioxide; Arsenicals; Chemical and Drug Induced Liver Injury; Cohort Studies; Disease-Free Survival; Female; Follow-Up Studies; Genetic Predisposition to Disease; Humans; Incidence; Leukemia, Promyelocytic, Acute; Liver; Liver Function Tests; Male; Methylenetetrahydrofolate Reductase (NADPH2); Oxides; Polymorphism, Genetic; Remission Induction; Risk Factors; Survival Rate; Treatment Outcome | 2006 |
Late first relapses in APL treated with all-trans-retinoic acid- and anthracycline- based chemotherapy: the European APL group experience (APL 91 and APL 93 trials).
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Combined Modality Therapy; Europe; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Prognosis; Recurrence; Risk Factors; Treatment Outcome; Tretinoin | 2006 |
Effects of arsenic trioxide administration styles on leukocytosis.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Humans; Infusions, Intravenous; K562 Cells; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Leukocytosis; Oxides | 2006 |
Arrhythmogenic effects of arsenic trioxide in patients with acute promyelocytic leukemia and an electrophysiological study in isolated guinea pig papillary muscles.
Topics: Action Potentials; Animals; Antineoplastic Agents; Antioxidants; Arrhythmias, Cardiac; Arsenic Trioxide; Arsenicals; Butylated Hydroxytoluene; Electrocardiography; Electrophysiology; Guinea Pigs; Humans; Leukemia, Promyelocytic, Acute; Lipid Peroxidation; Long QT Syndrome; Myocardial Contraction; Oxides; Papillary Muscles; Poisons; Reactive Oxygen Species; Tetrodotoxin | 2006 |
[Application of all-trans retinoic acid combining chemotherapy and As4S4 in the maintenance treatment of patients with acute promyelocytic leukemia].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Remission Induction; Sulfides; Treatment Outcome; Tretinoin | 2007 |
Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma.
Topics: Abdominal Pain; Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Constipation; Dermatitis; Dose-Response Relationship, Drug; Female; Headache; Humans; Hyperglycemia; Infusions, Intravenous; Leukemia, Promyelocytic, Acute; Lymphoma; Male; Nausea; Oxides; Pancreatitis; Pneumonia; Recurrence; Time Factors; Vomiting; Water-Electrolyte Balance | 2008 |
Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients.
Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Female; Humans; Leukemia, Promyelocytic, Acute; Leukocyte Count; Male; Metabolic Clearance Rate; Middle Aged; Neutrophils; Oxides; Receptors, Retinoic Acid; Recurrence; Remission Induction; Retinoic Acid Receptor alpha; Survival Rate; Time Factors | 1997 |
New retinoids and arsenic compounds for the treatment of refractory acute promyelocytic leukemia: clinical and basic studies for the next generation.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzoates; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Remission Induction; Retinoids; Tetrahydronaphthalenes; Treatment Outcome; Tumor Cells, Cultured | 1997 |
Relapsed acute promyelocytic leukemia previously treated with all-trans retinoic acid: clinical experience with a new synthetic retinoid, Am-80.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenicals; Benzoates; Biomarkers, Tumor; Cheilitis; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Hypercholesterolemia; Hypertriglyceridemia; Leukemia, Promyelocytic, Acute; Leukocytosis; Male; Middle Aged; Neoplasm Proteins; Oncogene Proteins, Fusion; Pilot Projects; Recurrence; Remission Induction; Salvage Therapy; Tetrahydronaphthalenes; Treatment Outcome; Tretinoin; Tumor Cells, Cultured | 1998 |
Tissue factors on acute promyelocytic leukemia and endothelial cells are differently regulated by retinoic acid, arsenic trioxide and chemotherapeutic agents.
Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blood Coagulation; Daunorubicin; Drug Screening Assays, Antitumor; Endothelium, Vascular; Female; Fibrinolysis; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Thromboplastin; Tretinoin | 1999 |
Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Disease-Free Survival; Drug Monitoring; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Male; Middle Aged; Oxides; Recurrence; Remission Induction; Translocation, Genetic | 1999 |
Long-term survival and prognostic study in acute promyelocytic leukemia treated with all-trans-retinoic acid, chemotherapy, and As2O3: an experience of 120 patients at a single institution.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; Survival Rate; Tretinoin | 1999 |
Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide.
Topics: Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Death, Sudden; Female; Humans; Kinetics; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Recurrence | 2001 |
United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia.
Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Electrocardiography; Female; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Male; Middle Aged; Nervous System Diseases; Oxides; Pilot Projects; Platelet Count; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Survival Analysis; Syndrome | 2001 |
[An analysis of the therapeutic effects and reactions in treating acute promyelocytic leukemia with intravenous arsenic trioxide or all-trans retinoic acid].
Topics: Adolescent; Adult; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Child; Disease-Free Survival; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Tretinoin | 1999 |
Tetra-arsenic tetra-sulfide for the treatment of acute promyelocytic leukemia: a pilot report.
Topics: Adolescent; Adult; Antineoplastic Agents; Area Under Curve; Arsenicals; Bone Marrow Cells; Cytogenetic Analysis; Disease-Free Survival; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Metabolic Clearance Rate; Middle Aged; Pilot Projects; Remission Induction; Sulfides | 2002 |
Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: a bridge to transplantation.
Topics: Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Leukocyte Count; Male; Middle Aged; Oxides; Remission Induction; Salvage Therapy; Stem Cell Transplantation; Survival Rate; Therapeutic Equivalency; Treatment Outcome | 2002 |
Efficacy and safety of early switching to an outpatient therapy model using oral arsenic plus retinoic acid based-regimen in newly diagnosed acute promyelocytic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic; Arsenic Trioxide; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Models, Biological; Survival Rate; Tretinoin | 2019 |
Oral arsenic and retinoic acid for non-high-risk acute promyelocytic leukemia.
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic; Female; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Pilot Projects; Tretinoin; Young Adult | 2014 |
Long-term survival of acute promyelocytic leukaemia patients treated with arsenic and retinoic acid.
Topics: Adult; Arsenic; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Remission Induction; Survival Analysis; Tretinoin | 2016 |
652 other study(ies) available for arsenic and Leukemia, Promyelocytic, Acute
| Article | Year |
|---|---|
Impact of sociodemographic factors on early mortality in acute promyelocytic leukemia in the United States: A time-trend analysis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Sociodemographic Factors; Treatment Outcome; Tretinoin; United States | 2022 |
Metabolic adaptation drives arsenic trioxide resistance in acute promyelocytic leukemia.
Topics: Animals; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Leukemia, Promyelocytic, Acute; Mice; Oxides; Tretinoin | 2022 |
The pharmacokinetics of therapeutic arsenic trioxide in acute promyelocytic leukemia patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin | 2022 |
Bone marrow necrosis as complication of treatment with all-trans retinoic acid and arsenic trioxide: case report and implications for treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Bone Marrow; Humans; Leukemia, Promyelocytic, Acute; Necrosis; Tretinoin | 2022 |
[Refractory acute promyelocytic leukemia with a complex karyotype].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenicals; Female; Hematopoietic Stem Cell Transplantation; Humans; Karyotype; Leukemia, Promyelocytic, Acute; Middle Aged; Oxides; Transplantation, Autologous; Treatment Outcome; Tretinoin | 2021 |
Gemtuzumab Ozogamicin Followed by Unrelated Cord Blood Transplantation With Reduced-intensity Conditioning for a Child With Refractory Acute Promyelocytic Leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cord Blood Stem Cell Transplantation; Female; Gemtuzumab; Humans; Infant; Leukemia, Promyelocytic, Acute; Oxides; Treatment Outcome; Tretinoin | 2022 |
Venetoclax for arsenic-resistant acute promyelocytic leukaemia.
Topics: Arsenic; Arsenic Trioxide; Arsenicals; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Promyelocytic, Acute; Oxides; Sulfonamides; Tretinoin | 2022 |
Evidence supporting that the attribution of first success in use of arsenic for the treatment of leukaemia should be to David Lissauer (1836-1892).
Topics: Arsenic; Arsenicals; Humans; Leukemia; Leukemia, Promyelocytic, Acute; Oxides | 2022 |
Single-cell transcriptomics profiling the compatibility mechanism of As
Topics: Animals; Antineoplastic Agents; Arsenicals; Bone Marrow; Indigo Carmine; Leukemia, Promyelocytic, Acute; Mesenchymal Stem Cells; Mice; Osteogenesis; Oxides; Transcriptome; Tumor Microenvironment | 2022 |
Estimation of the Frequency and Time of Human Exposure to Arsenic by Single Hair Analysis.
Topics: Arsenic; Arsenicals; Hair; Hair Analysis; Humans; Leukemia, Promyelocytic, Acute | 2022 |
Subcellular Partitioning of Arsenic Trioxide Revealed by Label-Free Imaging.
Topics: Antineoplastic Agents; Apoptosis; Arsenic; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Protein Aggregates; Sulfur; Tretinoin | 2022 |
Oral arsenic and retinoic acid for high-risk acute promyelocytic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Treatment Outcome; Tretinoin | 2022 |
Tetra-arsenic tetra-sulfide enhances NK-92MI mediated cellular immunotherapy in all-trans retinoic acid-resistant acute promyelocytic leukemia.
Topics: Animals; Arsenic; Arsenicals; Immunotherapy; Leukemia, Promyelocytic, Acute; Mice; Oxides; Sulfides; Tretinoin; Tumor Microenvironment | 2022 |
Higher than normal mitochondrial DNA content associated with better outcome in acute promyelocytic leukaemia? Maybe.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; DNA, Mitochondrial; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin | 2023 |
Long-term real-world outcomes of patients with acute promyelocytic leukaemia treated with arsenic trioxide and all-trans retinoic acid without chemotherapy-a retrospective, single-centre study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Retrospective Studies; Treatment Outcome; Tretinoin | 2023 |
Long-term retrospective study of retinoic acid combined with arsenic and chemotherapy for acute promyelocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Retrospective Studies; Treatment Outcome; Tretinoin | 2023 |
Targeting HDAC3 to overcome the resistance to ATRA or arsenic in acute promyelocytic leukemia through ubiquitination and degradation of PML-RARα.
Topics: Antineoplastic Agents; Arsenic; Arsenic Trioxide; Arsenicals; Cell Differentiation; Humans; Leukemia, Promyelocytic, Acute; Nuclear Proteins; Oxides; Transcription Factors; Tretinoin; Ubiquitination | 2023 |
Transglutaminase 2 associated with PI3K and PTEN in a membrane-bound signalosome platform blunts cell death.
Topics: Arsenic Trioxide; Arsenicals; Cell Death; Humans; Integrins; Leukemia, Promyelocytic, Acute; Mechanistic Target of Rapamycin Complex 2; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Protein Glutamine gamma Glutamyltransferase 2; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; TOR Serine-Threonine Kinases; Tretinoin | 2023 |
Monomethylarsonous acid binds to Cys-104α and Cys-112β of hemoglobin in acute promyelocytic leukemia patients treated with arsenic trioxide.
Topics: Antineoplastic Agents; Arsenic; Arsenic Trioxide; Arsenicals; Hemoglobins; Humans; Leukemia, Promyelocytic, Acute; Oxides | 2023 |
Type 2 diabetes affects arsenic metabolism via transporters in arsenic trioxide treated acute promyelocytic leukemia patients.
Topics: Antineoplastic Agents; Arsenic; Arsenic Trioxide; Arsenicals; Diabetes Mellitus, Type 2; Glucose; HEK293 Cells; Humans; Leukemia, Promyelocytic, Acute; Oxides | 2023 |
Torsemide increases arsenic concentrations by inhibition of multidrug resistance protein 4 in arsenic trioxide treated acute promyelocytic leukemia patients.
Topics: Animals; Antineoplastic Agents; Arsenic; Arsenic Trioxide; Arsenicals; Drug Resistance, Multiple; HEK293 Cells; Humans; Leukemia, Promyelocytic, Acute; Multidrug Resistance-Associated Proteins; Oxides; Rats; Torsemide | 2023 |
Variant acute promyelocytic leukaemia with novel NAB2::RARA fusion shows clinical all-trans retinoic acid and arsenic trioxide sensitivity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Oxides; Repressor Proteins; Retinoic Acid Receptor alpha; Tretinoin | 2023 |
Intracranial bleeding in acute promyelocytic leukemia treated with arsenic trioxide based regimens is associated with induction mortality but not with relapse.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Tretinoin | 2023 |
ATO Increases ROS Production and Apoptosis of Cells by Enhancing Calpain-Mediated Degradation of the Cancer Survival Protein TG2.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Calpain; Humans; Leukemia, Promyelocytic, Acute; Leukocytes, Mononuclear; Oxides; Protein Glutamine gamma Glutamyltransferase 2; Reactive Oxygen Species; Tretinoin | 2023 |
Dissection of scientific compatibility of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia from the perspective of toxicology.
Topics: Animals; Arsenic; Arsenicals; Leukemia, Promyelocytic, Acute; Mice | 2023 |
Utility of end of induction bone marrow biopsy and survival outcomes in acute promyelocytic leukemia treated with fixed-dose induction regimen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Bone Marrow; Humans; Leukemia, Promyelocytic, Acute; Oxides; Remission Induction; Retrospective Studies; Treatment Outcome; Tretinoin | 2023 |
Additional cytogenetic abnormalities in patients with newly diagnosed acute promyelocytic leukemia predict inferior event-free survival.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenicals; Chromosome Aberrations; Humans; Leukemia, Promyelocytic, Acute; Oxides; Progression-Free Survival; Retrospective Studies; Treatment Outcome; Tretinoin | 2023 |
miR-603 promotes cell proliferation and differentiation by targeting TrkB in acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Proliferation; Humans; Leukemia, Promyelocytic, Acute; MicroRNAs; Oxides | 2023 |
S-Dimethylarsino-glutathione (darinaparsin®) targets histone H3.3, leading to TRAIL-induced apoptosis in leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenicals; Cell Line, Tumor; Drug Screening Assays, Antitumor; Glutathione; Histones; Humans; Leukemia, Promyelocytic, Acute; Molecular Structure; TNF-Related Apoptosis-Inducing Ligand | 2019 |
Replacing chemotherapy with arsenic trioxide for the treatment of acute promyelocytic leukemia in the frontline setting: Is it cost-effective?
Topics: Arsenic Trioxide; Arsenicals; China; Cost-Benefit Analysis; Humans; Leukemia, Promyelocytic, Acute; Tretinoin | 2020 |
Ventricular repolarization dynamics in arsenic trioxide treatment of acute promyelocytic leukemia.
Topics: Arsenic Trioxide; Arsenicals; Electrocardiography; Heart Rate; Humans; Leukemia, Promyelocytic, Acute; Long QT Syndrome; Oxides | 2020 |
Arsenene: A Potential Therapeutic Agent for Acute Promyelocytic Leukaemia Cells by Acting on Nuclear Proteins.
Topics: Antineoplastic Agents; Apoptosis; Arsenicals; Cell Line, Tumor; Cell Nucleus; DNA Repair; DNA Replication; DNA-Directed DNA Polymerase; Gene Expression Regulation; Humans; Leukemia, Promyelocytic, Acute; Nanoparticles; Nuclear Proteins; Proteomics; Pyrimidines; Thioredoxins | 2020 |
[Efficacy of Arsenic Trioxide Combined with ATRA and Chemotherapy for Relapsed Acute Promyelocytic Leukemia Patients].
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Remission Induction; Treatment Outcome; Tretinoin | 2020 |
Dual Inhibition of Pyruvate Dehydrogenase Complex and Respiratory Chain Complex Induces Apoptosis by a Mitochondria-Targeted Fluorescent Organic Arsenical in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenicals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Electron Transport; Enzyme Inhibitors; Female; Humans; Leukemia, Promyelocytic, Acute; Mice; Mice, Inbred C57BL; Mitochondria; Molecular Structure; Neoplasms, Experimental; Pyruvate Dehydrogenase Complex; Reactive Oxygen Species | 2020 |
Severe Wernicke encephalopathy and acute pancreatitis due to all-trans-retinoic acid and arsenic trioxide during treatment of acute promyelocytic leukaemia: a case report.
Topics: Acute Disease; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Middle Aged; Oxides; Pancreatitis; Tretinoin; Wernicke Encephalopathy | 2020 |
Herpes zoster during arsenic trioxide therapy for acute promyelocytic leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Herpes Zoster; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin | 2021 |
Autologous stem cell transplantation finds a place in acute promyelocytic leukaemia.
Topics: Arsenic Trioxide; Arsenicals; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Recurrence, Local; Transplantation, Autologous; Tretinoin | 2021 |
Arsenic trioxide and all-trans retinoic acid in the treatment of children with newly diagnosed acute promyelocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin | 2021 |
Monomethylated arsenic was the Major methylated arsenic in Red blood cells of acute promyelocytic leukemia patients treated with arsenic trioxide.
Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Biotransformation; Cacodylic Acid; Child; Child, Preschool; Chromatography, High Pressure Liquid; Erythrocytes; Female; Hemoglobins; Humans; Infant; Infant, Newborn; Leukemia, Promyelocytic, Acute; Male; Methylation; Middle Aged; Protein Binding; Spectrometry, Fluorescence; Spectrophotometry, Atomic; Young Adult | 2021 |
Arsenic trioxide reduces the expression of E2F1, cyclin E, and phosphorylation of PI3K signaling molecules in acute leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cyclin E; E2F1 Transcription Factor; Humans; Leukemia, Promyelocytic, Acute; Oxides; Phosphatidylinositol 3-Kinases; Phosphorylation | 2021 |
Arsenic trioxide dose capping to decrease toxicity in the treatment of acute promyelocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Retrospective Studies; Treatment Outcome; Tretinoin | 2022 |
PML/RARA destabilization by hyperthermia: a new model for oncogenic fusion protein degradation?
Topics: Arsenic Trioxide; Arsenicals; Humans; Hyperthermia, Induced; Leukemia, Promyelocytic, Acute; Oxides; Proteolysis | 2021 |
Effects of co-administration of arsenic trioxide and Schiff base oxovanadium complex on the induction of apoptosis in acute promyelocytic leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Schiff Bases | 2021 |
Drug treatment options for acute promyelocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Pharmaceutical Preparations; Quality of Life; Treatment Outcome | 2022 |
Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasms, Second Primary; Oxides; Remission Induction; Survival Analysis; Treatment Outcome; Young Adult | 2017 |
Bruising and abnormal leucocytes on a blood film--a haematological emergency.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Contusions; Gingival Hemorrhage; Humans; Lethargy; Leukemia, Promyelocytic, Acute; Leukocytes; Male; Oxides; Tretinoin; Young Adult | 2017 |
Effect of ATRA and ATO on the expression of tissue factor in NB4 acute promyelocytic leukemia cells and regulatory function of the inflammatory cytokines TNF and IL-1β.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; CD11c Antigen; Cell Line, Tumor; Enzyme Inhibitors; Gene Expression Regulation, Leukemic; HL-60 Cells; Humans; Imidazoles; Interleukin-1beta; JNK Mitogen-Activated Protein Kinases; Leukemia, Promyelocytic, Acute; NF-kappa B; Oxides; p38 Mitogen-Activated Protein Kinases; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thromboplastin; Time Factors; Tretinoin; Tumor Necrosis Factor-alpha; U937 Cells | 2017 |
Arsenic trioxide induced rhabdomyolysis, a rare but severe side effect, in an APL patient: a case report.
Topics: Acute Kidney Injury; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Creatinine; Dyspnea; Female; Humans; Leukemia, Promyelocytic, Acute; Medicine, Chinese Traditional; Oxides; Rhabdomyolysis | 2017 |
High-dose ascorbate and arsenic trioxide selectively kill acute myeloid leukemia and acute promyelocytic leukemia blasts in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Oxides; Reactive Oxygen Species; Survival Analysis; Tumor Cells, Cultured | 2017 |
[Efficacy of Idarubicin-Based Stratified Therapy for Acute Promyelocytic Leukemia].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenicals; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Oxides; Remission Induction; Treatment Outcome; Tretinoin | 2017 |
All-trans retinoic acid and arsenic trioxide fail to derepress the monocytic differentiation driver Irf8 in acute promyelocytic leukemia cells.
Topics: Arsenic Trioxide; Arsenicals; Cell Differentiation; Female; Humans; Interferon Regulatory Factors; Leukemia, Promyelocytic, Acute; Male; Monocytes; Neoplasm Proteins; Oxides; Tretinoin | 2017 |
Mechanism of As2O3-Induced Action Potential Prolongation and Using hiPS-CMs to Evaluate the Rescue Efficacy of Drugs With Different Rescue Mechanism.
Topics: Action Potentials; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; ERG1 Potassium Channel; HEK293 Cells; Humans; Induced Pluripotent Stem Cells; Leukemia, Promyelocytic, Acute; Long QT Syndrome; Lysosomes; Myocytes, Cardiac; Oxides; Patch-Clamp Techniques; Proteolysis; Resveratrol; Stilbenes; Terfenadine | 2017 |
[Role of Microparticles Derived from Acute Promyelocytic Leukemia Cells in Coagulopathy].
Topics: Arsenicals; Blood Coagulation Disorders; Cell-Derived Microparticles; Humans; Leukemia, Promyelocytic, Acute; Oxides; Thromboplastin; Tretinoin | 2017 |
Infections caused by resistant organisms: Could organic arsenic compounds be an effective treatment?
Topics: Animals; Arsenic; Arsenic Trioxide; Arsenicals; Arsphenamine; Drug Resistance, Bacterial; Haptens; Humans; Inhibitory Concentration 50; Leukemia, Promyelocytic, Acute; Lyme Disease; Methicillin-Resistant Staphylococcus aureus; Models, Theoretical; Molecular Weight; Oxides; Staphylococcal Infections; Syphilis; Treatment Outcome | 2017 |
HPLC-HG-AFS determination of arsenic species in acute promyelocytic leukemia (APL) plasma and blood cells.
Topics: Arsenic; Arsenicals; Blood Cells; Chromatography, High Pressure Liquid; Humans; Leukemia, Promyelocytic, Acute; Mass Spectrometry | 2017 |
Arsenic trioxide consolidation in APL.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials, Phase III as Topic; Consolidation Chemotherapy; Disease-Free Survival; Humans; Leukemia, Promyelocytic, Acute; Oxides; Treatment Outcome | 2017 |
Effects of realgar (As
Topics: Amino Acid Substitution; Arsenic; Arsenicals; Drug Resistance, Neoplasm; HL-60 Cells; Humans; Inhibitory Concentration 50; Leukemia, Promyelocytic, Acute; Mutation, Missense; Oncogene Proteins, Fusion; Proteolysis; Sulfides; SUMO-1 Protein; Sumoylation; Tumor Cells, Cultured | 2017 |
Distinct TP73-DAPK2-ATG5 pathway involvement in ATO-mediated cell death versus ATRA-mediated autophagy responses in APL.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Autophagy; Autophagy-Related Protein 12; Autophagy-Related Protein 5; Cell Line, Tumor; Cell Nucleus; Death-Associated Protein Kinases; Gene Knockdown Techniques; HEK293 Cells; Humans; Leukemia, Promyelocytic, Acute; Models, Biological; Oxides; Promoter Regions, Genetic; Protein Binding; Protein Isoforms; Protein Stability; Signal Transduction; Transcription, Genetic; Tretinoin; Tumor Protein p73 | 2017 |
Acute promyelocytic leukemia and chronic lymphocytic leukemia diagnosed concurrently.
Topics: Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Arsenicals; Bone Marrow; Diabetes Mellitus, Type 2; Humans; Idarubicin; Immunophenotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasms, Multiple Primary; Remission Induction; Tretinoin | 2018 |
A new ETV6-NTRK3 cell line model reveals MALAT1 as a novel therapeutic target - a short report.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Line; Cell Proliferation; Humans; Leukemia, Promyelocytic, Acute; Mitogen-Activated Protein Kinase 1; Models, Biological; Oncogene Proteins, Fusion; Oxides; Pyrimidines; RNA, Long Noncoding | 2018 |
Redistribution of cell cycle by arsenic trioxide is associated with demethylation and expression changes of cell cycle related genes in acute promyelocytic leukemia cell line (NB4).
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Division; Cell Line, Tumor; Demethylation; DNA Methylation; Gene Expression Regulation, Leukemic; Genes, cdc; Humans; Leukemia, Promyelocytic, Acute; Oxides | 2018 |
[Comparison of Curative Effect between Fu Fang Huang Dai Pian and Arsenic Trioxide in Treatment of 45 Patients with Acute Promyelocytic Leukaemia].
Topics: Arsenic Trioxide; Arsenicals; Child; Humans; Leukemia, Promyelocytic, Acute; Medicine, Chinese Traditional; Oxides; Remission Induction; Retrospective Studies; Treatment Outcome; Tretinoin | 2017 |
Arsenic trioxide at conventional dosage does not aggravate hemorrhage in the first-line treatment of adult acute promyelocytic leukemia.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Blood Coagulation; Female; Hemorrhage; Humans; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Male; Middle Aged; Oxides; Platelet Adhesiveness; Platelet Aggregation; Platelet Function Tests; Remission Induction; Treatment Outcome; Young Adult | 2018 |
Antileukemic effect of paclitaxel in combination with metformin in HL-60 cell line.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Differentiation; Cell Line, Tumor; Drug Therapy, Combination; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; Metformin; NF-kappa B; Oxides; Paclitaxel; Signal Transduction | 2018 |
Relapse of acute promyelocytic leukemia in the external auditory canal confirmed by PML/RARA dual-fusion and RARA break-apart fluorescence in situ hybridization.
Topics: Abnormal Karyotype; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Combined Modality Therapy; DNA Probes; Ear Canal; Hematopoietic Stem Cell Transplantation; Humans; In Situ Hybridization, Fluorescence; Leukemia, Promyelocytic, Acute; Leukemic Infiltration; Male; Middle Aged; Oncogene Proteins, Fusion; Oxides; Positron-Emission Tomography; Recurrence; RNA, Messenger; RNA, Neoplasm; Tomography, X-Ray Computed; WT1 Proteins | 2018 |
[Analysis of Early-Death and Factors Affecting Prognosis of Patients with Acute Promyelocytic Leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Prognosis; Retrospective Studies; Tretinoin | 2018 |
[Acute Promyelocytic Leukemia - A Rare, Life-Threatening Disease with High Healing Chance].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Rare Diseases; Tretinoin | 2018 |
Case report: Purulent transformation of granulocytic sarcoma: An unusual pattern of differentiation in acute promyelocytic leukemia.
Topics: Abdomen; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cell Differentiation; Female; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Middle Aged; Oxides; Sarcoma, Myeloid; Suppuration; Tretinoin | 2018 |
Influence of acute promyelocytic leukemia therapeutic drugs on nuclear pore complex density and integrity.
Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Line; Cell Nucleus; Humans; Kinetics; Leukemia, Promyelocytic, Acute; Mitosis; Nuclear Envelope; Nuclear Pore; Oxides; Permeability; Tretinoin | 2018 |
Arsenic speciation in hair and nails of acute promyelocytic leukemia (APL) patients undergoing arsenic trioxide treatment.
Topics: Adult; Arsenic; Arsenic Trioxide; Arsenicals; Chromatography, High Pressure Liquid; Female; Hair; Humans; Leukemia, Promyelocytic, Acute; Male; Mass Spectrometry; Middle Aged; Nails; Oxides; Young Adult | 2018 |
Cutaneous herald: leukaemia cutis as presenting manifestation of relapse in acute promyelocytic leukaemia.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biopsy; Consolidation Chemotherapy; Daunorubicin; Female; Humans; Leukemia, Promyelocytic, Acute; Leukemic Infiltration; Oxides; Skin; Tretinoin | 2018 |
Self-Assembled Nanocomplex for Co-Delivery of Arsenic-Retinoic Acid Prodrug into Acute Promyelocytic Leukemia Cells.
Topics: Antineoplastic Agents; Arsenic; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Prodrugs; Tretinoin | 2018 |
[Relationship between the Therapeutic Dose of Arsenic Trioxide and Relapse in Acute Promyelocytic Leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Retrospective Studies; Tretinoin | 2018 |
Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; Drug Evaluation; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Proportional Hazards Models; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Treatment Outcome; Tretinoin; Young Adult | 2018 |
Salinomycin induces apoptosis and differentiation in human acute promyelocytic leukemia cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Humans; Imides; Leukemia, Promyelocytic, Acute; Oxides; Pyrans; Quinolines; Tretinoin; Wnt Signaling Pathway | 2018 |
[Three Waves of Arsenic Therapy for Leukemia and Related Innovations].
Topics: Antineoplastic Agents; Arsenic; Arsenicals; China; Humans; Leukemia, Promyelocytic, Acute; Medicine, Chinese Traditional; Oxides | 2017 |
Time course of arsenic species in red blood cells of acute promyelocytic leukemia (APL) patients treated with single agent arsenic trioxide.
Topics: Adult; Aged; Antineoplastic Agents; Arsenic; Arsenic Trioxide; Arsenicals; Cacodylic Acid; Child; Chromatography, High Pressure Liquid; Erythrocytes; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Mass Spectrometry; Middle Aged; Time Factors; Young Adult | 2019 |
Phenylarsine Oxide Can Induce Degradation of PLZF-RARα Variant Fusion Protein of Acute Promyelocytic Leukemia.
Topics: Arsenicals; HeLa Cells; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion | 2019 |
Hepatotoxicity from arsenic trioxide for pediatric acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Hodgkin Disease; Humans; Leukemia, Promyelocytic, Acute; Liver; Male; Oxides | 2013 |
The novel arsenical Darinaparsin circumvents BRG1-dependent, HO-1-mediated cytoprotection in leukemic cells.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Blast Crisis; Blotting, Western; Cell Cycle; Cell Proliferation; Chromatin Immunoprecipitation; Cytoprotection; DNA Helicases; Flow Cytometry; Glutathione; Heme Oxygenase-1; Humans; Leukemia, Promyelocytic, Acute; NF-E2-Related Factor 2; Nuclear Proteins; Oxides; Phosphorylation; Promoter Regions, Genetic; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transcription Factors; Tumor Cells, Cultured | 2013 |
Myocardial toxicity of acute promyelocytic leukaemia drug-arsenic trioxide.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Body Burden; Catalase; Glutathione; Glutathione Peroxidase; Glutathione Reductase; Glutathione Transferase; Heart Diseases; Leukemia, Promyelocytic, Acute; Lipid Peroxidation; Male; Myocytes, Cardiac; Oxides; Rats; Rats, Wistar; Superoxide Dismutase; Time Factors | 2013 |
Arsenic: an old enemy now turned friend.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides | 2013 |
Aquaporin 9, a promising predictor for the cytocidal effects of arsenic trioxide in acute promyelocytic leukemia cell lines and primary blasts.
Topics: Antigens, CD; Antineoplastic Agents; Apoptosis; Aquaporins; Arsenic Trioxide; Arsenicals; Drug Resistance, Neoplasm; Flow Cytometry; Gene Expression; HL-60 Cells; Humans; Jurkat Cells; K562 Cells; Leukemia, Promyelocytic, Acute; Oxides | 2013 |
Arsenic methylation metabolism and liver injury of acute promyelocytic leukemia patients undergoing arsenic trioxide treatment.
Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Liver; Liver Function Tests; Male; Methylation; Middle Aged; Oxides; Sex Factors; Young Adult | 2013 |
Mees lines and Beau lines.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Male; Nail Diseases; Oxides; Remission Induction; Tretinoin | 2013 |
Arsenic reverses glioblastoma resistance to mTOR-targeted therapies.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Leukemia, Promyelocytic, Acute; Oxides; Quinazolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2013 |
Acute promyelocytic leukemia complicated by massive intracerebral hemorrhage: safety and efficacy of replacing conventional chemotherapy with arsenic trioxide in an adolescent.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cerebral Hemorrhage; Drug Administration Schedule; Drug Substitution; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Long-Term Care; Oxides; Remission Induction; Tomography, X-Ray Computed | 2013 |
Azidothymidine hinders arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cells by induction of p21 and attenuation of G2/M arrest.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; G2 Phase Cell Cycle Checkpoints; Humans; Leukemia, Promyelocytic, Acute; M Phase Cell Cycle Checkpoints; Oxides; Zidovudine | 2013 |
Complete remission of acute promyelocytic leukemia in a very elderly patient after treatment with low dose arsenic trioxide and sequential retinoic acid: a case report.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Remission Induction; Tretinoin | 2014 |
Reactivation of hepatitis B virus in a hepatitis B surface antigen-negative patient with acute promyelocytic leukemia treated with arsenic trioxide.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; DNA, Viral; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis B virus; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Virus Activation | 2014 |
Urothelial cell intracytoplasmic inclusions after treatment of promyelocytic leukemia with arsenic trioxide.
Topics: Adult; Aged; Arsenic Trioxide; Arsenicals; Case-Control Studies; Female; Humans; Inclusion Bodies; Leukemia, Promyelocytic, Acute; Male; Microscopy, Electron, Transmission; Microscopy, Fluorescence; Middle Aged; Oxides; Urothelium | 2013 |
Coordinated regulation of the immunoproteasome subunits by PML/RARα and PU.1 in acute promyelocytic leukemia.
Topics: Antigen Presentation; Arsenic Trioxide; Arsenicals; Cysteine Endopeptidases; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Leukemic; HL-60 Cells; Humans; Immunologic Factors; Leukemia, Promyelocytic, Acute; Nuclear Proteins; Oxides; Promoter Regions, Genetic; Promyelocytic Leukemia Protein; Proteasome Endopeptidase Complex; Protein Binding; Protein Subunits; Proto-Oncogene Proteins; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Trans-Activators; Transcription Factors; Transcriptional Activation; Transcriptome; Tretinoin; Tumor Escape; Tumor Suppressor Proteins | 2014 |
BCR/ABL fusion gene detected in acute promyelocytic leukemia: a case study of clinical and laboratory results.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzamides; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Piperazines; Pyrimidines; Translocation, Genetic; Treatment Outcome; Tretinoin | 2014 |
Acute promyelocytic leukemia with Flt3-TKD and WT1 mutations relapsing in a testicle and followed by systemic relapse.
Topics: Adult; Arsenic Trioxide; Arsenicals; Combined Modality Therapy; Daunorubicin; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Promyelocytic, Acute; Male; Neoplasm Recurrence, Local; Oxides; Salvage Therapy; Sarcoma, Myeloid; Testicular Neoplasms; Testis; Tretinoin; WT1 Proteins | 2013 |
Effect of therapeutic arsenic exposure on pulmonary function.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Case-Control Studies; Cross-Sectional Studies; Dose-Response Relationship, Drug; Female; Forced Expiratory Volume; Humans; Leukemia, Promyelocytic, Acute; Lung Diseases; Male; Middle Aged; Oxides; Uteroglobin; Vital Capacity | 2013 |
Role of hematopoietic stem cell transplantation for relapsed acute promyelocytic leukemia: a retrospective analysis of JALSG-APL97.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzoates; Combined Modality Therapy; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Japan; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Recurrence; Retrospective Studies; Salvage Therapy; Tetrahydronaphthalenes; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Tretinoin; Young Adult | 2013 |
Targeting agents alone to cure acute promyelocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Tretinoin | 2013 |
Arsenic trioxide inhibits the Hedgehog pathway which is aberrantly activated in acute promyelocytic leukemia.
Topics: Adolescent; Adult; Aged; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Female; Hedgehog Proteins; Humans; Kruppel-Like Transcription Factors; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Nuclear Proteins; Oxides; Patched Receptors; Receptors, Cell Surface; Receptors, G-Protein-Coupled; Smoothened Receptor; Transcription Factors; Zinc Finger Protein GLI1; Zinc Finger Protein Gli2 | 2013 |
A single course of all-trans retinoic acid plus arsenic trioxide reached a long-term survival in a patient with newly diagnosed acute promyelocytic leukemia: a suggestion for reduction of treatment courses?
Topics: Adolescent; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Drug Administration Schedule; Drug Synergism; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Treatment Outcome; Tretinoin | 2013 |
3Omics: a web-based systems biology tool for analysis, integration and visualization of human transcriptomic, proteomic and metabolomic data.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Gene Expression Profiling; Humans; Internet; Leukemia, Promyelocytic, Acute; Metabolomics; Oxides; Proteomics; Statistics as Topic; Systems Biology; Tretinoin; Urinalysis | 2013 |
Retinoic acid plus arsenic trioxide, the ultimate panacea for acute promyelocytic leukemia?
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin | 2013 |
Overcoming treatment resistance in acute promyelocytic leukemia and beyond.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Molecular Targeted Therapy; Oxides; Tretinoin | 2013 |
Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; China; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Dexamethasone; Drug Evaluation; Female; Harringtonines; Homoharringtonine; Humans; Idarubicin; Infusions, Intravenous; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Male; Methotrexate; Middle Aged; Neoplasm, Residual; Oncogene Proteins, Fusion; Oxides; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Treatment Outcome; Tretinoin; Young Adult | 2014 |
Thyroid arsenic content and papillary thyroid carcinoma arising 10 years after oral arsenic trioxide therapy for refractory acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carcinoma; Carcinoma, Papillary; Female; Humans; Leukemia, Promyelocytic, Acute; Neoplasms, Second Primary; Oxides; Thyroid Cancer, Papillary; Thyroid Gland; Thyroid Neoplasms; Young Adult | 2014 |
Expression of PML-RARα is up-regulated during ATRA and arsenics combined induction without influence on long-term prognosis of acute promyelocytic leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oncogene Proteins, Fusion; Prognosis; Tretinoin; Up-Regulation; Young Adult | 2013 |
Importance of ERK activation in As2O3-induced differentiation and promyelocytic leukemia nuclear bodies formation in neuroblastoma cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Humans; Intranuclear Inclusion Bodies; Leukemia, Promyelocytic, Acute; MAP Kinase Signaling System; N-Myc Proto-Oncogene Protein; Neurites; Neuroblastoma; Nuclear Proteins; Oncogene Proteins; Oxides; Promyelocytic Leukemia Protein; Transcription Factors; Tumor Suppressor Proteins | 2013 |
Long-term prognosis of childhood acute promyelocytic leukaemia with arsenic trioxide administration in induction and consolidation chemotherapy phases: a single-centre experience.
Topics: Adolescent; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Consolidation Chemotherapy; Female; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Male; Neoplasm, Residual; Oxides; Prognosis; Treatment Outcome; Tretinoin | 2013 |
Arsenic trioxide combination improves survival in APL.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Prognosis; Remission Induction; Survival Rate; Tretinoin | 2013 |
High frequency of varicella zoster virus reactivation associated with the use of arsenic trioxide in patients with acute promyelocytic leukemia.
Topics: Acyclovir; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Herpes Zoster; Herpesvirus 3, Human; Humans; Incidence; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Retrospective Studies; Valacyclovir; Valine; Virus Activation | 2014 |
Treatment of acute promyelocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Tretinoin | 2013 |
Treatment of acute promyelocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Tretinoin | 2013 |
Carcinogenic risk of retained arsenic after successful treatment of acute promyelocytic leukemia with arsenic trioxide: a cause for concern?
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carcinoma; Carcinoma, Papillary; Female; Humans; Leukemia, Promyelocytic, Acute; Neoplasms, Second Primary; Oxides; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2014 |
Prognostic significance of additional cytogenetic abnormalities and FLT3 mutations in acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; fms-Like Tyrosine Kinase 3; Humans; Karyotype; Leukemia, Promyelocytic, Acute; Male; Mutation; Oxides | 2014 |
MicroRNAs contribute to promyelocyte apoptosis in As2O3-treated APL cells.
Topics: 3' Untranslated Regions; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Base Sequence; bcl-2-Associated X Protein; Caspase 3; Cell Line, Tumor; Cell Survival; DNA Fragmentation; Down-Regulation; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; MicroRNAs; Oxides; RNA, Messenger; Sequence Alignment; Up-Regulation | 2013 |
Outcomes and prognostic factors of first relapsed acute promyelocytic leukemia patients undergoing salvage therapy with intravenous arsenic trioxide and chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Combined Modality Therapy; Drug Evaluation; Female; Hematopoietic Stem Cell Transplantation; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Prognosis; Proportional Hazards Models; Recurrence; Retrospective Studies; Salvage Therapy; Treatment Outcome; Young Adult | 2014 |
Activation of a promyelocytic leukemia-tumor protein 53 axis underlies acute promyelocytic leukemia cure.
Topics: Animals; Arsenic Trioxide; Arsenicals; Computational Biology; Humans; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Mice; Microarray Analysis; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Proteolysis; Receptors, Retinoic Acid; Recombinant Fusion Proteins; Retinoic Acid Receptor alpha; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Transcription Factors; Tretinoin; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2014 |
Tetra-arsenic tetra-sulfide (As4S 4) promotes apoptosis in retinoid acid -resistant human acute promyelocytic leukemic NB4-R1 cells through downregulation of SET protein.
Topics: Apoptosis; Arsenicals; Cell Line, Tumor; Cell Proliferation; DNA-Binding Proteins; Drug Resistance, Neoplasm; Histone Chaperones; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; RNA, Messenger; Sulfides; Transcription Factors; Tretinoin | 2014 |
Arsenic sulfide promotes apoptosis in retinoid acid resistant human acute promyelocytic leukemic NB4-R1 cells through downregulation of SET protein.
Topics: Apoptosis; Arsenicals; Cell Line, Tumor; Cell Proliferation; Cell Shape; DNA-Binding Proteins; Down-Regulation; Drug Resistance, Neoplasm; Electrophoresis, Gel, Two-Dimensional; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Histone Chaperones; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Protein Phosphatase 2; Proteome; Proteomics; Retinoids; RNA, Messenger; RNA, Small Interfering; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Sulfides; Transcription Factors | 2014 |
Treatment of an acute promyelocytic leukemia relapse using arsenic trioxide and all-trans-retinoic in a 6-year-old child.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Female; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Tretinoin | 2014 |
Incorporation of arsenic trioxide in induction therapy improves survival of patients with newly diagnosed acute promyelocytic leukaemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Daunorubicin; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Retrospective Studies; Survival Analysis; Tretinoin | 2014 |
PML nuclear bodies mediate the therapeutic response of APL cells.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Cycle; Humans; Leukemia, Promyelocytic, Acute; Nuclear Proteins; Oncogene Proteins, Fusion; Oxides; Signal Transduction; Tretinoin | 2014 |
The acute promyelocytic leukaemia success story: curing leukaemia through targeted therapies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cell Transformation, Neoplastic; Epigenesis, Genetic; Humans; Leukemia, Promyelocytic, Acute; Molecular Targeted Therapy; Oxides; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Retinoid X Receptor alpha; Signal Transduction; Tretinoin | 2014 |
Normal CYP3A activity during arsenic trioxide therapy.
Topics: Arsenic Trioxide; Arsenicals; Cytochrome P-450 CYP3A; Enzyme Activation; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides | 2014 |
Resistance to arsenic therapy in acute promyelocytic leukemia.
Topics: Arsenic Trioxide; Arsenicals; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Mutation; Neoplasm Proteins; Oxides; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha | 2014 |
cAMP protects acute promyelocytic leukemia cells from arsenic trioxide-induced caspase-3 activation and apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-Associated Death Protein; Caspase 3; Cell Line, Tumor; Cell Proliferation; Colforsin; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; DNA; G1 Phase Cell Cycle Checkpoints; Humans; Leukemia, Promyelocytic, Acute; Oxides; Proto-Oncogene Mas; Tumor Suppressor Protein p53 | 2014 |
Metabolism of arsenic trioxide in acute promyelocytic leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cacodylic Acid; Cell Line, Tumor; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3A; DNA Methyltransferase 3B; Glutathione; Humans; Leukemia, Promyelocytic, Acute; Methyltransferases; Oxides; S-Adenosylhomocysteine; S-Adenosylmethionine | 2014 |
Arsenic trioxide induces oxidative stress, DNA damage, and mitochondrial pathway of apoptosis in human leukemia (HL-60) cells.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Caspase 3; Cytochromes c; DNA Damage; Drug Screening Assays, Antitumor; Glutathione; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; Lipid Peroxidation; Membrane Potential, Mitochondrial; Mitochondria; Oxidative Stress; Oxides; Protein Transport; Single-Cell Analysis | 2014 |
Guest editorial: acute promyelocytic leukemia: change from "highly fatal to highly curable" leukemia.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Disseminated Intravascular Coagulation; Forkhead Box Protein O3; Forkhead Transcription Factors; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Oxides; Tretinoin | 2014 |
Src family kinase inhibitor PP2 enhances differentiation of acute promyelocytic leukemia cell line induced by combination of all-trans-retinoic acid and arsenic trioxide.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; CD11b Antigen; Cell Differentiation; Cell Line, Tumor; Drug Synergism; Humans; Leukemia, Promyelocytic, Acute; Oxides; Pyrimidines; Tretinoin; Up-Regulation | 2014 |
Pregnancy in acute promyelocytic leukaemia after front-line therapy with arsenic trioxide and all-trans retinoic acid.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Fetus; Humans; Infant, Newborn; Leukemia, Promyelocytic, Acute; Oxides; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Tretinoin; Young Adult | 2014 |
Retinoic acid synergizes ATO-mediated cytotoxicity by precluding Nrf2 activity in AML cells.
Topics: Arsenic Trioxide; Arsenicals; Cell Survival; Drug Synergism; Glutathione; Heme Oxygenase-1; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; NF-E2-Related Factor 2; Oxides; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Tretinoin; Tumor Cells, Cultured | 2014 |
Torsade de Pointes during oral arsenic trioxide therapy for acute promyelocytic leukemia in a patient with heart failure.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Heart Failure; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Torsades de Pointes | 2015 |
Targeting catalase but not peroxiredoxins enhances arsenic trioxide-induced apoptosis in K562 cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Catalase; Cell Line, Tumor; Fusion Proteins, bcr-abl; Gene Knockdown Techniques; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Promyelocytic, Acute; Oxides; Peroxiredoxins; Reactive Oxygen Species | 2014 |
Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxide.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Incidence; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasms, Second Primary; Oxides; Tretinoin; Young Adult | 2015 |
ATO/ATRA/anthracycline-chemotherapy sequential consolidation achieves long-term efficacy in primary acute promyelocytic leukemia.
Topics: Adolescent; Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Consolidation Chemotherapy; Disease-Free Survival; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Oxides; Remission Induction; Retrospective Studies; Treatment Outcome; Tretinoin; Young Adult | 2014 |
Arsenic trioxide and resveratrol show synergistic anti-leukemia activity and neutralized cardiotoxicity.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Leukemia, Promyelocytic, Acute; Myocytes, Cardiac; Neoplasm Proteins; Oxides; Rats; Reactive Oxygen Species; Resveratrol; Stilbenes; Superoxide Dismutase | 2014 |
A prospective, observational study of added medium-dose cytosine arabinoside versus As2O3 for elderly patients with acute promyelocytic leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Polymerase Chain Reaction; Prospective Studies; Survival Rate; Tretinoin | 2014 |
Acute promyelocytic leukaemia with a PML-RARA insertional translocation and a chromosome 21 abnormality in XYY syndrome: case report.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Chromosomes, Human, Pair 21; Humans; In Situ Hybridization, Fluorescence; Karyotype; Leukemia, Promyelocytic, Acute; Male; Mutagenesis, Insertional; Oncogene Proteins, Fusion; Oxides; Sex Chromosome Disorders; Translocation, Genetic; Treatment Outcome; Tretinoin; XYY Karyotype | 2014 |
Resistance to therapy in acute promyelocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Mutation; Oncogene Proteins, Fusion; Oxides; Recurrence; Tretinoin | 2014 |
Clearance of PML/RARA-bound promoters suffice to initiate APL differentiation.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Cell Transformation, Neoplastic; Cells, Cultured; Chlorocebus aethiops; COS Cells; Gene Expression Profiling; Humans; Leukemia, Promyelocytic, Acute; Mice, Inbred C57BL; Mice, Inbred Strains; Mice, Nude; Mice, Transgenic; Oncogene Proteins, Fusion; Oxides; Promoter Regions, Genetic; Protein Binding; Retinoid X Receptor alpha; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Sumoylation; Transcriptional Activation; Tretinoin | 2014 |
Economic evaluation of arsenic trioxide compared to all-trans retinoic acid + conventional chemotherapy for treatment of relapsed acute promyelocytic leukemia in Canada.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Canada; Cost-Benefit Analysis; Female; Health Care Costs; Humans; Leukemia, Promyelocytic, Acute; Male; Markov Chains; Middle Aged; Monte Carlo Method; Oxides; Quality-Adjusted Life Years; Recurrence; Treatment Failure; Treatment Outcome; Tretinoin | 2015 |
Effects of arsenic compounds on growth, cell-cycle distribution and apoptosis of tretinoin-resistant human promyelocytic leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenicals; Caspase 3; Cell Cycle; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Tretinoin; Tumor Cells, Cultured | 2014 |
Economic evaluation of arsenic trioxide for treatment of newly diagnosed acute promyelocytic leukaemia in Canada.
Topics: Arsenic Trioxide; Arsenicals; Canada; Cost-Benefit Analysis; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides | 2015 |
Extramedullary relapse in RARA rearrangement-negative acute promyelocytic leukemia successfully treated in combination with chemotherapy, local radiotherapy, and cord blood transplantation.
Topics: Allografts; Arsenic Trioxide; Arsenicals; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; Female; Gene Rearrangement; Humans; Infant; Leukemia, Promyelocytic, Acute; Oxides; Receptors, Retinoic Acid; Recurrence; Retinoic Acid Receptor alpha | 2015 |
Real-life experience of a brief arsenic trioxide-based consolidation chemotherapy in the management of acute promyelocytic leukemia: favorable outcomes with limited anthracycline exposure and shorter consolidation therapy.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Consolidation Chemotherapy; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Proportional Hazards Models; Retrospective Studies; Treatment Outcome; Young Adult | 2015 |
Dose-adjusted arsenic trioxide for acute promyelocytic leukaemia in chronic renal failure.
Topics: Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Drug Monitoring; Female; Humans; Kidney Failure, Chronic; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Pilot Projects; Treatment Outcome | 2015 |
Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Child; Child, Preschool; Disease-Free Survival; Europe; Female; Humans; International Cooperation; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Prospective Studies; Recurrence; Registries; Treatment Outcome; Young Adult | 2015 |
How health-related quality-of-life outcomes in patients with acute promyelocytic leukemia can help physicians in decision making.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Quality of Life; Tretinoin | 2015 |
Reply to M. Koehler et al.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Quality of Life; Tretinoin | 2015 |
Arsenic Trioxide and Icariin Show Synergistic Anti-leukemic Activity.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Flavonoids; Humans; Leukemia, Promyelocytic, Acute; Membrane Potential, Mitochondrial; Oxides; Reactive Oxygen Species | 2015 |
Comparison of newly diagnosed and relapsed patients with acute promyelocytic leukemia treated with arsenic trioxide: insight into mechanisms of resistance.
Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Child; Child, Preschool; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Granulocyte Precursor Cells; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Mutation; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Prospective Studies; Recurrence; Transcription Factors; Tretinoin; Tumor Suppressor Proteins; Young Adult | 2015 |
Synergistic Leukemia Eradication by Combined Treatment with Retinoic Acid and HIF Inhibition by EZN-2208 (PEG-SN38) in Preclinical Models of PML-RARα and PLZF-RARα-Driven Leukemia.
Topics: Animals; Arsenic Trioxide; Arsenicals; Camptothecin; Cell Differentiation; Cell Movement; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Leukemia, Promyelocytic, Acute; Mice; Mutation; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Polyethylene Glycols; Tretinoin | 2015 |
Use of arsenic trioxide in a hemodialysis-dependent patient with relapsed acute promyelocytic leukemia.
Topics: Aged, 80 and over; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Drug Monitoring; Humans; Kidney Failure, Chronic; Leukemia, Promyelocytic, Acute; Male; Oxides; Renal Dialysis | 2016 |
[The clinical efficacy of all-trans retinoic acid plus arsenic trioxide in 177 newly diagnosed acute promyelocytic leukemia patients].
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Remission Induction; Retrospective Studies; Survival Rate; Tretinoin | 2015 |
The influence of joint application of arsenic trioxide and daunorubicin on primary acute promyelocytic leukaemia cells and apoptosis and blood coagulation of cell strain.
Topics: Adult; Annexin A2; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Blood Coagulation; Cell Line, Tumor; Daunorubicin; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Thrombomodulin; Thromboplastin; Time Factors; Tumor Cells, Cultured; Young Adult | 2015 |
Tetraarsenictetrasulfide and Arsenic Trioxide Exert Synergistic Effects on Induction of Apoptosis and Differentiation in Acute Promyelocytic Leukemia Cells.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Oxides; Reactive Oxygen Species; Sulfides | 2015 |
Prognostic factors of patients with newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide-based frontline therapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; CD56 Antigen; Chromosome Duplication; Female; fms-Like Tyrosine Kinase 3; Gene Expression; Humans; Injections, Intravenous; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Multivariate Analysis; Oncogene Proteins, Fusion; Oxides; Prognosis; Retrospective Studies; Risk Factors; Survival Analysis | 2015 |
Lessons taught by acute promyelocytic leukemia cure.
Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Mice; Oncogene Proteins, Fusion; Oxides; Tretinoin; Tumor Suppressor Protein p53 | 2015 |
Methylated arsenic metabolites bind to PML protein but do not induce cellular differentiation and PML-RARα protein degradation.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Biotransformation; Cacodylic Acid; Cell Differentiation; Cell Proliferation; Dose-Response Relationship, Drug; HEK293 Cells; HeLa Cells; Humans; Leukemia, Promyelocytic, Acute; Methylation; Nuclear Proteins; Oncogene Proteins, Fusion; Organometallic Compounds; Oxides; Promyelocytic Leukemia Protein; Proteasome Endopeptidase Complex; Protein Binding; Protein Interaction Domains and Motifs; Proteolysis; Sumoylation; Time Factors; Transcription Factors; Tumor Suppressor Proteins | 2015 |
Budgetary impact of treating acute promyelocytic leukemia patients with first-line arsenic trioxide and retinoic acid from an Italian payer perspective.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Italy; Leukemia, Promyelocytic, Acute; Male; Oxides; Tretinoin | 2015 |
Mutations of Epigenetic Modifier Genes as a Poor Prognostic Factor in Acute Promyelocytic Leukemia Under Treatment With All-Trans Retinoic Acid and Arsenic Trioxide.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Disease-Free Survival; DNA Mutational Analysis; Epigenesis, Genetic; Female; Genes, Modifier; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Mutation; Nucleophosmin; Oxides; Prognosis; Treatment Outcome; Tretinoin; Young Adult | 2015 |
Epigenetic Gene Mutations Impact on Outcome in Acute Myeloid Leukaemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Tretinoin | 2015 |
Evaluating frequency of PML-RARA mutations and conferring resistance to arsenic trioxide-based therapy in relapsed acute promyelocytic leukemia patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gene Frequency; Humans; Leukemia, Promyelocytic, Acute; Longitudinal Studies; Male; Middle Aged; Mutation, Missense; Oncogene Proteins, Fusion; Oxides; Recurrence; Young Adult | 2015 |
Induction, consolidation, and maintenance therapies with arsenic as a single agent for acute promyelocytic leukaemia in a 11-year follow-up.
Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Male; Neoplasm Recurrence, Local; Oxides; Remission Induction; Time Factors; Treatment Outcome; Young Adult | 2017 |
Chemotherapy-free treatment of acute promyelocytic leukemia.
Topics: Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cytarabine; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin | 2015 |
Cost-Effectiveness Analysis of Treating Acute Promyelocytic Leukemia Patients With Arsenic Trioxide and Retinoic Acid in the United States.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Case-Control Studies; Cost-Benefit Analysis; Humans; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Markov Chains; Models, Economic; Oxides; Treatment Outcome; Tretinoin; United States | 2015 |
Time to abandon traditional chemotherapy for acute promyelocytic leukaemia?
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenicals; Female; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Oxides; Tretinoin | 2015 |
Reduced medical costs and hospital days when using oral arsenic plus ATRA as the first-line treatment of acute promyelocytic leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; China; Cost Savings; Cost-Benefit Analysis; Direct Service Costs; Female; Health Care Costs; Hospitals, University; Humans; Length of Stay; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Male; Middle Aged; Oxides; Randomized Controlled Trials as Topic; Remission Induction; Retrospective Studies; Tretinoin; Young Adult | 2015 |
Time to improve health-related quality of life outcomes in patients with acute promyelocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Quality of Life; Survival Rate; Tretinoin | 2015 |
Acute promyelocytic leukemia with isochromosome 17q and cryptic PML-RARA successfully treated with all-trans retinoic acid and arsenic trioxide.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Chromosomes, Human, Pair 17; Female; Humans; Isochromosomes; Leukemia, Promyelocytic, Acute; Middle Aged; Oncogene Proteins, Fusion; Oxides; Remission Induction; Treatment Outcome; Tretinoin | 2015 |
Prohibitin promotes apoptosis of promyelocytic leukemia induced by arsenic sulfide.
Topics: Antineoplastic Agents; Apoptosis; Arsenicals; Blotting, Western; Cell Line, Tumor; Electrophoresis, Gel, Two-Dimensional; Gene Knockdown Techniques; Humans; Leukemia, Promyelocytic, Acute; Prohibitins; Real-Time Polymerase Chain Reaction; Repressor Proteins; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Sulfides; Tandem Mass Spectrometry; Transfection | 2015 |
Is There Still a Role for Low-Dose All-Transretinoic Acid in the Treatment of Acute Promyelocytic Leukemia in the Arsenic Trioxide Era?
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Humans; Idarubicin; Induction Chemotherapy; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Male; Middle Aged; Mitoxantrone; Oxides; Proportional Hazards Models; Treatment Outcome; Tretinoin; Young Adult | 2015 |
Varying responses of PML-RARA with different genetic mutations to arsenic trioxide.
Topics: Active Transport, Cell Nucleus; Arsenic Trioxide; Arsenicals; Cell Nucleus; Cells, Cultured; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; HeLa Cells; Hematopoietic Stem Cells; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Oxides; Point Mutation; Prognosis; Sumoylation; U937 Cells | 2016 |
Identification of Arsenic Direct-Binding Proteins in Acute Promyelocytic Leukaemia Cells.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Biotin; Biotinylation; Carrier Proteins; Cell Line, Tumor; Chromatography, Liquid; Glutathione S-Transferase pi; HSP70 Heat-Shock Proteins; Humans; Leukemia, Promyelocytic, Acute; Membrane Proteins; Mitochondrial Proteins; Neoplasm Proteins; Oxides; Protein Binding; Streptavidin; Tandem Mass Spectrometry; Thyroid Hormone-Binding Proteins; Thyroid Hormones | 2015 |
pVAX14DNA-mediated add-on immunotherapy combined with arsenic trioxide and all-trans retinoic acid targeted therapy effectively increases the survival of acute promyelocytic leukemia mice.
Topics: Adjuvants, Immunologic; Animals; Arsenic Trioxide; Arsenicals; Disease Models, Animal; DNA; Immunotherapy; Leukemia, Promyelocytic, Acute; Mice; Oxides; Tretinoin | 2015 |
Exceptions in patterns of arsenic compounds in urine of acute promyelocytic leukaemia patients treated with As2O3.
Topics: Adult; Arsenic Trioxide; Arsenicals; Cacodylic Acid; Female; Humans; Inactivation, Metabolic; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides | 2016 |
Mutations affecting both the rearranged and the unrearranged PML alleles in refractory acute promyelocytic leukaemia.
Topics: Adult; Aged; Alleles; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; DNA Mutational Analysis; DNA, Neoplasm; Drug Resistance, Neoplasm; Female; Gene Rearrangement; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Mutation; Neoplasm Proteins; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Transcription Factors; Tumor Suppressor Proteins; Young Adult | 2016 |
[History of acute promyelocytic leukemia].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; History, 20th Century; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin | 2015 |
Genital vasculitis secondary to all-trans-retinoic-acid.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Genitalia; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Tretinoin; Vasculitis | 2016 |
Tamoxifen enhances the differentiation-inducing and growth-inhibitory effects of all-trans retinoic acid in acute promyelocytic leukemia cells.
Topics: Animals; Anthracyclines; Antineoplastic Agents, Hormonal; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; CD11b Antigen; Cell Differentiation; Cell Division; Cell Line, Tumor; Cell Proliferation; Cell Survival; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Leukemic; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; Male; Mice; Mice, Inbred BALB C; Middle Aged; Oxides; Tamoxifen; Tretinoin | 2016 |
Microgranular acute promyelocytic leukemia presenting with leukopenia and an unusual immunophenotype.
Topics: Arsenic Trioxide; Arsenicals; Bone Marrow; Disseminated Intravascular Coagulation; Flow Cytometry; Humans; Immunophenotyping; Leukemia, Promyelocytic, Acute; Leukopenia; Male; Oxides; Treatment Outcome; Tretinoin; Young Adult | 2017 |
Addition of Arsenic Trioxide into Induction Regimens Could Not Accelerate Recovery of Abnormality of Coagulation and Fibrinolysis in Patients with Acute Promyelocytic Leukemia.
Topics: Adolescent; Adult; Aged; Arsenic Trioxide; Arsenicals; Blood Coagulation; Female; Fibrin Fibrinogen Degradation Products; Fibrinogen; Fibrinolysis; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Platelet Count; Prothrombin Time; Retrospective Studies; Tretinoin; Young Adult | 2016 |
A facile route to core-shell nanoparticulate formation of arsenic trioxide for effective solid tumor treatment.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Drug Carriers; Drug Liberation; Female; Humans; Leukemia, Promyelocytic, Acute; Liver Neoplasms; Mice; Mice, Inbred ICR; Microscopy, Electron, Transmission; Nanoparticles; Oxides; Porosity; Silicon Dioxide; Surface Properties; Transplantation, Heterologous | 2016 |
Carnosic Acid-combined Arsenic Trioxide Antileukaemia Cells in the Establishment of NB4/SCID Mouse Model.
Topics: Abietanes; Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Cell Line, Tumor; Disease Models, Animal; Drug Synergism; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Mice; Mice, SCID; Oxides; PTEN Phosphohydrolase; RNA, Messenger | 2016 |
Targeted Therapy Alone for Acute Promyelocytic Leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Follow-Up Studies; Humans; Intention to Treat Analysis; Leukemia, Promyelocytic, Acute; Oxides; Randomized Controlled Trials as Topic; Tretinoin | 2016 |
Role of Signal Regulatory Protein α in Arsenic Trioxide-induced Promyelocytic Leukemia Cell Apoptosis.
Topics: Antigens, Differentiation; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Humans; Leukemia, Promyelocytic, Acute; MicroRNAs; Oxides; Receptors, Immunologic | 2016 |
[Relapse of acute promyelocytic leukemia in the central nervous system revealed by isolated dementia].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Dementia; Female; Humans; Leukemia, Promyelocytic, Acute; Meningeal Neoplasms; Neoplasm Recurrence, Local; Oxides; Recurrence; Remission Induction | 2016 |
PCGF2 negatively regulates arsenic trioxide-induced PML-RARA protein degradation via UBE2I inhibition in NB4 cells.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Fluorescent Antibody Technique; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Immunoprecipitation; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Oxides; Polycomb Repressive Complex 1; Protein Binding; Proteolysis; RNA Interference; Signal Transduction; Sumoylation; Time Factors; Transfection; Ubiquitin-Conjugating Enzymes; Ubiquitination | 2016 |
Autologous transplant remains the preferred therapy for relapsed APL in CR2.
Topics: Adolescent; Adult; Aged; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Infant; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Recurrence; Remission Induction; Retrospective Studies; Survival Analysis; Transplantation, Autologous; Treatment Outcome; Young Adult | 2016 |
PHA-Induced Peripheral Blood Cytogenetics and Molecular Analysis: a Valid Diagnostic and Follow-up Modality for Acute Promyelocytic Leukemia Patients Treated with ATRA and/or Arsenic Tri-oxide.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Blood Cells; Child; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Cytogenetic Analysis; Female; Follow-Up Studies; Gene Rearrangement; Humans; In Situ Hybridization, Fluorescence; India; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oncogene Proteins, Fusion; Oxides; Phytohemagglutinins; Prognosis; Translocation, Genetic; Tretinoin | 2016 |
Nrf2 activation ameliorates cytotoxic effects of arsenic trioxide in acute promyelocytic leukemia cells through increased glutathione levels and arsenic efflux from cells.
Topics: Abietanes; Arsenic; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cytotoxins; Glutathione; Humans; Leukemia, Promyelocytic, Acute; NF-E2-Related Factor 2; Oxides; RNA, Small Interfering | 2016 |
Fucoidan enhances the therapeutic potential of arsenic trioxide and all-trans retinoic acid in acute promyelocytic leukemia, in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Humans; Leukemia, Promyelocytic, Acute; Mice; Mice, Inbred BALB C; Mice, Nude; Oxides; Polysaccharides; Tretinoin; Xenograft Model Antitumor Assays | 2016 |
The 12-year follow-up of survival, chronic adverse effects, and retention of arsenic in patients with acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Arsenic; Arsenic Trioxide; Arsenicals; Case-Control Studies; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Quality of Life; Survival Analysis | 2016 |
Oxidative stress-mediated intrinsic apoptosis in human promyelocytic leukemia HL-60 cells induced by organic arsenicals.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Cell Proliferation; Cytochromes c; Gene Expression Regulation, Neoplastic; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; MCF-7 Cells; Membrane Potential, Mitochondrial; Oxidative Stress; Oxides; Reactive Oxygen Species; Signal Transduction | 2016 |
Successful treatment of acute promyelocytic leukemia with arsenic trioxide and all-trans retinoic acid in a double lung and kidney transplanted patient.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Carcinoma, Squamous Cell; Humans; Immunocompromised Host; Kidney Transplantation; Leukemia, Promyelocytic, Acute; Lung Transplantation; Male; Middle Aged; Neoplasms, Second Primary; Oxides; Postoperative Complications; Skin Neoplasms; Tretinoin | 2016 |
PML at Mitochondria-Associated Membranes Is Critical for the Repression of Autophagy and Cancer Development.
Topics: Adenine; Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Autophagy; Calcium; Cell Line, Tumor; Disease Progression; Fibroblasts; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Promyelocytic, Acute; Membrane Potential, Mitochondrial; Mice; Mice, Knockout; Mitochondria; Mitochondrial Membranes; Oncogene Proteins, Fusion; Oxides; Promyelocytic Leukemia Protein; Signal Transduction; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2016 |
Rationale and efficacy of proteasome inhibitor combined with arsenic trioxide in the treatment of acute promyelocytic leukemia.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Autophagy; Bortezomib; Cell Line, Tumor; Cell Transplantation; Drug Synergism; Humans; Leukemia, Promyelocytic, Acute; Mice; NF-kappa B; Oxides; Proteasome Inhibitors; Reactive Oxygen Species; Transplantation, Heterologous; Tumor Cells, Cultured; Unfolded Protein Response | 2016 |
Autologous hematopoietic cell transplantation for acute promyelocytic leukemia in second complete remission: outcomes before and after the introduction of arsenic trioxide.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Japan; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Recurrence; Remission Induction; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult | 2017 |
Induction treatments for acute promyelocytic leukemia: a network meta-analysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Female; Humans; Induction Chemotherapy; Infant; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Network Meta-Analysis; Oxides; Randomized Controlled Trials as Topic; Tretinoin; Young Adult | 2016 |
Survivin isoform expression in arsenic trioxide-treated acute promyelocytic leukemia cell line and patients: The odd expression pattern of survivin-2α.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Bone Marrow; Case-Control Studies; Caspase 3; Cell Line, Tumor; Dose-Response Relationship, Drug; Down-Regulation; Humans; Inhibitor of Apoptosis Proteins; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Oxides; Protein Isoforms; Survivin | 2017 |
Recurrent acute myopericarditis without effusion during ATRA induction and ATO salvage of APL: a variant form of the differentiation syndrome?
Topics: Acute Disease; Adolescent; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Electrocardiography; Humans; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Male; Oxides; Pericarditis; Remission Induction; Tretinoin | 2017 |
Antileukemic activity of an arsenomolybdate in the human HL-60 and U937 leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenicals; Blotting, Western; Caspase 3; Cell Cycle; Cell Proliferation; Drug Stability; Flow Cytometry; Fluorescence; HL-60 Cells; Humans; Inhibitory Concentration 50; Leukemia, Promyelocytic, Acute; Molybdenum; U937 Cells | 2017 |
First experience of the AML-Berlin-Frankfurt-Münster group in pediatric patients with standard-risk acute promyelocytic leukemia treated with arsenic trioxide and all-trans retinoid acid.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Female; Humans; Infant; Leukemia, Promyelocytic, Acute; Male; Oxides; Retrospective Studies; Treatment Outcome; Tretinoin | 2017 |
[Very Severe Differentiation Syndrome in Low Risk Acute Promyelocytic Leukemia - A Peril of Differentiating Therapy].
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Diagnosis, Differential; Dyspnea; Female; Fever; Humans; Hypotension; Leukemia, Promyelocytic, Acute; Leukocytosis; Lung Diseases; Oxides; Risk Factors; Severity of Illness Index; Syndrome; Treatment Outcome; Tretinoin | 2017 |
RXRα ligand Z-10 induces PML-RARα cleavage and APL cell apoptosis through disrupting PML-RARα/RXRα complex in a cAMP-independent manner.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Caspases; Cell Line, Tumor; Chlorocebus aethiops; COS Cells; Cyclic AMP; Flow Cytometry; HEK293 Cells; Humans; Leukemia, Promyelocytic, Acute; Ligands; Naphthalenes; Nitro Compounds; Oncogene Proteins, Fusion; Oxides; Protein Binding; Proteolysis; Retinoid X Receptor alpha; Styrenes; Tretinoin | 2017 |
Resistance to arsenic trioxide and retinoic acid therapy in acute promyelocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; DNA Mutational Analysis; Drug Resistance, Neoplasm; Fatal Outcome; Humans; Leukemia, Promyelocytic, Acute; Male; Mutation, Missense; Oncogene Proteins, Fusion; Oxides; Tretinoin | 2017 |
Poisoning the Devil.
Topics: Arsenic Trioxide; Arsenicals; China; France; History, 20th Century; History, 21st Century; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin | 2017 |
Clinical impact of galectin-3 in newly diagnosed t (15;17)(q22;q21)/PML-RARa acute promyelocytic leukemia treated with all-trans retinoic acid and arsenic trioxide-based regimens.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Case-Control Studies; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Female; Galectin 3; Humans; Immunophenotyping; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oncogene Proteins, Fusion; Oxides; Proportional Hazards Models; Retrospective Studies; Risk Factors; Survival Analysis; Translocation, Genetic; Treatment Outcome; Tretinoin; Young Adult | 2017 |
Delayed hematological recovery following autologous transplantation utilizing peripheral blood stem cells harvested after treatment with arsenic trioxide.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Oxides; Peripheral Blood Stem Cell Transplantation; Reverse Transcriptase Polymerase Chain Reaction; Transplantation, Autologous | 2008 |
Telomerase activity and telomere length in patients with acute promyelocytic leukemia: indicative of proliferative activity, disease progression, and overall survival.
Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Growth Processes; Disease Progression; Enzyme Activation; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oncogene Proteins, Fusion; Oxides; Survival Rate; Telomerase; Telomere | 2008 |
Arsenic trioxide and auranofin inhibit selenoprotein synthesis: implications for chemotherapy for acute promyelocytic leukaemia.
Topics: Adenocarcinoma; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Arsenites; Auranofin; Cell Line, Tumor; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Leukemia, Promyelocytic, Acute; Lung Neoplasms; Oxides; Protein Biosynthesis; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; RNA, Messenger; RNA, Small Interfering; Selenium Radioisotopes; Selenoproteins; Sodium Compounds; Sodium Selenite; Thioredoxin Reductase 1 | 2008 |
PML/RARalpha fusion protein mediates the unique sensitivity to arsenic cytotoxicity in acute promyelocytic leukemia cells: Mechanisms involve the impairment of cAMP signaling and the aberrant regulation of NADPH oxidase.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Survival; Cyclic AMP; Dose-Response Relationship, Drug; Humans; Leukemia, Promyelocytic, Acute; NADPH Oxidases; Oncogene Proteins, Fusion; Oxides; Reactive Oxygen Species; Signal Transduction; Time Factors; Transfection; U937 Cells | 2008 |
Acute promyelocytic leukemia: recent advances in diagnosis and management.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Salvage Therapy; Treatment Outcome; Tretinoin | 2008 |
Determinants of cerebrospinal fluid arsenic concentration in patients with acute promyelocytic leukemia on oral arsenic trioxide therapy.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Arsenic; Arsenic Trioxide; Arsenicals; Cytarabine; Female; Humans; Injections, Spinal; Leukemia, Promyelocytic, Acute; Male; Methotrexate; Middle Aged; Oxides; Recurrence | 2008 |
Arsenic trioxide stimulates SUMO-2/3 modification leading to RNF4-dependent proteolytic targeting of PML.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Down-Regulation; Humans; Leukemia, Promyelocytic, Acute; Nuclear Proteins; Oxides; Proteasome Endopeptidase Complex; Small Ubiquitin-Related Modifier Proteins; Transcription Factors; Ubiquitination; Ubiquitins | 2008 |
Realgar-induced differentiation is associated with MAPK pathways in HL-60 cells.
Topics: Antineoplastic Agents; Arsenicals; CD11 Antigens; Cell Differentiation; Cell Transformation, Neoplastic; HL-60 Cells; Humans; JNK Mitogen-Activated Protein Kinases; Leukemia, Promyelocytic, Acute; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 3; Nanoparticles; p38 Mitogen-Activated Protein Kinases; RNA, Messenger; Sulfides | 2008 |
Arsenic trioxide mutational spectrum analysis in the mouse lymphoma assay.
Topics: Animals; Arsenic Trioxide; Arsenicals; Biological Assay; Cell Line, Tumor; Leukemia L5178; Leukemia, Promyelocytic, Acute; Mice; Mutagenicity Tests; Oxides; Spectrum Analysis; Thymidine Kinase | 2008 |
Oral arsenic treatment of leukemia and the risk of porphyria.
Topics: Administration, Oral; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Male; Oxides; Porphyrias; Porphyrins | 2009 |
Catalase activity and arsenic sensitivity in acute leukemia.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Catalase; Cell Line, Tumor; Enzyme Inhibitors; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Oxides; Tumor Cells, Cultured | 2008 |
Histopathological response of transitional cell carcinoma to arsenic trioxide during the treatment of concurrently diagnosed acute promyelocytic leukaemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Carcinoma, Transitional Cell; Female; Humans; Leukemia, Promyelocytic, Acute; Middle Aged; Neoplasms, Multiple Primary; Oxides; Remission Induction; Tretinoin; Urinary Bladder Neoplasms | 2008 |
Speciation of arsenic trioxide metabolites in blood cells and plasma of a patient with acute promyelocytic leukemia.
Topics: Arsenic Trioxide; Arsenicals; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Leukemia, Promyelocytic, Acute; Male; Mass Spectrometry; Middle Aged; Oxides; Recurrence; Remission Induction; Time Factors; Tretinoin | 2009 |
Apoptosis induction by (+)alpha-tocopheryl succinate in the absence or presence of all-trans retinoic acid and arsenic trioxide in NB4, NB4-R2 and primary APL cells.
Topics: alpha-Tocopherol; Antineoplastic Agents; Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Chromatography, High Pressure Liquid; Drug Therapy, Combination; Growth Inhibitors; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid; Leukemia, Promyelocytic, Acute; Lipid Peroxidation; Oxides; Tretinoin | 2009 |
[Can As2O3 improve the prognosis of childhood acute promyelocytic leukemia?--A single center experience].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Oncogene Proteins, Fusion; Oxides; Prognosis; Retrospective Studies; Treatment Outcome; Tretinoin | 2008 |
Evidence for basophilic differentiation of acute promyelocytic leukaemia cells during arsenic trioxide therapy.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Basophils; Cell Differentiation; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides | 2009 |
[New therapeutic perspectives for arsenic: from acute promyelocytic leukemia to autoimmune diseases].
Topics: Animals; Antineoplastic Agents; Arsenic; Arsenic Trioxide; Arsenicals; Autoimmune Diseases; Disease Models, Animal; Growth Inhibitors; Humans; Leukemia, Promyelocytic, Acute; Lupus Erythematosus, Systemic; Lymphoproliferative Disorders; Mice; Oxides | 2008 |
Curative strategies in acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Cytarabine; Daunorubicin; Disease-Free Survival; Growth Inhibitors; History, 20th Century; Humans; Leukemia, Promyelocytic, Acute; Middle Aged; Neoplasm Recurrence, Local; Oxides; Tretinoin | 2008 |
Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Drug Administration Schedule; Female; Follow-Up Studies; Gemtuzumab; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Polymerase Chain Reaction; Remission Induction; Survival Rate; Treatment Outcome; Tretinoin | 2009 |
[Effect of additional chromosome abnormalities on the outcome of newly diagnosed acute promyelocytic leukemia treated with red arsenic sulfide and all trans-retinoic acid plus anthracyclin based protocol].
Topics: Adolescent; Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenicals; Chromosome Aberrations; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Prognosis; Retrospective Studies; Sulfides; Treatment Outcome; Tretinoin; Young Adult | 2008 |
[Effects of PML-RARalpha on cAMP-induced AML cell differentiation].
Topics: Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Cyclic AMP; Gene Expression Regulation, Leukemic; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Oxides; Signal Transduction; Transfection | 2008 |
Curing APL: differentiation or destruction?
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cell Differentiation; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Oxides; Tretinoin | 2009 |
Characterization of cytotoxicity induced by arsenic trioxide (a potent anti-APL drug) in rat cardiac myocytes.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Calcium; Cell Line, Tumor; Cell Survival; Leukemia, Promyelocytic, Acute; Myocytes, Cardiac; Oxides; Rats; Rats, Wistar; Reactive Oxygen Species | 2009 |
Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia.
Topics: Aquaporins; Arsenic Trioxide; Arsenicals; Gene Expression Regulation, Leukemic; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Oxides; Prognosis; Survival Rate; Time Factors; Tretinoin | 2009 |
[Role of P27(Kip1) and TGF-beta1 in APL cell apoptosis induced by As(2)O(3)].
Topics: Adolescent; Adult; Aged; Apoptosis; Arsenic Trioxide; Arsenicals; Cyclin-Dependent Kinase Inhibitor p27; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Transforming Growth Factor beta1; Tumor Cells, Cultured; Young Adult | 2009 |
Role of SUMO in RNF4-mediated promyelocytic leukemia protein (PML) degradation: sumoylation of PML and phospho-switch control of its SUMO binding domain dissected in living cells.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bacterial Proteins; Cell Line; Fluorescence Resonance Energy Transfer; Humans; In Vitro Techniques; Kidney; Leukemia, Promyelocytic, Acute; Luciferases, Renilla; Luminescent Measurements; Luminescent Proteins; Mutagenesis, Site-Directed; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Protein Binding; Protein Structure, Tertiary; SUMO-1 Protein; Transcription Factors; Transfection; Tumor Suppressor Proteins | 2009 |
[The significance of combined therapy of arsenic trioxide and all-trans retinoic acid in treating acute promyelocytic leukemia].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Remission Induction; Retrospective Studies; Tretinoin; Young Adult | 2009 |
Downregulation of the c-MYC target gene, peroxiredoxin III, contributes to arsenic trioxide-induced apoptosis in acute promyelocytic leukemia.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Base Sequence; Cell Line, Tumor; Chromatin Immunoprecipitation; DNA Primers; Down-Regulation; Genes, myc; Humans; Leukemia, Promyelocytic, Acute; Oxides; Peroxiredoxins; Reactive Oxygen Species; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering | 2009 |
Arsenic trioxide induces apoptosis and G2/M phase arrest by inducing Cbl to inhibit PI3K/Akt signaling and thereby regulate p53 activation.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; G2 Phase; Gene Expression Regulation, Leukemic; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Promyelocytic, Acute; Metaphase; Neoplasm Proteins; Oxides; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-cbl; Signal Transduction; Stomach Neoplasms; Tumor Suppressor Protein p53; Ubiquitination; Up-Regulation | 2009 |
[Construction of subtractive cDNA library of apoptosis-related genes in NB4 cells treated by arsenic trioxide].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; DNA, Complementary; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Library; Humans; Leukemia, Promyelocytic, Acute; Nucleic Acid Hybridization; Oligonucleotide Array Sequence Analysis; Oxides; Sequence Analysis, DNA | 2009 |
Differential cytotoxic effects of arsenic compounds in human acute promyelocytic leukemia cells.
Topics: Apoptosis; Arsenicals; Autophagy; Caspase 3; Cell Survival; Flow Cytometry; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; Microscopy, Electron, Scanning; Microscopy, Electron, Transmission; Microtubule-Associated Proteins; Structure-Activity Relationship | 2009 |
Use of arsenic trioxide in secondary acute promyelocytic leukemia developing after treatment of multiple sclerosis with mitoxantrone.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Enzyme Inhibitors; Humans; Leukemia, Promyelocytic, Acute; Male; Mitoxantrone; Multiple Sclerosis; Oxides; Remission Induction; Topoisomerase II Inhibitors; Treatment Outcome | 2009 |
Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy.
Topics: Adult; Aged; Arsenic Trioxide; Arsenicals; Blood Chemical Analysis; Bone Marrow; Cohort Studies; Confidence Intervals; Female; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Monitoring, Physiologic; Multivariate Analysis; Neoplasm Recurrence, Local; Neoplasm, Residual; Oncogene Proteins, Fusion; Oxides; Predictive Value of Tests; Probability; Prognosis; Proportional Hazards Models; Prospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Severity of Illness Index; Survival Analysis; Treatment Outcome; Tretinoin | 2009 |
Arsenic trioxide associated toothache.
Topics: Arsenic Trioxide; Arsenicals; Humans; Infusions, Intravenous; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Toothache; Tretinoin | 2010 |
Successful pregnancy after arsenic trioxide therapy for relapsed acute promyelocytic leukaemia.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Humans; Infant, Newborn; Leukemia, Promyelocytic, Acute; Male; Oxides; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Recurrence | 2009 |
[Influence of As(2)O(3) on proteasome beta(1)-subunit in NB4 cells].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Oxides; Proteasome Endopeptidase Complex; Tumor Cells, Cultured | 2009 |
Therapy-related acute promyelocytic leukemia: further insights into the molecular basis of the disease and showing the way forward in therapy.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Medical Oncology; Neoplasms, Second Primary; Oxides; Translocation, Genetic; Treatment Outcome; Tretinoin | 2009 |
[Clinical study on the fibrinolytic activity in patients with acute promyelocytic leukemia].
Topics: Adolescent; Adult; Aged; Annexin A2; Arsenic Trioxide; Arsenicals; Female; Fibrinolysis; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; RNA, Messenger; Tretinoin; Urokinase-Type Plasminogen Activator; Young Adult | 2009 |
Two cases of monocular visual loss during oral arsenic trioxide therapy of acute promyelocytic leukemia.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blindness; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Treatment Outcome | 2009 |
Speciation of arsenic trioxide penetrates into cerebrospinal fluid in patients with acute promyelocytic leukemia.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Chromatography, High Pressure Liquid; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides | 2010 |
Arsenic-induced pericardial and pleural effusion without acute promyelocytic leukemia differentiation syndrome.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Pericardial Effusion; Pleural Effusion | 2010 |
Arsenic trioxide downregulates the expression of annexin II in bone marrow cells from patients with acute myelogenous leukemia.
Topics: Adult; Annexin A2; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; Cell Survival; Cells, Cultured; Down-Regulation; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Reverse Transcriptase Polymerase Chain Reaction; Young Adult | 2009 |
How I treat acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Bone Marrow Examination; Dose-Response Relationship, Drug; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Outcome Assessment, Health Care; Oxides; Practice Guidelines as Topic; Reverse Transcriptase Polymerase Chain Reaction; Tretinoin | 2009 |
Mobilization of PML/RARalpha negative peripheral blood stem cells with a combination of G-CSF and CXCR4 blockade in relapsed acute promyelocytic leukemia pre-treated with arsenic trioxide.
Topics: Adult; Arsenic Trioxide; Arsenicals; Combined Modality Therapy; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Leukemia, Promyelocytic, Acute; Nuclear Proteins; Oxides; Peripheral Blood Stem Cell Transplantation; Promyelocytic Leukemia Protein; Receptors, CXCR4; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Secondary Prevention; Transcription Factors; Tumor Suppressor Proteins | 2010 |
Arsenic trioxide in a hemodialytic patient with acute promyelocytic leukemia.
Topics: Acute Kidney Injury; Aged; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Renal Dialysis | 2009 |
Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen.
Topics: Adolescent; Adult; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Child; Combined Modality Therapy; Female; Humans; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Myeloablative Agonists; Oncogene Proteins, Fusion; Oxides; Peripheral Blood Stem Cell Transplantation; Recurrence; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Tretinoin; Young Adult | 2009 |
Chemokine induction by all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia: triggering the differentiation syndrome.
Topics: Anti-Inflammatory Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Chemokine CCL2; Chemokine CCL24; Chemokine CCL7; Chemokines; Dexamethasone; Enzyme-Linked Immunosorbent Assay; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Humans; Leukemia, Promyelocytic, Acute; Oligonucleotide Array Sequence Analysis; Oxides; Receptors, Retinoic Acid; Reverse Transcriptase Polymerase Chain Reaction; Syndrome; Tretinoin; Tumor Cells, Cultured | 2009 |
Arsenic trioxide as first-line treatment for acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin | 2009 |
Evaluation of adverse cardiac effects induced by arsenic trioxide, a potent anti-APL drug.
Topics: Action Potentials; Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Dose-Response Relationship, Drug; Drug Antagonism; Edema, Cardiac; Guinea Pigs; Heart; Leukemia, Promyelocytic, Acute; Male; Membrane Transport Modulators; Myocardium; Oxidants; Oxides; Oxidoreductases; Vasodilator Agents | 2009 |
[Apoptosis of MR2 cells induced by Tanshinone II A combined with arsenic trioxide].
Topics: Abietanes; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Arsenic Trioxide; Arsenicals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Humans; Leukemia, Promyelocytic, Acute; Oxides; Phenanthrenes; Tretinoin | 2009 |
[Comparison of efficacy and adverse effects between arsenic trioxide and all-trans retinoic acid in patients with acute promyelocytic leukemia].
Topics: Adolescent; Adult; Aged; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Remission Induction; Retrospective Studies; Treatment Outcome; Tretinoin; Young Adult | 2009 |
Association of oxidative stress with realgar-induced differentiation in human leukemia HL-60 cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenicals; CD11b Antigen; Cell Cycle; Cell Differentiation; Flow Cytometry; Gene Expression Regulation, Leukemic; Glutathione; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; Membrane Potential, Mitochondrial; Oxidative Stress; Reactive Oxygen Species; Sulfides; Time Factors | 2009 |
Arsenic trioxide and olanzapine co-administration: case analysis.
Topics: Adult; Antineoplastic Agents; Antipsychotic Agents; Arsenic Trioxide; Arsenicals; Benzodiazepines; Drug Administration Schedule; Drug Interactions; Drug Monitoring; Electrocardiography; Humans; Leukemia, Promyelocytic, Acute; Long QT Syndrome; Male; Mental Disorders; Olanzapine; Oxides; Patient Safety; Risk Factors | 2011 |
[Retrospective analysis of 76 children with acute promyelocytic leukemia].
Topics: Adolescent; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Retrospective Studies; Survival Rate; Treatment Outcome | 2009 |
Successful post-remission therapy with a combination of all-trans retinoic acid and arsenic trioxide in an elderly Japanese patient newly diagnosed with acute promyelocytic leukemia.
Topics: Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Asian People; Female; Humans; Leukemia, Promyelocytic, Acute; Oxides; Remission Induction; Tretinoin | 2010 |
Gangrenous cheilitis associated with all-trans retinoic acid therapy for acute promyelocytic leukemia.
Topics: Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Biopsy; Cheilitis; Female; Gangrene; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin | 2010 |
Potent reducing effects of vitamin D3 on the frequency of apoptosis induced by arsenic trioxide in NB4 cell line.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Survival; Cholecalciferol; Dose-Response Relationship, Drug; Humans; Leukemia, Promyelocytic, Acute; Oxides | 2010 |
Phosphatidylserine exposure and procoagulant activity in acute promyelocytic leukemia.
Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blood Coagulation; Blood Coagulation Tests; Cell Differentiation; Cell Line, Tumor; Cell Membrane; Cell Survival; Daunorubicin; Etoposide; Factor Xa; Female; Flow Cytometry; Humans; Leukemia, Promyelocytic, Acute; Male; Membrane Glycoproteins; Microscopy, Confocal; Milk Proteins; Oxides; Phosphatidylserines; Thrombin; Thromboplastin; Tretinoin; Young Adult | 2010 |
Autophagy modification augmented the treatment effects initiated by arsenic trioxide in NB4 cells.
Topics: Adenine; Antibiotics, Antineoplastic; Apoptosis; Arsenic Trioxide; Arsenicals; Autophagy; Cell Line, Tumor; Cell Survival; Flow Cytometry; Humans; Leukemia, Promyelocytic, Acute; Oxides; Sirolimus | 2011 |
Arsenic trioxide-mediated antiplatelet activity: pivotal role of the phospholipase C gamma 2-protein kinase C-p38 MAPK cascade.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blood Platelets; Cell Adhesion Molecules; Collagen; Enzyme Activation; Humans; Hydroxyl Radical; In Vitro Techniques; Leukemia, Promyelocytic, Acute; MAP Kinase Signaling System; Microfilament Proteins; Oxides; p38 Mitogen-Activated Protein Kinases; Phospholipase C gamma; Phosphoproteins; Phosphorylation; Platelet Activation; Platelet Aggregation Inhibitors; Protein Kinase C | 2010 |
Non-lethal bone marrow necrosis under first-line arsenic trioxide therapy in acute promyelocytic leukaemia.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Necrosis; Oxides; Treatment Outcome | 2010 |
The expression of p38, ERK1 and Bax proteins has increased during the treatment of newly diagnosed acute promyelocytic leukemia with arsenic trioxide.
Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Blotting, Western; Bone Marrow; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Mitogen-Activated Protein Kinase 3; Neoplasm Staging; Oxides; p38 Mitogen-Activated Protein Kinases; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Treatment Outcome; Young Adult | 2010 |
External auditory canal and middle ear relapse of acute promyelocytic leukemia treated with arsenic trioxide: case report and review of the literature.
Topics: Arsenic Trioxide; Arsenicals; Child; Ear Canal; Ear Neoplasms; Ear, Middle; Female; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Recurrence, Local; Oxides; Treatment Outcome | 2010 |
Gefitinib enhances arsenic trioxide (AS2O3)-induced differentiation of acute promyelocytic leukemia cell line.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Humans; Leukemia, Promyelocytic, Acute; Oxides; Quinazolines | 2010 |
Treatment of therapy related acute promyelocytic leukemia with the combination of all trans retinoic acid and arsenic trioxide without chemotherapy: a series of three patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Choriocarcinoma; Female; Humans; Kidney Neoplasms; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neuroectodermal Tumors; Ovarian Neoplasms; Oxides; Prognosis; Tretinoin | 2010 |
[Apoptosis of NB4 cells induced by Tanshinone II A combined with arsenic trioxide].
Topics: Abietanes; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Humans; Leukemia, Promyelocytic, Acute; Oxides | 2010 |
Medicine. Poisonous contacts.
Topics: Arsenic; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Mutant Proteins; Mutation; Nuclear Proteins; Oncogene Proteins, Fusion; Oxides; Promyelocytic Leukemia Protein; Protein Multimerization; Transcription Factors; Tumor Suppressor Proteins; Zinc Fingers | 2010 |
Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML.
Topics: Arsenic; Arsenic Trioxide; Arsenicals; Cell Line; Humans; Leukemia, Promyelocytic, Acute; Mutant Proteins; Mutation; Nuclear Proteins; Oncogene Proteins, Fusion; Oxazines; Oxides; Promyelocytic Leukemia Protein; Protein Conformation; Protein Multimerization; Protein Structure, Secondary; Protein Structure, Tertiary; Receptors, Retinoic Acid; Recombinant Fusion Proteins; Retinoic Acid Receptor alpha; Small Ubiquitin-Related Modifier Proteins; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Transcription Factors; Tumor Suppressor Proteins; Ubiquitination; Zinc Fingers | 2010 |
Comparative proteome study of apoptosis induced by As4S4 in retinoid acid resistant human acute promyelocytic leukemia NB4-R1 cells.
Topics: Apoptosis; Arsenicals; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Prohibitins; Proteomics; Signal Transduction; Sulfides; Tretinoin | 2010 |
Relapsed APL patient with variant NPM-RARalpha fusion responded to arsenic trioxide-based therapy and achieved long-term survival.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Female; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Oxides; Recurrence; Remission Induction | 2010 |
All-trans retinoic acid and arsenic rescue patients with acute promyelocytic leukemia from a potential 'perfect storm'.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Neoplasms; Oxides; Prognosis; Tretinoin | 2010 |
Eradication of acute promyelocytic leukemia-initiating cells by PML/RARA-targeting.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Transformation, Neoplastic; Gene Expression Regulation, Neoplastic; Granulocyte Precursor Cells; Humans; Leukemia, Promyelocytic, Acute; Mice; Oncogene Proteins, Fusion; Oncogenes; Oxides; Tretinoin | 2010 |
Retrospective study of arsenic trioxide for childhood acute promyelocytic leukemia in China: a single-center experience.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Bone Marrow; Child; Child, Preschool; China; Disseminated Intravascular Coagulation; Female; Humans; Incidence; Leukemia, Promyelocytic, Acute; Male; Oxides; Retrospective Studies; Treatment Outcome; Tretinoin | 2010 |
Sweet fruit from a poisonous kiss.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Oxides | 2010 |
CNS relapse in acute promyeloctyic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Bone Marrow Neoplasms; Brain Neoplasms; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Cranial Irradiation; Cytarabine; Drug Administration Schedule; Female; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Magnetic Resonance Imaging; Mercaptopurine; Methotrexate; Mutation; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Receptors, Retinoic Acid; Recurrence; Remission Induction; Retinoic Acid Receptor alpha; Reverse Transcriptase Polymerase Chain Reaction; Transcription Factors; Translocation, Genetic; Transplantation, Autologous; Treatment Outcome; Tretinoin; Tumor Suppressor Proteins | 2010 |
Autophagy contributes to therapy-induced degradation of the PML/RARA oncoprotein.
Topics: Arsenic Trioxide; Arsenicals; Autophagy; Cell Differentiation; Cell Line, Tumor; HeLa Cells; Humans; Intracellular Signaling Peptides and Proteins; Leukemia, Promyelocytic, Acute; Nuclear Proteins; Oncogene Proteins, Fusion; Oxides; Promyelocytic Leukemia Protein; Protein Serine-Threonine Kinases; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; RNA, Small Interfering; Solubility; TOR Serine-Threonine Kinases; Transcription Factors; Tretinoin; Tumor Suppressor Proteins | 2010 |
Arsenic trioxide promotes mitochondrial DNA mutation and cell apoptosis in primary APL cells and NB4 cell line.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Base Sequence; Cell Line, Tumor; DNA Mutational Analysis; DNA, Mitochondrial; Humans; Leukemia, Promyelocytic, Acute; Molecular Sequence Data; Mutation; Oxides; Polymerase Chain Reaction; Tumor Cells, Cultured | 2010 |
[Arsenic trioxide treatment in a patient with recurrent acute promyelocytic leukemia (APL)].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Recurrence | 2010 |
PML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blotting, Western; Chlorocebus aethiops; CHO Cells; COS Cells; Cricetinae; Cricetulus; Disulfides; Embryo, Mammalian; Fibroblasts; Hematopoietic Stem Cells; Humans; Intranuclear Inclusion Bodies; Leukemia, Promyelocytic, Acute; Mice; Mice, Knockout; Mutation; Nuclear Proteins; Oncogene Proteins, Fusion; Oxides; Promyelocytic Leukemia Protein; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Processing, Post-Translational; Reactive Oxygen Species; Signal Transduction; Small Ubiquitin-Related Modifier Proteins; Transcription Factors; Tumor Suppressor Proteins | 2010 |
Arsenic trioxide cooperates with all trans retinoic acid to enhance mitogen-activated protein kinase activation and differentiation in PML-RARalpha negative human myeloblastic leukemia cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Cycle; Cell Differentiation; Cell Proliferation; Drug Synergism; Flow Cytometry; Humans; Leukemia, Promyelocytic, Acute; Mitogen-Activated Protein Kinases; Oncogene Proteins, Fusion; Oxides; Tretinoin; Tumor Cells, Cultured | 2010 |
The NRF2-mediated oxidative stress response pathway is associated with tumor cell resistance to arsenic trioxide across the NCI-60 panel.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Cell Line, Tumor; Humans; Leukemia, Promyelocytic, Acute; National Cancer Institute (U.S.); NF-E2-Related Factor 2; Oxidative Stress; Oxides; RNA Interference; United States | 2010 |
Clinical efficacy of arsenic trioxide in a patient with acute promyelocytic leukemia with recurrent central nervous system involvement.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Central Nervous System; Central Nervous System Neoplasms; Female; Humans; Leukemia, Promyelocytic, Acute; Leukemic Infiltration; Meningeal Neoplasms; Oxides; Recurrence; Treatment Outcome | 2011 |
Autophagic degradation of an oncoprotein.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Autophagy; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Oxides; Proteasome Endopeptidase Complex; Tretinoin | 2010 |
Outcome of therapy-related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasms, Radiation-Induced; Oxides; Treatment Outcome; Tretinoin | 2011 |
Synergistic apoptosis induction in leukemic cells by miR-15a/16-1 and arsenic trioxide.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Drug Synergism; Fusion Proteins, bcr-abl; Humans; K562 Cells; Leukemia, Promyelocytic, Acute; MicroRNAs; Mitochondria; Oxides | 2010 |
Long-term survey of outcome in acute promyelocytic leukemia: a single center experience in 340 patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Survival Rate; Time Factors; Treatment Outcome; Tretinoin; Young Adult | 2011 |
Treatment of patients with acute promyelocytic leukemia: a consensus statement on risk-adapted approaches to therapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Humans; Leukemia, Promyelocytic, Acute; Oxides; Risk Assessment; Treatment Outcome; Tretinoin | 2010 |
Utilization of molecular phenotypes to detect relapse and optimize the management of acute promyelocytic leukemia.
Topics: Adaptor Proteins, Signal Transducing; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Molecular Targeted Therapy; Oxides; Phenotype; Prognosis; Recurrence; Translocation, Genetic; Tretinoin | 2010 |
The expression of annexin II and its role in the fibrinolytic activity in acute promyelocytic leukemia.
Topics: Adolescent; Adult; Aged; Annexin A2; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Blood Coagulation Tests; Blotting, Western; Cell Proliferation; Female; Fibrinolysin; Fibrinolysis; Flow Cytometry; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Plasminogen; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Tissue Plasminogen Activator; Tretinoin; Young Adult | 2011 |
Don't just stand there, do something: strategies for the prevention of early death in acute promyelocytic leukemia: a commentary.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Disseminated Intravascular Coagulation; Hemorrhage; Humans; Leukemia, Promyelocytic, Acute; Oxides; Remission Induction; Secondary Prevention; Survival Rate; Time Factors; Treatment Failure; Tretinoin | 2011 |
[A successful case of tanshinone II A treatment for relapsed acute promyelocytic leukemia after maintainance therapy of all-trans retinoic acid and arsenic trioxide].
Topics: Abietanes; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Male; Mercaptopurine; Methotrexate; Neoplasm Recurrence, Local; Oxides; Tretinoin; Young Adult | 2010 |
[Effect of post-remission therapy mainly with compound huangdai tablet on long-term survival of patients with acute promyelocytic leukemia].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenicals; Child; Child, Preschool; Disease-Free Survival; Drugs, Chinese Herbal; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Phytotherapy; Remission Induction; Survival Analysis; Young Adult | 2010 |
Long-term remission after first-line single-agent treatment with arsenic trioxide of relapsed acute promyelocytic leukemia in an 8-year-old boy.
Topics: Arsenic Trioxide; Arsenicals; Child; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Recurrence; Remission Induction; Time Factors | 2011 |
Treatment of acute promyelocytic leukemia for older patients.
Topics: Age Factors; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Consolidation Chemotherapy; Humans; Leukemia, Promyelocytic, Acute; Middle Aged; Oxides; Prognosis; Treatment Outcome; Tretinoin | 2011 |
Arsenic trioxide may improve the prognosis of APL with ider(17)(q10): report of a rare adult case of acute promyelocytic leukemia with ider(17)(q10)t(15;17) showing poor response to all-trans retinoic acid.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Middle Aged; Oxides; Prognosis; Recombinant Fusion Proteins; Tretinoin | 2011 |
Therapy-related acute promyelocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Neoplasms, Second Primary; Oxides; Radiotherapy, Computer-Assisted | 2011 |
Successful treatment of relapsed and refractory extramedullary acute promyelocytic leukemia with tamibarotene.
Topics: Adult; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzoates; Bone Marrow; Bone Neoplasms; Combined Modality Therapy; Doxorubicin; Drug Resistance, Neoplasm; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Leukemic Infiltration; Male; Mercaptopurine; Methotrexate; Oxides; Radionuclide Imaging; Remission Induction; Salvage Therapy; Sarcoma, Myeloid; Soft Tissue Neoplasms; Tetrahydronaphthalenes; Tretinoin | 2011 |
[Establishment of two-dimensional electrophoresis proteomic profiles of retinoid acid resistant human acute promyelocytic leukemia NB4-R1 cells with apoptosis induced by realgar].
Topics: Apoptosis; Arsenicals; Cell Line, Tumor; Drug Resistance, Neoplasm; Electrophoresis, Gel, Two-Dimensional; Humans; Leukemia, Promyelocytic, Acute; Proteome; Sulfides; Tretinoin | 2011 |
Treatment of relapsed acute promyelocytic leukemia by arsenic trioxide in Iran.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Cohort Studies; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Iran; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Oxides; Remission Induction; Salvage Therapy; Treatment Outcome; Tretinoin; Young Adult | 2011 |
Characterization of arsenic-induced cytogenetic alterations in acute promyelocytic leukemia cell line, NB4.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Survival; Chromosome Aberrations; Humans; In Situ Hybridization, Fluorescence; Leukemia, Promyelocytic, Acute; Neoplasm Recurrence, Local; Oxides; Tumor Cells, Cultured | 2012 |
[Mechanism of apoptosis induced by bortezomib and As2O3 in APL cell line NB4].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cell Line, Tumor; Humans; Leukemia, Promyelocytic, Acute; Oxides; Pyrazines | 2011 |
Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Binding Sites; Cytoplasm; Drug Resistance, Neoplasm; Female; HeLa Cells; Humans; Immunoblotting; Leukemia, Promyelocytic, Acute; Male; Microscopy, Fluorescence; Middle Aged; Mutation, Missense; Neoplasm Recurrence, Local; Nuclear Proteins; Oncogene Proteins, Fusion; Oxides; Promyelocytic Leukemia Protein; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Reverse Transcriptase Polymerase Chain Reaction; Sumoylation; Transcription Factors; Transcription, Genetic; Tumor Suppressor Proteins; U937 Cells; Young Adult | 2011 |
Newly diagnosed acute promyelocytic leukemia: arsenic moves front and center.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Developing Countries; Humans; Leukemia, Promyelocytic, Acute; Oxides; Survival Analysis; Tretinoin | 2011 |
Arsenic trioxide for the treatment of a relapsed acute promyelocytic leukemia with acute renal failure.
Topics: Acute Kidney Injury; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Fatal Outcome; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Recurrence | 2011 |
Efficacy of prolonged therapy with combined arsenic trioxide and ATRA for relapse of acute promyelocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Treatment Outcome; Tretinoin | 2011 |
Monomorphic ventricular tachycardia caused by arsenic trioxide therapy for acute promyelocytic leukaemia.
Topics: Adult; Anti-Arrhythmia Agents; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Electrocardiography; Female; Humans; Leukemia, Promyelocytic, Acute; Magnesium; Manitoba; Metoprolol; Oxides; Potassium; Tachycardia, Ventricular | 2011 |
[Mechanism of apoptosis of NB4 cells induced by arsenic trioxide and cyclooxygenase-2 expression].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cyclooxygenase 2; Humans; Leukemia, Promyelocytic, Acute; Membrane Potential, Mitochondrial; Oxides | 2011 |
(+)α-Tocopheryl succinate inhibits the mitochondrial respiratory chain complex I and is as effective as arsenic trioxide or ATRA against acute promyelocytic leukemia in vivo.
Topics: alpha-Tocopherol; Animals; Antineoplastic Agents; Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Caspases; Cell Line, Tumor; Cytochromes c; Disease Models, Animal; Electron Transport Complex I; Electron Transport Complex II; Humans; Leukemia, Promyelocytic, Acute; Membrane Potential, Mitochondrial; Mice; Mice, Transgenic; Mitochondria; Neoplastic Stem Cells; Oncogene Proteins, Fusion; Oxides; Protein Stability; Rats; Reactive Oxygen Species; Transplantation, Isogeneic; Tretinoin | 2012 |
Arsenic trioxide in the management of APL: proceed with caution.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides | 2011 |
Oral arsenic trioxide for relapsed acute promyelocytic leukemia in pediatric patients.
Topics: Administration, Oral; Adolescent; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Recurrence; Time Factors | 2012 |
Epstein - Barr virus Latent Membrane Protein 1 suppresses reporter activity through modulation of promyelocytic leukemia protein-nuclear bodies.
Topics: Arsenic Trioxide; Arsenicals; beta-Galactosidase; Cell Line; Dose-Response Relationship, Drug; Epstein-Barr Virus Infections; Gene Expression Regulation, Leukemic; Gene Expression Regulation, Viral; Gene Silencing; Genes, Reporter; Herpesvirus 4, Human; Humans; Intranuclear Inclusion Bodies; Leukemia, Promyelocytic, Acute; Luciferases; Nuclear Proteins; Oxides; Plasmids; Promyelocytic Leukemia Protein; RNA, Small Interfering; Transcription Factors; Transcription, Genetic; Transfection; Tumor Suppressor Proteins; Viral Matrix Proteins | 2011 |
Alteration in miRNA gene expression pattern in acute promyelocytic leukemia cell induced by arsenic trioxide: a possible mechanism to explain arsenic multi-target action.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression; Humans; Leukemia, Promyelocytic, Acute; MicroRNAs; Oxides | 2012 |
Research on acute promyelocytic leukemia conducted in Iran.
Topics: Antineoplastic Agents; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides | 2012 |
Use of arsenic trioxide as a first-line single agent in the treatment of acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides | 2012 |
Realgar-induced apoptosis and differentiation in all-trans retinoic acid (ATRA)-sensitive NB4 and ATRA-resistant MR2 cells.
Topics: Apoptosis; Arsenicals; Cell Differentiation; Cell Line, Tumor; Disease-Free Survival; DNA, Neoplasm; Gene Expression Profiling; Humans; Leukemia, Promyelocytic, Acute; Microarray Analysis; Oncogene Proteins, Fusion; Signal Transduction; Sulfides; Tretinoin | 2012 |
Promyelocytic leukemia nuclear bodies support a late step in DNA double-strand break repair by homologous recombination.
Topics: Arsenic Trioxide; Arsenicals; Cell Nucleus; DNA Breaks, Double-Stranded; DNA End-Joining Repair; DNA, Neoplasm; Genomic Instability; Histones; Humans; Leukemia, Promyelocytic, Acute; Nuclear Proteins; Oncogene Proteins, Fusion; Oxides; Phosphorylation; Promyelocytic Leukemia Protein; Rad51 Recombinase; Recombinational DNA Repair; RNA Interference; Transcription Factors; Tretinoin; Tumor Suppressor Proteins | 2012 |
Speciation of arsenic trioxide metabolites in peripheral blood and bone marrow from an acute promyelocytic leukemia patient.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow; Chromatography, High Pressure Liquid; Drug Monitoring; Female; Humans; Leukemia, Promyelocytic, Acute; Mass Spectrometry; Middle Aged; Neoplasm Recurrence, Local; Oxides; Prognosis; Remission Induction; Salvage Therapy; Tissue Distribution | 2012 |
Sustained molecular remission after arsenic trioxide and gemutuzumab ozogamicin in a pediatric patient with relapsed acute promyelocytic leukemia.
Topics: Aminoglycosides; Antibodies, Monoclonal, Humanized; Arsenic Trioxide; Arsenicals; Benzoates; Child; Drug Administration Schedule; Gemtuzumab; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Recurrence; Remission Induction; Tetrahydronaphthalenes; Tretinoin | 2012 |
Role of minimal residual disease monitoring in acute promyelocytic leukemia treated with arsenic trioxide in frontline therapy.
Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Molecular Diagnostic Techniques; Monitoring, Physiologic; Neoadjuvant Therapy; Neoplasm, Residual; Oncogene Proteins, Fusion; Oxides; Predictive Value of Tests; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Young Adult | 2012 |
Long-term remission in a case of acute promyelocytic leukemia patient with marked myelofibrosis treated with arsenic trioxide, all-trans retinoic acid and consolidation therapy with daunorubicin plus cytarabine.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Promyelocytic, Acute; Oxides; Primary Myelofibrosis; Remission Induction; Survivors; Tretinoin | 2012 |
[Regulation of all-trans retinoic acid and arsenic trioxide on CD44v6 expression in NB4 cells].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Gene Expression Regulation, Leukemic; Humans; Hyaluronan Receptors; Leukemia, Promyelocytic, Acute; Oxides; Signal Transduction; Tretinoin | 2012 |
Quantification of PML/RARa transcript after induction predicts outcome in children with acute promyelocytic leukemia.
Topics: Adolescent; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Disease-Free Survival; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Multivariate Analysis; Neoplasm, Residual; Oncogene Proteins, Fusion; Oxides; Prognosis; Real-Time Polymerase Chain Reaction; Remission Induction; Transcription, Genetic; Treatment Outcome; Tretinoin | 2012 |
Mitochondrial myopathy caused by arsenic trioxide therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; DNA Mutational Analysis; Female; Humans; Leukemia, Promyelocytic, Acute; Mitochondria, Muscle; Mitochondrial Myopathies; Oxides; Tretinoin | 2012 |
Parenthood in patients with acute promyelocytic leukemia after treatment with arsenic trioxide: a case series.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Fertility; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Pregnancy; Pregnancy Outcome | 2012 |
Does arsenic trioxide impact fertility?
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Fertility; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Pregnancy | 2012 |
Combination therapy with arsenic trioxide, all-trans retinoic acid, and chemotherapy in acute promyelocytic leukemia patients with various relapse risks.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Staging; Oxides; Recurrence; Remission Induction; Retrospective Studies; Risk Factors; Treatment Outcome; Tretinoin; Young Adult | 2012 |
Cardiac conduction block at multiple levels caused by arsenic trioxide therapy.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Chelating Agents; Dimercaprol; Electrocardiography; Female; Follow-Up Studies; Growth Inhibitors; Heart Block; Heart Conduction System; Humans; Leukemia, Promyelocytic, Acute; Middle Aged; Oxides | 2013 |
The arsenic-based cure of acute promyelocytic leukemia promotes cytoplasmic sequestration of PML and PML/RARA through inhibition of PML body recycling.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Nucleus; Cytoplasm; Fluorescent Antibody Technique; Humans; Leukemia, Promyelocytic, Acute; Mutation; Nuclear Pore Complex Proteins; Nuclear Proteins; Oncogene Proteins, Fusion; Oxides; Promyelocytic Leukemia Protein; Recycling; Sumoylation; Transcription Factors; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2012 |
Acute promyelocytic leukemia: a population-based study on incidence and survival in the United States, 1975-2008.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arsenic Trioxide; Arsenicals; Female; Humans; Incidence; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; SEER Program; Time Factors; Tretinoin; United States | 2012 |
The organic arsenic derivative GMZ27 induces PML-RARα-independent apoptosis in myeloid leukemia cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 9; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Dose-Response Relationship, Drug; Enzyme Activation; Female; HL-60 Cells; Humans; Leukemia, Myelomonocytic, Acute; Leukemia, Promyelocytic, Acute; Mice; Oncogene Proteins, Fusion; Oxides; Oxygen | 2012 |
[Effect of arsenic trioxide and daunorubicin on procoagulant activity of acute promyelocytic leukemia cells].
Topics: Adult; Arsenic Trioxide; Arsenicals; Blood Coagulation; Blood Coagulation Tests; Case-Control Studies; Daunorubicin; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Phosphatidylserines; Thromboplastin; Tumor Cells, Cultured; Young Adult | 2012 |
Kidney transplantation in a patient with end stage renal disease after complete remission of acute promyelocytic leukemia.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; Humans; Kidney Failure, Chronic; Kidney Transplantation; Leukemia, Promyelocytic, Acute; Male; Oxides; Receptors, Retinoic Acid; Remission Induction; Retinoic Acid Receptor alpha; Ultrasonography | 2012 |
Upfront maintenance therapy with arsenic trioxide in acute promyelocytic leukemia provides no benefit for non-t(15;17) subtype.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Humans; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Male; Mercaptopurine; Middle Aged; Oxides; Retrospective Studies; Tretinoin | 2012 |
Oral administration of arsenic trioxide in the treatment of acute promyelocytic leukaemia and accelerated phase chronic myeloid leukaemia: an Australian single-centre study.
Topics: Administration, Oral; Adult; Aged; Arsenic Trioxide; Arsenicals; Australia; Female; Growth Inhibitors; Humans; Leukemia, Myeloid, Accelerated Phase; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Treatment Outcome | 2012 |
ATRA plus arsenic gets another "A" in APL.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Oxides; Tretinoin | 2012 |
Long-term efficacy and safety of arsenic trioxide for first-line treatment of elderly patients with newly diagnosed acute promyelocytic leukemia.
Topics: Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Prognosis; Recurrence | 2013 |
Granulocyte colony-stimulating factor potentiates differentiation induction by all-trans retinoic acid and arsenic trioxide and enhances arsenic uptake in the acute promyelocytic leukemia cell line HT93A.
Topics: Antigens, CD34; Apoptosis; Aquaporins; Arsenic Trioxide; Arsenicals; Biological Transport; Biomarkers, Tumor; CD11b Antigen; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Promyelocytic, Acute; Lewis X Antigen; Oxides; Tretinoin; Up-Regulation | 2012 |
Cytotoxic effect of arsenic trioxide on acute promyelocytic leukemia cells through suppression of NFkβ-dependent induction of hTERT due to down-regulation of Pin1 transcription.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA-Binding Proteins; Down-Regulation; Gene Expression Regulation, Leukemic; Genes, myc; Humans; Inhibitor of Apoptosis Proteins; Leukemia, Promyelocytic, Acute; NF-kappa B; NIMA-Interacting Peptidylprolyl Isomerase; Nuclear Proteins; Oxides; Peptidylprolyl Isomerase; Phosphorylation; Survivin; Telomerase; Telomere Shortening; Transcription, Genetic; Tumor Protein p73; Tumor Suppressor Proteins | 2012 |
[microRNAs expression profile in acute promyelocytic leukemia cell differentiation induced by all-trans retinoic acid and arsenic trioxide].
Topics: Arsenic Trioxide; Arsenicals; Cell Differentiation; Humans; Leukemia, Promyelocytic, Acute; MicroRNAs; Oxides; RNA, Messenger; Tretinoin; Tumor Cells, Cultured | 2012 |
High efficacy of arsenic trioxide plus all-trans retinoic acid based induction and maintenance therapy in newly diagnosed acute promyelocytic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Retrospective Studies; Tretinoin | 2013 |
Feasibility of oral arsenic trioxide treatment for acute promyelocytic leukemia during hemodialysis.
Topics: Administration, Oral; Adult; Arsenic Trioxide; Arsenicals; Feasibility Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Renal Dialysis; Treatment Outcome | 2013 |
Outcome of elderly patients with acute promyelocytic leukemia: results of the German Acute Myeloid Leukemia Cooperative Group.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Bone Marrow; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Follow-Up Studies; Germany; Humans; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Leukocyte Count; Maintenance Chemotherapy; Male; Middle Aged; Mitoxantrone; Multicenter Studies as Topic; Oxides; Prognosis; Randomized Controlled Trials as Topic; Remission Induction; Risk; Thioguanine; Treatment Outcome; Tretinoin | 2013 |
Prognostic significance of CD44v6/v7 in acute promyelocytic leukemia.
Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; Female; Humans; Hyaluronan Receptors; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Tretinoin; Tumor Cells, Cultured; Young Adult | 2012 |
[Management of relapsed acute promyelocytic leukemia].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzoates; Brain; Humans; Leukemia, Promyelocytic, Acute; Leukemic Infiltration; Oxides; Recurrence; Tetrahydronaphthalenes | 2012 |
Long term curative effects of sequential therapy with all-trans retinoic acid, arsenious oxide and chemotherapy on patients with acute promyelocytic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Consolidation Chemotherapy; Female; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Male; Middle Aged; Oncogene Proteins, Fusion; Oxides; Treatment Outcome; Tretinoin; Young Adult | 2012 |
The deubiquitinating enzyme USP37 regulates the oncogenic fusion protein PLZF/RARA stability.
Topics: Animals; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Transformation, Neoplastic; Endopeptidases; Gene Expression Regulation, Leukemic; Humans; Leukemia, Promyelocytic, Acute; Mice; Oncogene Proteins, Fusion; Oxides; Protein Stability; Translocation, Genetic | 2013 |
[Effects of cucurmosin combined with common chemotherapeutics on proliferation and apoptosis of NB4 cells].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Humans; Leukemia, Promyelocytic, Acute; Oxides; Plant Proteins; Tretinoin | 2012 |
All-trans retinoic acid and arsenic trioxide resistance of acute promyelocytic leukemia with the variant STAT5B-RARA fusion gene.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oncogene Proteins, Fusion; Oxides; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; STAT5 Transcription Factor; Tretinoin | 2013 |
BIBR 1532 increases arsenic trioxide-mediated apoptosis in acute promyelocytic leukemia cells: therapeutic potential for APL.
Topics: Aminobenzoates; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Promyelocytic, Acute; Naphthalenes; Oxides; Telomerase | 2013 |
Ultrastructural localization of F-actin using phalloidin and quantum dots in HL-60 promyelocytic leukemia cell line after cell death induction by arsenic trioxide.
Topics: Actins; Apoptosis; Arsenic Trioxide; Arsenicals; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; Microscopy, Electron, Transmission; Oxides; Phalloidine; Quantum Dots | 2013 |
Arsenic speciation in saliva of acute promyelocytic leukemia patients undergoing arsenic trioxide treatment.
Topics: Adult; Antineoplastic Agents; Arsenates; Arsenic Trioxide; Arsenicals; Arsenites; Cacodylic Acid; Chromatography, High Pressure Liquid; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Leukemia, Promyelocytic, Acute; Male; Methylation; Middle Aged; Oxides; Saliva; Spectrophotometry, Atomic | 2013 |
Role of arsenic trioxide in acute promyelocytic leukemia.
Topics: Aminoglycosides; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials, Phase III as Topic; Gemtuzumab; Humans; Leukemia, Promyelocytic, Acute; Oxides; Prognosis; Randomized Controlled Trials as Topic; Tretinoin | 2013 |
Determination of arsenic metabolites in patients with newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide.
Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Chromatography, High Pressure Liquid; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Metabolomics; Middle Aged; Oxides; Young Adult | 2013 |
Targeted removal of PML-RARalpha protein is required prior to inhibition of histone deacetylase for overcoming all-trans retinoic acid differentiation resistance in acute promyelocytic leukemia.
Topics: Acetamides; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Butyrates; Cell Differentiation; Drug Interactions; Drug Resistance, Neoplasm; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Tretinoin; Tumor Cells, Cultured | 2002 |
[Diamide and cyclosporin A enhanced arsenic trioxide-induced apoptosis in NB4 cells].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cyclosporine; Diamide; Drug Synergism; Enzyme Inhibitors; Humans; Leukemia, Promyelocytic, Acute; Membrane Potentials; Mitochondria; Oxides; Sulfhydryl Reagents; Tumor Cells, Cultured | 2002 |
Arsenic trioxide, retinoic acid and Ara-c regulated the expression of annexin II on the surface of APL cells, a novel co-receptor for plasminogen/tissue plasminogen activator.
Topics: Adolescent; Adult; Annexin A2; Antineoplastic Agents; AraC Transcription Factor; Arsenic Trioxide; Arsenicals; Bacterial Proteins; Female; Fibrinolysin; Gene Expression Regulation; Hemorrhage; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Plasminogen Activators; Repressor Proteins; RNA, Messenger; Tissue Plasminogen Activator; Transcription Factors; Transfection; Tretinoin; Tumor Cells, Cultured | 2002 |
Atypical blasts and bone marrow necrosis associated with near-triploid relapse of acute promyelocytic leukemia after arsenic trioxide treatment.
Topics: Adult; Arsenic Trioxide; Arsenicals; Biopsy; Bone Marrow; Chromosome Aberrations; Fatal Outcome; Female; Humans; Karyotyping; Leukemia, Promyelocytic, Acute; Necrosis; Oxides; Ploidies; Recurrence | 2002 |
Real-time quantification of the multidrug resistance-1 gene expression in relapsed acute promyelocytic leukemia treated with arsenic trioxide.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Dose-Response Relationship, Drug; Female; Genes, MDR; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Recurrence; Reverse Transcriptase Polymerase Chain Reaction | 2002 |
Arsenic trioxide promotes histone H3 phosphoacetylation at the chromatin of CASPASE-10 in acute promyelocytic leukemia cells.
Topics: Acetylation; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Northern; Blotting, Western; Caspase 10; Caspases; Chromatin; DNA, Complementary; Dose-Response Relationship, Drug; Enzyme Activation; Histones; Humans; Leukemia, Promyelocytic, Acute; Oligonucleotide Array Sequence Analysis; Oligopeptides; Oxides; Phosphorylation; Polymerase Chain Reaction; Precipitin Tests; Protease Inhibitors; Protein Binding; Serine; Time Factors; Tumor Cells, Cultured | 2002 |
In vivo activation of cAMP signaling induces growth arrest and differentiation in acute promyelocytic leukemia.
Topics: Animals; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Division; Cyclic AMP; Leukemia, Promyelocytic, Acute; Mice; Mice, Transgenic; Oxides; Signal Transduction; Theophylline; Tretinoin; Tumor Cells, Cultured | 2002 |
[Experimental study of low dose arsenic trioxide in treatment of patients with acute promyelocytic leukemia].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Drug Interactions; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Isoquinolines; Leukemia, Promyelocytic, Acute; Oxides; Sulfonamides; Thionucleotides; Tumor Cells, Cultured | 2002 |
Two cases of therapy-related acute promyelocytic leukemia (t-APL) after mantle cell lymphoma and gestational trophoblastic disease.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Arsenic Trioxide; Arsenicals; Etoposide; Female; Gestational Trophoblastic Disease; Humans; Leukemia, Promyelocytic, Acute; Lymphoma, Mantle-Cell; Male; Neoplasms, Second Primary; Oxides; Pregnancy; Tretinoin | 2002 |
Molecular remission and reconstitution of a full chimera with arsenic trioxide in a patient with acute promyelocytic leukemia relapsed after allogeneic bone marrow transplantation.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Transplantation; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Molecular Diagnostic Techniques; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Recurrence; Remission Induction; RNA, Neoplasm; Salvage Therapy; Transplantation Chimera; Transplantation, Homologous | 2002 |
[The comparison between the mechanisms of sodium selenite induced apoptosis and arsenic trioxide induced apoptosis in human acute promyelocytic leukemia cell line NB4 cells].
Topics: Acetylcysteine; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Division; DNA, Neoplasm; Flow Cytometry; Glutathione; Humans; Intracellular Membranes; Leukemia, Promyelocytic, Acute; Membrane Potentials; Mitochondria; Oxides; Reactive Oxygen Species; Sodium Selenite; Tumor Cells, Cultured | 2002 |
P-glycoprotein (P-gp) and multidrug resistance-associated protein 1 (MRP1) are induced by arsenic trioxide (As(2)O(3)), but are not the main mechanism of As(2)O(3)-resistance in acute promyelocytic leukemia cells.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Drug Resistance, Neoplasm; Gene Expression Regulation; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tumor Cells, Cultured | 2003 |
Effects of red orpiment on cell morphology and expression of PML mRNA and protein in NB4 and HL-60 cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenicals; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; Medicine, Chinese Traditional; Neoplasm Proteins; Nuclear Proteins; Promyelocytic Leukemia Protein; RNA, Messenger; Transcription Factors; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2003 |
[Successful treatment after acute promyelocytic leukemia (APL) syndrome of relapsed API with arsenic trioxide].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Drug Administration Schedule; Female; Humans; Informed Consent; Leukemia, Promyelocytic, Acute; Middle Aged; Oxides; Recurrence; Remission Induction | 2003 |
[In vitro study of the effects of arsenic trioxide combined with 8-CPT-cAMP on differentiation induction in retinoic acid resistant acute promyelocytic leukemia cells].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Cyclic AMP; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Humans; Leukemia, Promyelocytic, Acute; Oxides; Thionucleotides; Tretinoin | 2003 |
[Clinical observation of the short-term efficacy of the treatment with combination of all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) in newly diagnosed acute promyelocytic leukemia (APL)].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Female; Follow-Up Studies; Gene Expression; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oncogene Proteins, Fusion; Oxides; Remission Induction; Time Factors; Treatment Outcome; Tretinoin | 2003 |
[Preliminary observation of the combination of arsenic trioxide and all-trans retinoic acid for the treatment of acute promyelocytic leukemia].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Remission Induction; Treatment Outcome; Tretinoin | 2003 |
Sustained molecular remission in advanced acute promyelocytic leukemia with combined pulsed retinoic acid and arsenic trioxide. Clinical evidence of synergistic effect and real-time quantification of minimal residual disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Drug Synergism; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm, Residual; Oxides; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Tretinoin | 2003 |
Arsenic trioxide in comparison with chemotherapy and bone marrow transplantation for the treatment of relapsed acute promyelocytic leukaemia.
Topics: Adolescent; Adult; Arsenic Trioxide; Arsenicals; Bone Marrow Transplantation; Child; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Retrospective Studies; Secondary Prevention; Survival Rate | 2003 |
Methylated metabolites of arsenic trioxide are more potent than arsenic trioxide as apoptotic but not differentiation inducers in leukemia and lymphoma cells.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Differentiation; Coculture Techniques; Glutathione Peroxidase; Hematopoietic Stem Cells; Humans; Hydrogen Peroxide; K562 Cells; Leukemia, Promyelocytic, Acute; Liver Neoplasms; Lymphoma; Methylation; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Tumor Cells, Cultured | 2003 |
Glutathione depletion overcomes resistance to arsenic trioxide in arsenic-resistant cell lines.
Topics: Annexin A5; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; Cell Division; Drug Resistance, Neoplasm; Electrophoretic Mobility Shift Assay; Glutathione; Humans; In Situ Nick-End Labeling; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Reactive Oxygen Species; Tumor Cells, Cultured | 2003 |
[In vitro study on realgar induced apoptosis of all-trans acid resistant acute promeylocytic leukemia cell line (MR2)].
Topics: Antineoplastic Agents; Apoptosis; Arsenicals; Cell Division; Cell Survival; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Materia Medica; Sulfides; Tretinoin; Tumor Cells, Cultured | 2002 |
[Investigation on NB4 cell responses to realgar by cDNA microarray].
Topics: Antineoplastic Agents; Arsenicals; Gene Expression Profiling; Gene Expression Regulation; Genes, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Materia Medica; Oligonucleotide Array Sequence Analysis; Sulfides; Tumor Cells, Cultured | 2002 |
[A serial study of in cytogenetic change and morphology on the tetra-arsenic tetra-sulfide treatment in untreated or recurrent acute promyelocytic leukemia].
Topics: Adult; Arsenicals; Bone Marrow; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Female; Humans; In Situ Hybridization, Fluorescence; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Recurrence; Sulfides; Translocation, Genetic | 2003 |
Arsenic trioxide-induced mitotic arrest and apoptosis in acute promyelocytic leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caffeine; Dithiothreitol; Drug Interactions; Humans; Leukemia, Promyelocytic, Acute; Membrane Potentials; Mitochondria; Mitosis; Oxides; Tumor Cells, Cultured | 2003 |
Gene expression profile changes in NB4 cells induced by arsenic trioxide.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Humans; Leukemia, Promyelocytic, Acute; Oligonucleotide Array Sequence Analysis; Oncogenes; Oxides; Tumor Cells, Cultured | 2003 |
Gene expression profile changes in NB4 cells induced by realgar.
Topics: Arsenicals; Down-Regulation; Gene Expression; Humans; Leukemia, Promyelocytic, Acute; Oligonucleotide Array Sequence Analysis; Sulfides; Tumor Cells, Cultured; Up-Regulation | 2003 |
Prolonged molecular remission after arsenic trioxide and all-trans retinoic acid for acute promyelocytic leukemia relapsed after allogeneic stem cell transplantation.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Combined Modality Therapy; Female; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Remission Induction; Salvage Therapy; Stem Cell Transplantation; Transplantation, Homologous; Tretinoin | 2003 |
Effect of arsenic trioxide on QT interval in patients with advanced malignancies.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Clinical Trials as Topic; Electrocardiography; Female; Humans; Leukemia, Promyelocytic, Acute; Long QT Syndrome; Male; Middle Aged; Neoplasms; Oxides; Retrospective Studies; Torsades de Pointes | 2003 |
Leukemia-associated translocation products able to activate RAS modify PML and render cells sensitive to arsenic-induced apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Arsenicals; Benzamides; Enzyme Inhibitors; Fibroblasts; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Genes, ras; Humans; Imatinib Mesylate; Leukemia, Promyelocytic, Acute; Monocytes; Oxides; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Isoforms; Proto-Oncogene Proteins c-abl; Pyrimidines; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Transgenes; Translocation, Genetic; Tumor Cells, Cultured; U937 Cells; Up-Regulation | 2003 |
[Change of PML/PML-RARalpha protein during treatment with tetraarsenic tetrasulfide (As4S4) in patients with acute promyelocytic leukemia].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Arsenicals; Female; Fluorescent Antibody Technique, Indirect; Humans; In Situ Nick-End Labeling; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Proteins; Nuclear Proteins; Oncogene Proteins, Fusion; Promyelocytic Leukemia Protein; Transcription Factors; Tretinoin; Tumor Suppressor Proteins | 2003 |
Arsenic trioxide uses caspase-dependent and caspase-independent death pathways in myeloma cells.
Topics: Acetylcysteine; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase Inhibitors; Caspases; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Oxides; Plasma Cells; Superoxides; Tumor Cells, Cultured | 2003 |
[Effects of As2O3 on tissue factor, plasminogen activator inhibitor-1 and -2 expression in NB4, HL-60 and THP-1 cells].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Gene Expression Regulation, Leukemic; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; Oxides; Plasminogen Activator Inhibitor 1; Plasminogen Activator Inhibitor 2; Thromboplastin; Tumor Cells, Cultured | 2003 |
[Study on cardiac toxicity in acute promyelocyte leukemia treatment of arsenic trioxide intravenous infusion in general dose].
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Calcium Channels; Electrocardiography; Female; Heart; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides | 2003 |
The revival of the ancient drug--arsenic.
Topics: Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Medicine, Chinese Traditional; Oxides | 2003 |
Effect of arsenic trioxide on cytokine expression by acute promyelocytic leukemia cells.
Topics: Arsenic Trioxide; Arsenicals; Cells, Cultured; Cytokines; Granulocyte Colony-Stimulating Factor; Humans; Interleukin-1; Interleukin-6; Interleukin-8; Leukemia, Promyelocytic, Acute; Oxides; Tumor Necrosis Factor-alpha | 2003 |
The effect of arsenic trioxide on QT interval prolongation during APL therapy.
Topics: Arsenic Trioxide; Arsenicals; Electrocardiography; Humans; Leukemia, Promyelocytic, Acute; Oxides | 2003 |
Arsenic enhances the activation of Stat1 by interferon gamma leading to synergistic expression of IRF-1.
Topics: Apoptosis; Arsenic; Arsenic Trioxide; Arsenicals; Cell Differentiation; DNA-Binding Proteins; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Interferon Regulatory Factor-1; Interferon-gamma; Leukemia, Promyelocytic, Acute; Oxides; Phosphoproteins; Promoter Regions, Genetic; Signal Transduction; STAT1 Transcription Factor; Superoxides; Trans-Activators; Tretinoin; Tumor Cells, Cultured | 2003 |
Impairment of heart rate variability control during arsenic trioxide treatment for acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Heart Rate; Humans; Leukemia, Promyelocytic, Acute; Oxides | 2004 |
JNK activation is a mediator of arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cells.
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cells, Cultured; Clone Cells; Drug Resistance, Neoplasm; Enzyme Activation; Glutathione; Humans; JNK Mitogen-Activated Protein Kinases; Leukemia, Promyelocytic, Acute; Mice; Mice, Knockout; Mitogen-Activated Protein Kinase 8; Mitogen-Activated Protein Kinases; Oxides; Receptor, EphA4 | 2004 |
[Clinical and experimental study of cardiac effects of conventional dosage arsenic trioxide in APL patients].
Topics: Adult; Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Calcium; Calcium Channels, L-Type; Cricetinae; Electrocardiography; Female; Heart; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides | 2004 |
[Successful bone marrow transplantation with a matched unrelated donor in an acute promyelocytic leukemia patient after reinduction therapy with arsenic trioxide].
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Transplantation; Combined Modality Therapy; Histocompatibility Testing; Humans; Infusions, Intravenous; Leukemia, Promyelocytic, Acute; Male; Oxides; Remission Induction; Tissue Donors; Transplantation, Homologous; Treatment Outcome | 2004 |
[Effects of realgar on tissue factor expression of NB4 and MR2 cells].
Topics: Antineoplastic Agents; Arsenicals; Blood Coagulation Factors; Cysteine Endopeptidases; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; HL-60 Cells; Humans; K562 Cells; Leukemia, Promyelocytic, Acute; Materia Medica; Neoplasm Proteins; RNA, Messenger; Sulfides; Thromboplastin; Tretinoin | 2003 |
Herpes zoster during treatment with arsenic trioxide.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Herpes Zoster; Humans; Leukemia, Promyelocytic, Acute; Oxides | 2004 |
Herpes zoster during treatment with arsenic trioxide.
Topics: 2-Aminopurine; Antineoplastic Agents; Antiviral Agents; Arsenic Trioxide; Arsenicals; Famciclovir; Female; Herpes Zoster; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Treatment Outcome | 2004 |
Biography of Zhu Chen.
Topics: Arsenic Trioxide; Arsenicals; China; Hematology; History, 20th Century; History, 21st Century; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin | 2004 |
[Effects of combination therapy with all-trans retinoic acid and arsenic trioxide on acute promyelocytic leukemia].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Blood Coagulation; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Tretinoin | 2004 |
Bone marrow necrosis in a patient with acute promyelocytic leukemia during re-induction therapy with arsenic trioxide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Bone Marrow; Bone Marrow Diseases; Fever; Humans; Hydroxyurea; Leukemia, Promyelocytic, Acute; Male; Mercaptopurine; Middle Aged; Necrosis; Oxides; Pancytopenia; Remission Induction | 2004 |
Death by arsenic: implications of PML sumoylation.
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; MAP Kinase Signaling System; Neoplasm Proteins; Nuclear Proteins; Oxides; Phosphorylation; Promyelocytic Leukemia Protein; Transcription Factors; Tumor Suppressor Proteins | 2004 |
Phosphorylation of PML by mitogen-activated protein kinases plays a key role in arsenic trioxide-mediated apoptosis.
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Cells, Cultured; CHO Cells; Cricetinae; Growth Inhibitors; HeLa Cells; Humans; Leukemia, Promyelocytic, Acute; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Neoplasm Proteins; Nuclear Proteins; Oncogene Proteins, Fusion; Oxides; Phosphorylation; Promyelocytic Leukemia Protein; Signal Transduction; Small Ubiquitin-Related Modifier Proteins; Transcription Factors; Tumor Suppressor Proteins | 2004 |
Acute promyelocytic leukemia cell line AP-1060 established as a cytokine-dependent culture from a patient clinically resistant to all-trans retinoic acid and arsenic trioxide.
Topics: Arsenic Trioxide; Arsenicals; Cell Culture Techniques; Cell Line, Tumor; Cytokines; Drug Resistance, Neoplasm; Humans; Karyotyping; Leukemia, Promyelocytic, Acute; Mutation, Missense; Oxides; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Telomerase; Telomere; Tretinoin | 2004 |
Arsenic trioxide in the treatment of advanced acute promyelocytic leukemia.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Transplantation; Child, Preschool; Combined Modality Therapy; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Recurrence; Remission Induction | 2004 |
[Arsenic absorption and retention in acute promyelocytic leukemia patients treated with tetra-arsenic tetra-sulfide].
Topics: Absorption; Antineoplastic Agents; Arsenic; Arsenicals; Hair; Humans; Leukemia, Promyelocytic, Acute | 2004 |
Extramedullary relapse in a patient with acute promyelocytic leukemia: successful treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies.
Topics: Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Breast Neoplasms; Female; Gemtuzumab; Humans; Leukemia, Promyelocytic, Acute; Leukemic Infiltration; Middle Aged; Oxides; Recurrence; Tretinoin | 2004 |
Inhibition of apoptosis in acute promyelocytic leukemia cells leads to increases in levels of oxidized protein and LMP2 immunoproteasome.
Topics: Aging; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase Inhibitors; Cell Line, Tumor; Cysteine Endopeptidases; Enzyme Inhibitors; Humans; Hydrogen Peroxide; Iron; Leukemia, Promyelocytic, Acute; Oxidation-Reduction; Oxidative Stress; Oxides; Proteins | 2004 |
Phenylarsine oxide (PAO) more intensely induces apoptosis in acute promyelocytic leukemia and As2O3-resistant APL cell lines than As2O3 by activating the mitochondrial pathway.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; bcl-X Protein; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Membrane Potentials; Mitochondria; Oxides; Proto-Oncogene Proteins c-bcl-2 | 2004 |
[Effect of the tetra-arsenic tetra-sulfide (As4S4) on the corrected QT interval in the treatment of acute promyelocytic leukemia].
Topics: Adolescent; Adult; Antineoplastic Agents; Arsenicals; Electrocardiography; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Sulfides | 2004 |
Treatment of acute promyelocytic leukemia in children: arsenic or ATRA.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Humans; Leukemia, Promyelocytic, Acute; Oxides; Remission Induction; Survival Rate; Treatment Outcome; Tretinoin | 2004 |
Treatment of children with newly diagnosed acute promyelocytic leukemia with arsenic trioxide: a single center experience.
Topics: Adolescent; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Remission Induction; Survival Rate; Treatment Outcome | 2004 |
Molecular remission with arsenic trioxide in patients with newly diagnosed acute promyelocytic leukemia.
Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Child; Drug Evaluation; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Polymerase Chain Reaction; Proto-Oncogene Proteins c-bcr; Remission Induction; Retrospective Studies; Treatment Outcome | 2004 |
Nursing considerations for nontraditional treatment approaches to hematologic malignancies.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Multiple Myeloma; Myelodysplastic Syndromes; Nurse's Role; Oncology Nursing; Oxides; Treatment Outcome | 2004 |
Sodium selenite induces apoptosis in acute promyelocytic leukemia-derived NB4 cells by a caspase-3-dependent mechanism and a redox pathway different from that of arsenic trioxide.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Caspases; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Humans; Leukemia, Promyelocytic, Acute; Mitochondria; Oxidation-Reduction; Oxides; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Signal Transduction; Sodium Selenite; Sulfhydryl Compounds; Tretinoin | 2004 |
Arsenic trioxide: new preparation. Acute promyelocytic leukaemia: encouraging results but persistent doubts.
Topics: Antineoplastic Agents; Arsenicals; Clinical Trials as Topic; Disease-Free Survival; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Neoplasm Recurrence, Local; Oxides; Remission Induction | 2004 |
Arsenic trioxide (ATO) and MEK1 inhibition synergize to induce apoptosis in acute promyelocytic leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Inhibitors; Flavonoids; Growth Inhibitors; Humans; Kinetics; Leukemia, Promyelocytic, Acute; MAP Kinase Kinase 1; Membrane Potentials; Mitochondria; Oxides; RNA, Small Interfering; Transfection | 2005 |
Hematological and molecular remission with combination chemotherapy in a patient with PLZF-RARalpha acute promyelocytic leukemia (APML).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Translocation, Genetic | 2005 |
[In vitro study on arsenic trioxide-inducing apoptosis in primary acute promyelocytic leukemie cells].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Proliferation; Cells, Cultured; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Oxides | 1997 |
[Effect of arsenic trioxide on drug transporting molecules in acute promyelocytic leukemia cell line].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Oxides; Tretinoin; Vault Ribonucleoprotein Particles | 2004 |
[Effects of protein tyrosine kinase, protein tyrosine phosphatase and protein kinase C on the apoptosis of arsenic trioxide treated NB4 cells and human cortex neurons].
Topics: Adult; Apoptosis; Arsenic Trioxide; Arsenicals; Calcium; Cell Line, Tumor; Cells, Cultured; Cerebral Cortex; Cytoplasm; Dose-Response Relationship, Drug; Humans; Leukemia, Promyelocytic, Acute; Male; Neurons; Oxides; Protein Kinase C; Protein Tyrosine Phosphatases; Protein-Tyrosine Kinases | 2004 |
PRAM-1 potentiates arsenic trioxide-induced JNK activation.
Topics: Adaptor Proteins, Signal Transducing; Arsenic Trioxide; Arsenicals; Caspase 3; Caspases; Cell Line, Tumor; Cysteine Proteinase Inhibitors; Enzyme Activation; Humans; JNK Mitogen-Activated Protein Kinases; Kinetics; Leukemia, Promyelocytic, Acute; Microfilament Proteins; Oligopeptides; Oxides; Proteins; src Homology Domains; Tretinoin | 2005 |
Repeated arsenic trioxide intravenous infusion causes focal bone marrow necrosis in two acute promyelocytic leukemia patients.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow; Bone Marrow Diseases; Child; Female; Humans; Infusions, Intravenous; Leukemia, Promyelocytic, Acute; Male; Necrosis; Oxides | 2004 |
Arsenic trioxide triggers a regulated form of caspase-independent necrotic cell death via the mitochondrial death pathway.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; bcl-X Protein; Caspase 2; Caspase 9; Caspases; Cell Death; Cell Line, Tumor; Fibroblasts; Humans; Kinetics; Leukemia, Promyelocytic, Acute; Mitochondria; Necrosis; Oxides; Proto-Oncogene Proteins c-bcl-2 | 2005 |
Significance of intracellular arsenic trioxide for therapeutic response in acute promyelocytic leukemia.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Biological Transport; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Humans; Leukemia, Promyelocytic, Acute; Oxides; Prognosis | 2005 |
Simultaneous and ultrarapid determination of reactive oxygen species and reduced glutathione in apoptotic leukemia cells by microchip electrophoresis.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; Electrophoresis, Microchip; Fluorescent Dyes; Glutathione; Humans; Lasers; Leukemia, Promyelocytic, Acute; Miniaturization; Oxides; Reactive Oxygen Species; Reproducibility of Results; Rhodamines; Signal Transduction; Spectrometry, Fluorescence; Tumor Cells, Cultured | 2005 |
Triterpenoid CDDO-Im downregulates PML/RARalpha expression in acute promyelocytic leukemia cells.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Caspases; Cell Line, Tumor; Down-Regulation; Gene Expression Regulation, Leukemic; Humans; Imidazoles; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Nuclear Proteins; Oleanolic Acid; Oxides; Promyelocytic Leukemia Protein; Receptors, Retinoic Acid; Recombinant Fusion Proteins; Retinoic Acid Receptor alpha; Transcription Factors; Tretinoin; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2005 |
Requirement for myeloid growth factors in the differentiation of acute promyelocytic leukaemia.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Bryostatins; Cell Cycle; Cell Line, Tumor; Cell Transformation, Neoplastic; Flow Cytometry; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Growth Inhibitors; Humans; Leukemia, Promyelocytic, Acute; Macrolides; Myelopoiesis; Oxides; Tretinoin | 2005 |
[Arsenic treatment for leukemia: new model of human cancer target treatment].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzamides; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Promyelocytic, Acute; Oxides; Piperazines; Pyrimidines; Tretinoin | 2005 |
Successful treatment of relapsed acute promyelocytic leukemia in a patient receiving continuous ambulatory peritoneal dialysis with oral arsenic trioxide.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Oxides; Peritoneal Dialysis, Continuous Ambulatory; Recurrence; Treatment Outcome | 2005 |
Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Computational Biology; Drug Synergism; Electrophoresis, Gel, Two-Dimensional; Gene Expression Regulation, Neoplastic; Granulocytes; Humans; Leukemia, Promyelocytic, Acute; Mass Spectrometry; Oligonucleotide Array Sequence Analysis; Oxides; Proteomics; Reverse Transcriptase Polymerase Chain Reaction; Systems Biology; Tretinoin | 2005 |
Efficacy of gemtuzumab ozogamicin on ATRA- and arsenic-resistant acute promyelocytic leukemia (APL) cells.
Topics: Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Arsenic Trioxide; Arsenicals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Cycle; Cell Proliferation; Drug Resistance, Neoplasm; Gemtuzumab; Humans; Leukemia, Promyelocytic, Acute; Oxides; Treatment Outcome; Tretinoin; Tumor Cells, Cultured | 2005 |
Fluid retention during arsenic trioxide treatment in acute promyelocytic leukemia.
Topics: Aged; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; Edema; Humans; Leukemia, Promyelocytic, Acute; Leukocyte Count; Male; Oxides | 2005 |
[Therapeutic effects of combination of arsenic trioxide with low-dose all-trans retinoic acid on induction of remission acute promyeloeytic leukemia].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Drug Administration Schedule; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Remission Induction; Treatment Outcome; Tretinoin | 2005 |
As2O3 enhances the anion transport activity of band 3 and the action is related with the C-terminal 16 residues of the protein.
Topics: 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid; Adult; Anion Exchange Protein 1, Erythrocyte; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Erythrocytes; Female; Gene Deletion; HeLa Cells; Humans; In Vitro Techniques; Leukemia, Promyelocytic, Acute; Male; Oxides; Transfection; Yeasts | 2005 |
Clinical effects of arsenic trioxide by slowing-intravenous infusion on acute promyelocyte leukemia.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cerebral Hemorrhage; Humans; Infusions, Intravenous; Leukemia, Promyelocytic, Acute; Leukocytosis; Oxides | 2005 |
[Clinical observation and follow-up study on acute promyelocytic leukemia in childhood treated mainly with arsenic trioxide].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Remission Induction; Survival Rate; Treatment Outcome | 2005 |
Retinoid/arsenic combination therapy of promyelocytic leukemia: induction of telomerase-dependent cell death.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; DNA-Binding Proteins; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Remission Induction; Telomerase; Telomere; Tretinoin; Tumor Cells, Cultured | 2005 |
Phosphoinositide 3-kinase/Akt inhibition increases arsenic trioxide-induced apoptosis of acute promyelocytic and T-cell leukaemias.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Line, Tumor; Flow Cytometry; Humans; In Situ Nick-End Labeling; Jurkat Cells; Leukemia; Leukemia, Promyelocytic, Acute; Leukemia, T-Cell; Oxides; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; RNA, Small Interfering; Signal Transduction; Transfection; Tumor Cells, Cultured | 2005 |
Arsenic trioxide in the treatment of relapsed and refractory acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Japan; Leukemia, Promyelocytic, Acute; Oxides; Recurrence | 2005 |
Delayed recovery of normal hematopoiesis in arsenic trioxide treatment of acute promyelocytic leukemia: a comparison to all-trans retinoic acid treatment.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blood Coagulation; Erythrocyte Count; Hematopoiesis; Humans; Leukemia, Promyelocytic, Acute; Leukocyte Count; Leukocytes; Oxides; Platelet Count; Time Factors; Tretinoin | 2005 |
Cardiotoxicity in African-American patients treated with arsenic trioxide for acute promyelocytic leukemia.
Topics: Adult; Antineoplastic Agents; Arrhythmias, Cardiac; Arsenic Trioxide; Arsenicals; Black or African American; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Retrospective Studies | 2006 |
Arsenic trioxide inhibits nuclear receptor function via SEK1/JNK-mediated RXRalpha phosphorylation.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Carcinogens, Environmental; Chlorocebus aethiops; COS Cells; Environmental Exposure; Humans; JNK Mitogen-Activated Protein Kinases; Leukemia, Promyelocytic, Acute; MAP Kinase Kinase 4; Oxides; Phosphorylation; Receptors, Estrogen; Receptors, Glucocorticoid; Retinoid X Receptor alpha; Serine; Signal Transduction; Transcription, Genetic; Transcriptional Activation | 2005 |
[The impact of arsenic trioxide or all-trans retinoic acid treatment on coagulopathy in acute promyelocytic leukemia].
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blood Coagulation Disorders; Down-Regulation; Female; Hemorrhage; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; RNA, Messenger; Thrombomodulin; Thromboplastin; Tretinoin | 2001 |
Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Disease-Free Survival; Female; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Male; Middle Aged; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm, Residual; Oncogene Proteins, Fusion; Oxides; Prognosis; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Survival Rate; Treatment Outcome | 2006 |
[A clinical pharmacokinetic study of multi-dose oral tetra-arsenic tetra-sulfide combination therapy in acute promyelocytic leukemia].
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents; Area Under Curve; Arsenic; Arsenicals; Female; Hair; Humans; Leukemia, Promyelocytic, Acute; Male; Sulfides | 2005 |
Current management and new approaches in the treatment of APL.
Topics: Aminoglycosides; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Drug Monitoring; Gemtuzumab; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Stem Cell Transplantation; Tretinoin | 2003 |
Hypoxia-simulating agents selectively stimulate arsenic trioxide-induced growth arrest and cell differentiation in acute promyelocytic leukemic cells.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Division; Cell Hypoxia; Cobalt; Deferoxamine; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Tretinoin; U937 Cells | 2005 |
Hypoxia-simulating agents and selective stimulation of arsenic trioxide-induced growth arrest and cell differentiation in acute promyelocytic leukemic cells.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow; Cell Differentiation; Cell Division; Cell Hypoxia; Cell Line, Tumor; Cobalt; Deferoxamine; Drug Synergism; Gene Expression Regulation, Leukemic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Oxygen; Reverse Transcriptase Polymerase Chain Reaction; Tretinoin; U937 Cells | 2005 |
Serial studies of methylation of CDKN2B and CDKN2A in relapsed acute promyelocytic leukaemia treated with arsenic trioxide.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Case-Control Studies; Cyclin-Dependent Kinase Inhibitor p15; Cyclin-Dependent Kinase Inhibitor p16; Humans; Leukemia, Promyelocytic, Acute; Methylation; Neoplasm, Residual; Oxides; Reverse Transcriptase Polymerase Chain Reaction | 2005 |
[Oral administration of arsenic trioxide induced molecular remission in relapsed acute promyelocytic leukemia].
Topics: Administration, Oral; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Male; Neoplasm Recurrence, Local; Oxides; Remission Induction | 2005 |
[Acute pancreatitis during the treatment of relapsed acute promyelocytic leukemia with As2O3].
Topics: Acute Disease; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Pancreatitis; Recurrence | 2006 |
Elemental arsenic entered the cerebrospinal fluid during oral arsenic trioxide treatment of meningeal relapse of acute promyelocytic leukemia.
Topics: Administration, Oral; Antineoplastic Agents; Arsenic; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Male; Meningeal Neoplasms; Middle Aged; Oxides; Recurrence | 2006 |
Induction of human promyelocytic leukemia HL-60 cell differentiation into monocytes by arsenic sulphide: involvement of serine/threonine protein phosphatases.
Topics: Arsenicals; Cell Differentiation; Cell Proliferation; Dose-Response Relationship, Drug; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; Monocytes; Phosphoprotein Phosphatases; Serine; Structure-Activity Relationship; Sulfides; Threonine | 2006 |
Clinical pharmacokinetic study of arsenic trioxide in an acute promyelocytic leukemia (APL) patient: speciation of arsenic metabolites in serum and urine.
Topics: Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Chromatography, High Pressure Liquid; Drug Resistance, Neoplasm; Humans; Injections, Intravenous; Leukemia, Promyelocytic, Acute; Male; Methylation; Oxides; Seafood; Tretinoin | 2006 |
Solid tumors subsequent to arsenic trioxide treatment for acute promyelocytic leukemia.
Topics: Adenocarcinoma; Adult; Aged; Arsenic Trioxide; Arsenicals; Colonic Neoplasms; Female; Growth Inhibitors; Humans; Leukemia, Promyelocytic, Acute; Male; Nasopharyngeal Neoplasms; Neoplasms; Oxides | 2007 |
Role of GSTP1-1 in mediating the effect of As2O3 in the Acute Promyelocytic Leukemia cell line NB4.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Enzyme Activation; Glutathione S-Transferase pi; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Oxidation-Reduction; Oxidative Stress; Oxides; Time Factors | 2006 |
Superiority of an arsenic trioxide-based regimen over a historic control combining all-trans retinoic acid plus intensive chemotherapy in the treatment of relapsed acute promyelocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Drug Evaluation; Humans; Leukemia, Promyelocytic, Acute; Middle Aged; Oxides; Retrospective Studies; Salvage Therapy; Treatment Outcome; Tretinoin | 2006 |
Two cases of acute promyelocytic leukemia complicated by torsade de pointes during arsenic trioxide therapy.
Topics: Adult; Anthracyclines; Antifungal Agents; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cardiomyopathies; Female; Fluconazole; Humans; Hypokalemia; Leukemia, Promyelocytic, Acute; Middle Aged; Oxides; Time Factors; Torsades de Pointes | 2006 |
Recurrent extramedullary relapse of acute promyelocytic leukemia after allogeneic stem cell transplantation: successful treatment by arsenic trioxide in combination with local radiotherapy.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Combined Modality Therapy; Female; Humans; Leukemia, Promyelocytic, Acute; Middle Aged; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Radiography; Recurrence; Remission Induction; Sarcoma, Myeloid; Stem Cell Transplantation; Translocation, Genetic; Transplantation, Homologous; Tretinoin | 2006 |
[Mechanism of tetra-arsenic tetra-sulfide in inducing apoptosis of acute promyelocytic leukemia cells].
Topics: Apoptosis; Apoptosis Regulatory Proteins; Apoptotic Protease-Activating Factor 1; Arsenic; Arsenicals; Cell Line, Tumor; Gene Expression; Gene Expression Profiling; Humans; Leukemia, Promyelocytic, Acute; Oligonucleotide Array Sequence Analysis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sulfides | 2006 |
[Adverse effects of intravenous arsenic trioxide and their prevention].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Drug-Related Side Effects and Adverse Reactions; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides | 2006 |
[Long-term survival analysis in 170 cases of acute promyelocytic leukemia].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oncogene Proteins, Fusion; Oxides; Prognosis; Proportional Hazards Models; Remission Induction; Retrospective Studies; Survival Analysis; Survival Rate; Tretinoin | 2006 |
Use of Novoseven for arsenic trioxide-induced bleeding in PML.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Factor VII; Factor VIIa; Hemorrhage; Humans; Leukemia, Promyelocytic, Acute; Lung Diseases; Oxides; Recombinant Proteins | 2006 |
Role of the p38 mitogen-activated protein kinase pathway in the generation of arsenic trioxide-dependent cellular responses.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Promyelocytic, Acute; MAP Kinase Signaling System; Mice; Mice, Knockout; Oxides; p38 Mitogen-Activated Protein Kinases; Phosphorylation | 2006 |
Real-time PCR analysis of PML-RAR alpha in newly diagnosed acute promyelocytic leukaemia patients treated with arsenic trioxide as a front-line therapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Child; Early Diagnosis; Female; Follow-Up Studies; Gene Expression; Glucosephosphate Dehydrogenase; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Oncogene Proteins, Fusion; Oxides; Protein Isoforms; Recombinant Fusion Proteins; Recurrence; Reverse Transcriptase Polymerase Chain Reaction | 2006 |
[Chronic hepatic damage in acute promyelocytic leukemia patients treated with tetra-arsenic tetra-sulfide].
Topics: Adolescent; Adult; Aged; Arsenicals; Collagen Type IV; Fatty Liver; Female; Fibrosis; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Liver; Male; Middle Aged; Sulfides; Young Adult | 2006 |
Arsenic-induced APL differentiation in cerebrospinal fluid.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Cell Differentiation; Cerebrospinal Fluid; Female; Humans; Leukemia, Promyelocytic, Acute; Leukocytes; Oxides; Remission Induction; Treatment Outcome | 2007 |
Arsenic trioxide-responsive leukemia cutis in a patient with acute promyelocytic leukemia after ATRA treatment.
Topics: Adolescent; Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cytarabine; Female; Humans; Leukemia; Leukemia, Promyelocytic, Acute; Oxides; Risk; Skin; Tretinoin | 2006 |
Pharmacokinetics of arsenic species in Japanese patients with relapsed or refractory acute promyelocytic leukemia treated with arsenic trioxide.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Arsenic; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Prospective Studies | 2007 |
Relationship of expression of aquaglyceroporin 9 with arsenic uptake and sensitivity in leukemia cells.
Topics: Acute Disease; Aquaporins; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Gene Expression Profiling; Humans; K562 Cells; Leukemia, Myeloid; Leukemia, Promyelocytic, Acute; Oxides; Point Mutation; Reverse Transcriptase Polymerase Chain Reaction; Sensitivity and Specificity; Tretinoin; Up-Regulation | 2007 |
Pharmacologic inhibitors of extracellular signal-regulated kinase (ERKs) and c-Jun NH(2)-terminal kinase (JNK) decrease glutathione content and sensitize human promonocytic leukemia cells to arsenic trioxide-induced apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Glutathione; Humans; JNK Mitogen-Activated Protein Kinases; Leukemia; Leukemia, Promyelocytic, Acute; Oxides; Peroxides; Reactive Oxygen Species | 2006 |
A survival study and prognostic factors analysis on acute promyelocytic leukemia at a single center.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Disease-Free Survival; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oncogene Proteins, Fusion; Oxides; Recurrence; Remission Induction; Retrospective Studies; Risk Factors; Survival Rate; Tretinoin | 2007 |
Anion exchanger 2 mediates the action of arsenic trioxide.
Topics: Anion Transport Proteins; Annexin A5; Antiporters; Apoptosis; Arsenic Trioxide; Arsenicals; Biomarkers; Blotting, Western; CD11b Antigen; CD11c Antigen; Cell Line, Tumor; Cell Survival; Flow Cytometry; Humans; Hydrogen-Ion Concentration; Leukemia, Promyelocytic, Acute; Oxides; Reverse Transcriptase Polymerase Chain Reaction; SLC4A Proteins | 2006 |
Arsenic trioxide induced acute flare-up of rheumatoid arthritis in a patient with APL.
Topics: Aged; Arsenic Trioxide; Arsenicals; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides | 2007 |
Increased oxidative DNA products in patients with acute promyelocytic leukemia during arsenic therapy.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Arsenic Trioxide; Arsenicals; Deoxyguanosine; DNA; Humans; Leukemia, Promyelocytic, Acute; Oxidation-Reduction; Oxides; Reactive Oxygen Species | 2006 |
Leukocytosis and retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Dyspnea; Female; Fever; Humans; Leukemia, Promyelocytic, Acute; Leukocyte Count; Leukocytosis; Male; Middle Aged; Oxides; Remission Induction; Syndrome | 2006 |
Prolonged molecular remission in a newly diagnosed acute promyelocytic leukaemia with a severe cardiomyopathy using low-dose gemtuzumab ozogamicin and all-trans retinoic acid.
Topics: Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cardiomyopathies; Drug Therapy, Combination; Echocardiography; Gemtuzumab; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oncogene Proteins, Fusion; Oxides; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome; Tretinoin | 2007 |
Arsenic trioxide induces apoptosis via the mitochondrial pathway by upregulating the expression of Bax and Bim in human B cells.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Inducing Factor; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; B-Lymphocytes; bcl-2-Associated X Protein; Bcl-2-Like Protein 11; Cytochromes c; Cytoplasm; Humans; Leukemia, Promyelocytic, Acute; Male; Membrane Potentials; Membrane Proteins; Mitochondria; Oxidative Stress; Oxides; Proto-Oncogene Proteins; Up-Regulation | 2007 |
Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia.
Topics: Adult; Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Gemtuzumab; Humans; Leukemia, Promyelocytic, Acute; Middle Aged; Neoplasm Recurrence, Local; Oxides; Remission Induction; Treatment Outcome; Tretinoin | 2007 |
Arsenic trioxide induces p53-dependent apoptotic signals in myeloma cells with SiRNA-silenced p53: MAP kinase pathway is preferentially activated in cells expressing inactivated p53.
Topics: Antineoplastic Agents; APOBEC Deaminases; Apoptosis; Arsenic Trioxide; Arsenicals; Cyclin-Dependent Kinase Inhibitor p21; Cytidine Deaminase; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Mitochondrial Membranes; Mitogen-Activated Protein Kinase Kinases; Muscle Proteins; Mutation; Oxides; Receptors, TNF-Related Apoptosis-Inducing Ligand; RNA, Small Interfering; TNF-Related Apoptosis-Inducing Ligand; Tumor Suppressor Protein p53 | 2007 |
Current treatment of acute promyelocytic leukemia.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Clinical Trials as Topic; Computer Systems; Disease Management; Drug Monitoring; Hematopoietic Stem Cells; Humans; Leukemia, Promyelocytic, Acute; Leukocyte Count; Mice; Multicenter Studies as Topic; Oncogene Proteins, Fusion; Oxides; Polymerase Chain Reaction; Predictive Value of Tests; Recurrence; Sensitivity and Specificity; Transfection; Tretinoin | 2007 |
Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RARalpha-positive leukemic stem cells.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Ataxin-1; Ataxins; Biomarkers, Tumor; Cell Division; Cell Line, Tumor; Female; Growth Inhibitors; Hematopoietic Stem Cells; Humans; Leukemia, Promyelocytic, Acute; Mice; Mice, Inbred C57BL; Neoplastic Stem Cells; Nerve Tissue Proteins; Nuclear Proteins; Oncogene Proteins, Fusion; Oxides; Recombinant Fusion Proteins; Transfection; Tretinoin; Tumor Stem Cell Assay | 2007 |
Arsenic trioxide represses NF-kappaB activation and increases apoptosis in ATRA-treated APL cells.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Base Sequence; DNA Probes; Humans; Leukemia, Promyelocytic, Acute; NF-kappa B; Oxides; Tretinoin | 2006 |
Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement.
Topics: Adult; Antineoplastic Agents; Arsenic; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides | 2007 |
Chinese folk treatment reveals power of arsenic to treat cancer, new studies under way.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; China; Clinical Trials, Phase III as Topic; Humans; Leukemia, Promyelocytic, Acute; National Institutes of Health (U.S.); Oxides; United States | 2007 |
[Effects of arsenic trioxide or retinoic acid on mRNA and protein expression of tissue factor and thrombomodulin and procoagulant activity in NB4 cells].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; RNA, Messenger; Thrombomodulin; Thromboplastin; Tretinoin; Tumor Cells, Cultured | 2007 |
Arsenic trioxide induces accumulation of cytotoxic levels of ceramide in acute promyelocytic leukemia and adult T-cell leukemia/lymphoma cells through de novo ceramide synthesis and inhibition of glucosylceramide synthase activity.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Ceramides; Glucosyltransferases; Humans; Leukemia-Lymphoma, Adult T-Cell; Leukemia, Promyelocytic, Acute; Metabolic Networks and Pathways; Oxides | 2007 |
Eosinophils derived from acute promyelocytic leukemia cells after arsenic trioxide treatment.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Lineage; Eosinophils; Female; Humans; Leukemia, Promyelocytic, Acute; Middle Aged; Oxides | 2007 |
Oral arsenic trioxide therapy for acute promyelocytic leukemia before and after liver transplantation for hepatitis B virus-related liver failure.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Hepatitis B; Hepatitis B virus; Humans; Leukemia, Promyelocytic, Acute; Liver Failure; Liver Transplantation; Male; Oxides; RNA, Viral; Time Factors; Transplantation, Homologous; Virus Activation | 2007 |
Glycolytic metabolism confers resistance to combined all-trans retinoic acid and arsenic trioxide-induced apoptosis in HL60rho0 cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Drug Resistance, Neoplasm; Genes, Mitochondrial; Glycolysis; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin | 2008 |
Impact of FLT3 mutations and secondary cytogenetic changes on the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with a single agent arsenic trioxide regimen.
Topics: Arsenic Trioxide; Arsenicals; Cytogenetics; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Promyelocytic, Acute; Mutation; Oxides; Prognosis; Retrospective Studies; Treatment Outcome | 2007 |
Advances in management of acute promyelocytic leukemia with arsenic trioxide.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin | 2007 |
Acute intestinal pseudo-obstruction after induction treatment of relapsed acute promyelocytic leukemia with arsenic trioxide.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Digestive System Surgical Procedures; Female; Humans; Intestinal Pseudo-Obstruction; Leukemia, Promyelocytic, Acute; Neoplasm Recurrence, Local; Oxides | 2008 |
Entry of elemental arsenic into the central nervous system in patients with acute promyelocytic leukemia during arsenic trioxide treatment.
Topics: Antineoplastic Agents; Arsenic; Arsenic Trioxide; Arsenicals; Central Nervous System; Humans; Leukemia, Promyelocytic, Acute; Oxides | 2008 |
The PRKAR1A gene is fused to RARA in a new variant acute promyelocytic leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Australia; Base Sequence; Bone Marrow; Chromosome Aberrations; Clinical Trials as Topic; Cyclic AMP-Dependent Protein Kinase RIalpha Subunit; DNA Mutational Analysis; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Mutant Chimeric Proteins; Neoplasm Proteins; Oxides; Receptors, Retinoic Acid; Registries; Remission Induction; Retinoic Acid Receptor alpha; RNA, Messenger; Sequence Deletion; Tretinoin | 2007 |
Arsenic trioxide entered cerebrospinal fluid with the help of mannitol overwhelm the meningeal relapse of acute promyelocytic leukemia.
Topics: Adult; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Female; Humans; Injections, Intravenous; Leukemia, Promyelocytic, Acute; Magnetic Resonance Imaging; Mannitol; Meningeal Neoplasms; Neoplasm Recurrence, Local; Oxides; Remission Induction | 2007 |
NADPH oxidase-derived reactive oxygen species are responsible for the high susceptibility to arsenic cytotoxicity in acute promyelocytic leukemia cells.
Topics: Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Survival; Humans; Leukemia, Promyelocytic, Acute; NADPH Oxidases; Oxides; Reactive Oxygen Species | 2008 |
Prolonged oral arsenic trioxide therapy and nephrolithiasis [corrected].
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Arsenic; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Case-Control Studies; Drug Administration Schedule; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Nephrolithiasis; Oxides; Time Factors | 2007 |
Reply to 'Arsenic patent keeps drug for rare cancer out of reach for many'.
Topics: Adult; Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; China; Humans; Leukemia, Promyelocytic, Acute; Oxides; Patents as Topic; United States; United States Food and Drug Administration | 2007 |
Adhesion molecules and Differentiation Syndrome: phenotypic and functional analysis of the effect of ATRA, As2O3, phenylbutyrate, and G-CSF in acute promyelocytic leukemia.
Topics: Animals; Antigens, CD; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Adhesion; Cell Adhesion Molecules; Cell Differentiation; Gene Expression Regulation, Leukemic; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Promyelocytic, Acute; Mice; Mice, Inbred BALB C; Mice, Knockout; Neoplasm Proteins; Oxides; Phenylbutyrates; Syndrome; Tretinoin; Tumor Cells, Cultured | 2007 |
QT prolongation: a case of arsenical pericardial and pleural effusion.
Topics: Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Long QT Syndrome; Male; Oxides; Pericardial Effusion; Pleural Effusion; Recovery of Function; Withholding Treatment | 2008 |
[Effect of arsenic trioxide on the expression of apoptosis-related genes in NB4 cells].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; CDC2 Protein Kinase; Cell Line, Tumor; Cyclin B; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinases; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; Leukemia, Promyelocytic, Acute; Microtubule-Associated Proteins; Oxides; Survivin | 2007 |
Analytical artefacts in the speciation of arsenic in clinical samples.
Topics: Arsenic Trioxide; Arsenicals; Artifacts; Chromatography, High Pressure Liquid; Humans; Leukemia, Promyelocytic, Acute; Mass Spectrometry; Multiple Myeloma; Oxides; Spectrometry, Fluorescence | 2008 |
Insight into the selectivity of arsenic trioxide for acute promyelocytic leukemia cells by characterizing Saccharomyces cerevisiae deletion strains that are sensitive or resistant to the metalloid.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Biological Transport; Cell Line, Tumor; Cytoskeletal Proteins; DNA Repair; Gene Deletion; Glutathione; Humans; Leukemia, Promyelocytic, Acute; Membrane Proteins; Mitogen-Activated Protein Kinases; Osmotic Pressure; Oxidative Stress; Oxides; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Vacuoles | 2008 |
Optical neuropathy possibly related to arsenic during acute promyelocytic leukemia treatment.
Topics: Adult; Arsenic; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Optic Neuropathy, Ischemic; Oxides | 2008 |
[Successful cyclosporine treatment for thrombocytopenia after salvage therapy with arsenic trioxide therapy followed by autologous hematopoietic stem cell transplantation in acute promyelocytic leukemia].
Topics: Arsenic Trioxide; Arsenicals; Autoimmune Diseases; Cyclosporine; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Salvage Therapy; Thrombocytopenia; Transplantation, Autologous | 2007 |
Simultaneous appearance of central nervous system relapse and subarachnoid hemorrhage during the treatment for acute promyelocytic leukemia.
Topics: Adolescent; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Transplantation; Combined Modality Therapy; Endothelium, Vascular; Gemtuzumab; Humans; Injections, Spinal; Leukemia, Promyelocytic, Acute; Leukemic Infiltration; Magnetic Resonance Imaging; Male; Meninges; Middle Aged; Oxides; Postoperative Complications; Recurrence; Subarachnoid Hemorrhage; Tomography, X-Ray Computed | 2008 |
Effect of the combination of ATRA, ATO and DNR on CD11b expression in NB4 cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; CD11b Antigen; Cell Line, Tumor; Daunorubicin; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin | 2008 |
All-trans-retinoic acid and arsenic trioxide as initial therapy for acute promyelocytic leukemia.
Topics: Adolescent; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Dysplastic Nevus Syndrome; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Tretinoin | 2008 |
Regulation of arsenic trioxide-induced cellular responses by Mnk1 and Mnk2.
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Blast Crisis; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Enzyme Activation; Enzyme Inhibitors; Eukaryotic Initiation Factor-4E; Fibroblasts; Gene Targeting; Humans; Intracellular Signaling Peptides and Proteins; Leukemia, Promyelocytic, Acute; Mice; Mitogen-Activated Protein Kinases; Oxides; Phosphorylation; Protein Serine-Threonine Kinases; Tumor Stem Cell Assay | 2008 |
Hyperleukocytosis from arsenic trioxide.
Topics: Adolescent; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Male; Oxides; Recurrence | 2008 |
Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia.
Topics: Animals; Aquaporins; Arsenicals; Cell Differentiation; Cell Line, Tumor; Disease Models, Animal; Drug Synergism; Drugs, Chinese Herbal; G1 Phase; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Promyelocytic, Acute; Medicine, Chinese Traditional; Mice; Oncogene Proteins, Fusion; Protein Processing, Post-Translational; Resting Phase, Cell Cycle; Sulfides; Transcription, Genetic; Ubiquitination; Up-Regulation | 2008 |
Arsenic trioxide inhibits ATRA-induced prostaglandin E2 and cyclooxygenase-1 in NB4 cells, a model of acute promyelocytic leukemia.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; CD11c Antigen; Cell Differentiation; Cyclooxygenase 1; Dinoprostone; Drug Therapy, Combination; Humans; Indomethacin; Leukemia, Promyelocytic, Acute; Models, Biological; Oxides; Tretinoin; Tumor Cells, Cultured | 2008 |
Combination brings long-term remission in acute promyelocytic leukemia refractory for both all-trans retinoic acid and arsenic trioxide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Middle Aged; Oxides; Remission Induction; Salvage Therapy; Tretinoin | 2008 |
Retrospective analysis of 65 Chinese children with acute promyelocytic leukemia: a single center experience.
Topics: Adolescent; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Female; Humans; Infant; Leukemia, Promyelocytic, Acute; Male; Oxides; Prognosis; Recurrence; Retrospective Studies; Treatment Outcome; Tretinoin | 2008 |
Acute renal failure, gastrointestinal bleeding, and cardiac arrhythmia after administration of arsenic trioxide for acute promyelocytic leukemia.
Topics: Acute Kidney Injury; Aged, 80 and over; Antineoplastic Agents; Arrhythmias, Cardiac; Arsenic Trioxide; Arsenicals; Fatal Outcome; Female; Gastrointestinal Hemorrhage; Humans; Leukemia, Promyelocytic, Acute; Oxides | 2008 |
Arsenic trioxide augments Chk2/p53-mediated apoptosis by inhibiting oncogenic Wip1 phosphatase.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Ataxia Telangiectasia Mutated Proteins; Cell Cycle; Cell Cycle Proteins; Checkpoint Kinase 1; Checkpoint Kinase 2; DNA Damage; DNA-Binding Proteins; Dose-Response Relationship, Drug; Enzyme Activation; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; MAP Kinase Signaling System; Oxides; p38 Mitogen-Activated Protein Kinases; Phosphoprotein Phosphatases; Phosphorylation; Protein Kinases; Protein Phosphatase 2C; Protein Serine-Threonine Kinases; RNA, Small Interfering; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2008 |
Death-associated protein 5 (DAP5/p97/NAT1) contributes to retinoic acid-induced granulocytic differentiation and arsenic trioxide-induced apoptosis in acute promyelocytic leukemia.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Base Sequence; Cell Differentiation; Cell Line, Tumor; Eukaryotic Initiation Factor-2; Eukaryotic Initiation Factor-4G; Granulocytes; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; Models, Biological; Oxides; Phosphatidylinositol 3-Kinases; Protein Kinases; Proto-Oncogene Proteins c-akt; RNA-Binding Proteins; RNA, Small Interfering; Signal Transduction; TOR Serine-Threonine Kinases; Tretinoin; Up-Regulation | 2008 |
Ancient remedy performs new tricks.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Medicine, Chinese Traditional; Oxides; Remission Induction | 1996 |
In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Gene Expression Regulation, Leukemic; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; Lymphoma, Large B-Cell, Diffuse; Medicine, Chinese Traditional; Monocytes; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; RNA, Neoplasm; Tumor Cells, Cultured | 1996 |
The PML and PML/RARalpha domains: from autoimmunity to molecular oncology and from retinoic acid to arsenic.
Topics: Animals; Antibodies, Antinuclear; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Autoantigens; Autoimmune Diseases; Cell Differentiation; CHO Cells; Cricetinae; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Nuclear Proteins; Oncogene Proteins, Fusion; Oxides; Promyelocytic Leukemia Protein; Transcription Factors; Transfection; Tretinoin; Tumor Suppressor Proteins | 1996 |
Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Cell Adhesion; Cell Division; Cell Survival; DNA, Neoplasm; Drug Resistance, Neoplasm; Humans; Immunophenotyping; Kinetics; Leukemia, Promyelocytic, Acute; Oxides; Phagocytosis; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Subcellular Fractions; Time Factors; Tretinoin; Tumor Cells, Cultured | 1997 |
Arsenic and apoptosis in the treatment of acute promyelocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Tretinoin | 1998 |
Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Northern; Blotting, Western; Down-Regulation; Electrophoresis, Polyacrylamide Gel; Flow Cytometry; Humans; Leukemia, Promyelocytic, Acute; Oxides; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Transglutaminases; Tretinoin; Tumor Cells, Cultured | 1998 |
Combined arsenic and retinoic acid treatment enhances differentiation and apoptosis in arsenic-resistant NB4 cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Drug Resistance, Neoplasm; Drug Synergism; Humans; Leukemia, Promyelocytic, Acute; Microscopy, Confocal; Oxides; Tretinoin; Tumor Cells, Cultured | 1998 |
Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARalpha independent manner.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; Cell Division; Embryo, Mammalian; Fibroblasts; Gene Expression Regulation; Humans; Leukemia, Myeloid; Leukemia, Promyelocytic, Acute; Melarsoprol; Mice; Neoplasm Proteins; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Proto-Oncogene Proteins c-bcl-2; Receptors, Retinoic Acid; Transcription Factors; Tumor Cells, Cultured; Tumor Suppressor Proteins | 1998 |
[Double effects of arsenic trioxide (As2O3) on acute promyelocytic leukemic cell line].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Transformation, Neoplastic; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Oxides; Tumor Cells, Cultured | 1997 |
Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide.
Topics: Adolescent; Adult; Aged; Antigens, CD; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; Caspases; Cell Differentiation; Child; Humans; Immunophenotyping; Leukemia, Promyelocytic, Acute; Leukocytes, Mononuclear; Middle Aged; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Recurrence; Remission Induction | 1998 |
Arsenic--new life for an old potion.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Remission Induction | 1998 |
Acute promyelocytic leukemia: a curable disease.
Topics: Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Drug Resistance; Hematopoietic Stem Cell Transplantation; Humans; Immunophenotyping; Karyotyping; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Neoplasm, Residual; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Recurrence; Research; Rome; Transcription Factors; Tretinoin; Tumor Suppressor Proteins | 1998 |
Scientists explore use of arsenic in therapy.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Neoplasms; Oxides | 1998 |
Application of heavy metal and cytokine for differentiation-inducing therapy in acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Transformation, Neoplastic; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin; Tumor Cells, Cultured | 1998 |
Acute and chronic arsenic poisoning associated with treatment of acute promyelocytic leukaemia.
Topics: Acute Disease; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Chronic Disease; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence | 1998 |
Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARalpha fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Differentiation; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 17; DNA-Binding Proteins; Drug Resistance, Neoplasm; Fluorescent Antibody Technique; Humans; Kruppel-Like Transcription Factors; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Oxides; Promyelocytic Leukemia Zinc Finger Protein; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Transcription Factors; Translocation, Genetic; Tretinoin; Tumor Cells, Cultured | 1999 |
Treatment of acute promyelocytic leukemia with arsenic trioxide.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Bone Marrow; Caspases; Humans; Leukemia, Promyelocytic, Acute; Oxides; Remission Induction | 1999 |
Treatment of acute promyelocytic leukemia with arsenic trioxide.
Topics: Antineoplastic Agents; Arsenic; Arsenic Trioxide; Arsenicals; History, 16th Century; History, 18th Century; History, 19th Century; History, 20th Century; Humans; Leukemia; Leukemia, Promyelocytic, Acute; Oxides; Remission Induction | 1999 |
PIC-1/SUMO-1-modified PML-retinoic acid receptor alpha mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemia.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Caspase Inhibitors; Caspases; Cell Nucleus; DNA; Humans; Leukemia, Promyelocytic, Acute; Molecular Weight; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-bcl-2; Rabbits; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Staining and Labeling; SUMO-1 Protein; U937 Cells; Ubiquitins | 1999 |
In acute promyelocytic leukemia NB4 cells, the synthetic retinoid CD437 induces contemporaneously apoptosis, a caspase-3-mediated degradation of PML/RARalpha protein and the PML retargeting on PML-nuclear bodies.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Caspases; Cell Line; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Retinoids; Transcription Factors; Tumor Suppressor Proteins | 1999 |
Complete atrioventricular block after arsenic trioxide treatment in an acute promyelocytic leukemic patient.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Dose-Response Relationship, Drug; Electrocardiography; Female; Heart Block; Humans; Leukemia, Promyelocytic, Acute; Oxides | 1999 |
Arsenic: a new place?
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin | 1999 |
Arsenic and all-trans retinoic acid as induction therapy before autograft in a case of relapsed resistant secondary acute promyelocytic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Bone Marrow Transplantation; Humans; Leukemia, Promyelocytic, Acute; Male; Neoplasms, Second Primary; Oxides; Recurrence; Transplantation, Autologous; Tretinoin | 1999 |
Successful treatment with arsenic trioxide of a patient with ATRA-resistant relapse of acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow; Chromosome Banding; Colony-Forming Units Assay; Drug Resistance, Neoplasm; Feeding and Eating Disorders; Female; Humans; Leukemia, Promyelocytic, Acute; Leukocyte Count; Metaphase; Middle Aged; Musculoskeletal Diseases; Oxides; Pain; Polymerase Chain Reaction; Recurrence; Tretinoin | 1999 |
Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway.
Topics: Amitrole; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Catalase; Cytochrome c Group; Cytosol; Flow Cytometry; Glutathione Peroxidase; HL-60 Cells; Humans; Hydrogen Peroxide; Intracellular Membranes; K562 Cells; Kinetics; Leukemia, Promyelocytic, Acute; Membrane Potentials; Mitochondria; Oxides; Thiomalates; Tumor Cells, Cultured; U937 Cells | 1999 |
Re: Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Growth Inhibitors; Humans; Leukemia, Promyelocytic, Acute; Lymphocytes; Neoplasms, Second Primary; Oxides | 1999 |
Missense mutations in the PML/RARalpha ligand binding domain in ATRA-resistant As(2)O(3) sensitive relapsed acute promyelocytic leukemia.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Binding Sites; Bone Marrow; Carrier Proteins; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Ligands; Male; Middle Aged; Mutation, Missense; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Point Mutation; Protein Structure, Tertiary; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tretinoin | 1999 |
Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Caspases; Cell Differentiation; DNA, Neoplasm; Electrophoresis, Agar Gel; Enzyme Precursors; Flow Cytometry; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; Membrane Potentials; Microscopy, Electron; Mitochondria; Mutation; Oxides; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Tretinoin; Tumor Cells, Cultured | 2000 |
Pseudotumor cerebri after treatment of relapsed acute promyelocytic leukemia with arsenic trioxide.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Neoplasms; Diplopia; Female; Humans; Leukemia, Promyelocytic, Acute; Oxides; Papilledema; Pseudotumor Cerebri | 2000 |
In vitro exposure of acute promyelocytic leukemia cells to arsenic trioxide (As2O3) induces the solitary expression of CD66c (NCA-50/90), a member of the CEA family.
Topics: Antigens, CD; Antigens, Differentiation; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Adhesion Molecules; Cell Membrane; Epitopes; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tumor Cells, Cultured | 1999 |
Arsenic trioxide (As2O3)-induced apoptosis and differentiation in retinoic acid-resistant acute promyelocytic leukemia model in hGM-CSF-producing transgenic SCID mice.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; bcl-Associated Death Protein; bcl-X Protein; Carrier Proteins; Cell Cycle; Cell Differentiation; Cell Division; Drug Resistance, Neoplasm; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Promyelocytic, Acute; Mice; Mice, SCID; Mice, Transgenic; Neoplasm Proteins; Neoplasm Transplantation; Oxides; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Recombinant Fusion Proteins; Transplantation, Heterologous; Tretinoin; Tumor Cells, Cultured | 2000 |
Histone deacetylase inhibitor but not arsenic trioxide differentiates acute promyelocytic leukaemia cells with t(11;17) in combination with all-trans retinoic acid.
Topics: Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 17; Drug Therapy, Combination; Enzyme Inhibitors; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Leukemia, Promyelocytic, Acute; Male; Oxides; Translocation, Genetic; Tretinoin; Tumor Cells, Cultured | 2000 |
Arsenic trioxide (As2O3) gradually downregulates tissue factor expression without affecting thrombomodulin expression in acute promyelocytic leukemia cells.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Promyelocytic, Acute; Oxides; Reverse Transcriptase Polymerase Chain Reaction; Thrombomodulin; Thromboplastin; Transcription, Genetic; Tretinoin; Tumor Cells, Cultured | 2000 |
Successful treatment of all-trans retinoic acid resistant and chemotherapy naïve acute promyelocytic patients with arsenic trioxide--two case reports.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Pregnancy; Tretinoin | 2000 |
Retinoic acid syndrome induced by arsenic trioxide in treating recurrent all-trans retinoic acid resistant acute promyelocytic leukemia.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Tretinoin | 2000 |
[Successful treatment of relapsed and refractory acute promyelocytic leukemia with arsenic trioxide (As2O3)].
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Drug Resistance, Neoplasm; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Neoplasm Recurrence, Local; Oxides; Pleural Effusion; Remission Induction; Treatment Outcome; Tretinoin | 2000 |
Arsenic trioxide treatment of relapsed acute promyelocytic leukaemia: initial Australian experience.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Australia; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Oxides | 1999 |
Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Dyspnea; Fever; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Oxides; Pleural Effusion; Syndrome; Tretinoin | 2000 |
Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Humans; Leukemia, Promyelocytic, Acute; Mice; Mice, Nude; Mice, Transgenic; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Translocation, Genetic; Transplantation, Heterologous; Tretinoin | 2000 |
Pathologic, cytogenetic and molecular assessment of acute promyelocytic leukemia patients treated with arsenic trioxide (As2O3).
Topics: Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cytogenetics; DNA, Neoplasm; Drug Resistance, Neoplasm; Female; Flow Cytometry; Humans; Leukemia, Promyelocytic, Acute; Leukocyte Count; Male; Middle Aged; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Reverse Transcriptase Polymerase Chain Reaction; Tretinoin | 2000 |
Unusual manifestations of acute leukemia. Case 1. CNS extramedullary relapse of acute promyelocytic leukemia after arsenic trioxide-induced remission.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Central Nervous System; Humans; Leukemia, Promyelocytic, Acute; Leukemic Infiltration; Male; Oxides; Remission Induction | 2000 |
Involvement of CD95-independent caspase 8 activation in arsenic trioxide-induced apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 8; Caspase 9; Caspases; Enzyme Activation; fas Receptor; Glutathione; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tumor Cells, Cultured | 2000 |
From the Food and Drug Administration.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Buprenorphine; Child; Drug and Narcotic Control; Drug Combinations; Drugs, Investigational; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Leukemia, Promyelocytic, Acute; Lopinavir; Opioid-Related Disorders; Oxides; Pyrimidinones; Receptors, Opioid; Ritonavir; United States; United States Food and Drug Administration | 2000 |
Arsenic compound approved as cancer chemotherapy agent.
Topics: Adolescent; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Clinical Trials as Topic; Humans; Leukemia, Promyelocytic, Acute; Oxides; Treatment Outcome | 2000 |
Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Electrocardiography, Ambulatory; Female; Humans; Leukemia, Promyelocytic, Acute; Long QT Syndrome; Male; Middle Aged; Oxides; Prospective Studies; Recurrence; Remission Induction; Tachycardia, Ventricular | 2000 |
Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Northern; Blotting, Western; Cell Culture Techniques; Cell Differentiation; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Resistance; Female; Humans; Leukemia, Experimental; Leukemia, Promyelocytic, Acute; Mice; Mice, SCID; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Survival Rate; Tretinoin | 2001 |
Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene.
Topics: Anastrozole; Anticarcinogenic Agents; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Arsenic Trioxide; Arsenicals; Bexarotene; Breast Neoplasms; Drug Approval; Female; Humans; Leukemia, Promyelocytic, Acute; Lymphoma, T-Cell, Cutaneous; Nitriles; Oxides; Paclitaxel; Tamoxifen; Tetrahydronaphthalenes; Triazoles; United States; United States Food and Drug Administration | 2001 |
Molecular remission without blood product support using all-trans retinoic acid (ATRA) induction and combined arsenic trioxide/ATRA consolidation in a Jehovah's Witness with de novo acute promyelocytic leukaemia.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; Christianity; Cytogenetic Analysis; Drug Therapy, Combination; Female; Humans; Leukemia, Promyelocytic, Acute; Leukocyte Count; Middle Aged; Oxides; Platelet Count; Reverse Transcriptase Polymerase Chain Reaction; Tretinoin | 2000 |
Hyperleukocytosis during induction therapy with arsenic trioxide for relapsed acute promyelocytic leukemia associated with central nervous system infarction.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Brain Infarction; Fatal Outcome; Female; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Oxides; Recurrence; Remission Induction | 2000 |
[Studies on red orpiment induction of NB4 and HL-60 cell apoptosis].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; Materia Medica; Oxides; Tumor Cells, Cultured | 1998 |
[Tissue factor expression during all-trans retinoic acid or arsenic trioxide treatment in acute promyelocytic leukemia].
Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Hemostatics; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; RNA, Messenger; Thromboplastin; Tretinoin | 1998 |
[In vitro study on arsenic trioxide-induced apoptosis of retinoic acid resistant acute promyelocytic leukemia cell line(MR-2)].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin; Tumor Cells, Cultured | 1998 |
Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide.
Topics: Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Drug Monitoring; Electrocardiography; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Torsades de Pointes | 2001 |
Co-biomodulation with arsenic trioxide in multiple myeloma.
Topics: Adjuvants, Immunologic; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Dose-Response Relationship, Drug; Humans; Killer Cells, Lymphokine-Activated; Leukemia, Promyelocytic, Acute; Multiple Myeloma; Oxides | 2001 |
Regulation of Pax3 transcriptional activity by SUMO-1-modified PML.
Topics: 3T3 Cells; Animals; Arsenic Trioxide; Arsenicals; Carrier Proteins; Cell Nucleus; Cells, Cultured; Co-Repressor Proteins; DNA-Binding Proteins; Embryo, Mammalian; Interferon-alpha; Intracellular Signaling Peptides and Proteins; Leukemia, Promyelocytic, Acute; Mice; Molecular Chaperones; Neoplasm Proteins; Nuclear Proteins; Oxides; Paired Box Transcription Factors; PAX3 Transcription Factor; Promyelocytic Leukemia Protein; Repressor Proteins; SUMO-1 Protein; Transcription Factors; Transcription, Genetic; Tumor Suppressor Proteins; Ubiquitins | 2001 |
Pharmacokinetics of intravenous arsenic trioxide in the treatment of acute promyelocytic leukemia.
Topics: Adolescent; Adult; Arsenic Trioxide; Arsenicals; Female; Humans; Infusions, Intravenous; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Recurrence | 1998 |
Arsenic trioxide- and idarubicin-induced remissions in relapsed acute promyelocytic leukaemia: clinicopathological and molecular features of a pilot study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Drug Evaluation; Drug Synergism; Female; Follow-Up Studies; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Proteins; Neoplasm, Residual; Oncogene Proteins, Fusion; Oxides; Pilot Projects; Prospective Studies; Recurrence; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Salvage Therapy; Treatment Outcome | 2001 |
Central nervous system relapse in a patient with acute promyelocytic leukaemia treated with arsenic tri-oxide.
Topics: Adult; Animals; Antineoplastic Agents; Arsenic; Arsenic Trioxide; Arsenicals; Central Nervous System Diseases; Choroid Plexus; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Recurrence | 2001 |
Studies on the clinical efficacy and pharmacokinetics of low-dose arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia: a comparison with conventional dosage.
Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Recurrence | 2001 |
Effects of all-trans-retinoic acid and arsenic trioxide on the hemostatic disturbance associated with acute promyelocytic leukemia.
Topics: Adolescent; Adult; Arsenic Trioxide; Arsenicals; Case-Control Studies; Female; Hemorrhage; Hemostasis; Hemostatics; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Thromboplastin; Tretinoin | 2001 |
Hot on the TRAIL of acute promyelocytic leukemia.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Caspases; Cell Differentiation; Humans; Leukemia, Promyelocytic, Acute; Ligands; Membrane Glycoproteins; Neoplasm Proteins; NF-kappa B; Oncogene Proteins, Fusion; Oxides; Receptors, Tumor Necrosis Factor; TNF-Related Apoptosis-Inducing Ligand; Tretinoin; Tumor Necrosis Factor-alpha | 2001 |
Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Caspases; Cell Differentiation; Coculture Techniques; Humans; Immunoblotting; Inhibitor of Apoptosis Proteins; Leukemia, Promyelocytic, Acute; Membrane Glycoproteins; Neoplasm Proteins; NF-kappa B; Oncogene Proteins, Fusion; Oxides; Paracrine Communication; Proteins; Receptors, Tumor Necrosis Factor; Recombinant Fusion Proteins; Signal Transduction; TNF Receptor-Associated Factor 1; TNF-Related Apoptosis-Inducing Ligand; Tretinoin; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2001 |
[Treatment of leukemia with traditional Chinese drugs containing arsenic].
Topics: Arsenicals; Drugs, Chinese Herbal; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Promyelocytic, Acute | 1998 |
A novel differentiation-inducing therapy for acute promyelocytic leukemia with a combination of arsenic trioxide and GM-CSF.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Drug Resistance, Neoplasm; Drug Therapy, Combination; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Promyelocytic, Acute; Mice; Mice, SCID; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Tumor Cells, Cultured | 2001 |
XAS applied to pharmaceuticals: drug administration and bioavailability.
Topics: Arsenic Trioxide; Arsenicals; Biological Availability; Chemistry, Pharmaceutical; Hair; Histidine; Humans; Leukemia, Promyelocytic, Acute; Menkes Kinky Hair Syndrome; Organometallic Compounds; Oxides; Parenteral Nutrition; Spectrometry, X-Ray Emission; Synchrotrons; Zinc | 2001 |
Arsenic trioxide induces G2/M growth arrest and apoptosis after caspase-3 activation and bcl-2 phosphorylation in promonocytic U937 cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Caspases; Cell Division; Cycloheximide; Enzyme Activation; G2 Phase; Growth Inhibitors; Humans; Leukemia, Promyelocytic, Acute; Mitosis; Monocytes; Myeloid Progenitor Cells; Oxides; Phosphorylation; Protein Synthesis Inhibitors; Proto-Oncogene Proteins c-bcl-2; U937 Cells | 2001 |
Unusual sites of involvement by hematologic malignancies. Case 3. External auditory canal tumor: a rare chloroma in acute promyelocytic leukemia with a complete response to arsenic trioxide.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Ear Canal; Ear Neoplasms; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Tretinoin | 2001 |
Arsenic trioxide is a potent inhibitor of the interaction of SMRT corepressor with Its transcription factor partners, including the PML-retinoic acid receptor alpha oncoprotein found in human acute promyelocytic leukemia.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Nucleus; DNA-Binding Proteins; Enzyme Activation; Humans; Leukemia, Promyelocytic, Acute; MAP Kinase Signaling System; Microscopy, Confocal; Nuclear Receptor Co-Repressor 2; Oxides; Phosphorylation; Plasmids; Precipitin Tests; Protein Binding; Receptors, Retinoic Acid; Repressor Proteins; Retinoic Acid Receptor alpha; Signal Transduction; Time Factors; Transfection; Two-Hybrid System Techniques | 2001 |
Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Electrocardiography; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tachycardia, Ventricular | 2001 |
[The mechanisms of arsenic trioxide-induced apoptosis in hematopoietic malignant cells].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tumor Cells, Cultured; U937 Cells | 1999 |
[Effects of all-trans retinoic acid, arsenic trioxide and daunorubicin on tissue factor expression in NB4 cells].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Daunorubicin; Factor VIII; Humans; Leukemia, Promyelocytic, Acute; Oxides; RNA, Messenger; Thromboplastin; Tretinoin; Tumor Cells, Cultured | 1999 |
Prolonged molecular remission in advanced acute promyelocytic leukaemia after treatment with gemtuzumab ozogamicin (Mylotarg CMA-676).
Topics: Adult; Aminoglycosides; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Arsenic Trioxide; Arsenicals; Central Nervous System; Combined Modality Therapy; Female; Gemtuzumab; Gene Rearrangement; Genes, MDR; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Promyelocytic, Acute; Leukemic Infiltration; Oxides; Sialic Acid Binding Ig-like Lectin 3; Translocation, Genetic; Tretinoin | 2001 |
Successful treatment of a case of relapsed acute promyelocytic leukemia with arsenic trioxide.
Topics: Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow; Female; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Remission Induction; Treatment Outcome | 2001 |
Hemostatic abnormalities associated with acute promyelocytic leukemia and corrective effects of all-trans-retinoic acid or arsenic trioxide treatment.
Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blood Coagulation Factors; Female; Hemostasis; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Thromboplastin; Tretinoin | 2000 |
Long-term survey of outcome in acute promyelocytic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Leukocyte Count; Male; Middle Aged; Neoplasm Recurrence, Local; Oxides; Prognosis; Remission Induction; Time Factors; Treatment Outcome; Tretinoin | 2000 |
[Drug resistance of acute promyelocytic leukemia (APL) to all-trans retinoic acid (ATRA) and its reversion].
Topics: Alprostadil; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Arsenic Trioxide; Arsenicals; Cell Survival; Drug Interactions; Drug Resistance; Harringtonines; HL-60 Cells; Homoharringtonine; Humans; Interferon alpha-2; Interferon-alpha; Leukemia, Promyelocytic, Acute; Oxides; Recombinant Proteins; Tretinoin | 2000 |
Effect of all-trans retinoic acid and arsenic trioxide on tissue factor expression in acute promyelocytic leukemia cells.
Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Gene Expression Regulation, Leukemic; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; RNA, Messenger; Thromboplastin; Tretinoin; Tumor Cells, Cultured | 2001 |
[Ailing No. I in treating 62 cases of acute promyelocytic leukemia].
Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Drugs, Chinese Herbal; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides | 1999 |
[Cell differentiation and apoptosis of tumor cells].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Transformation, Neoplastic; Humans; Leukemia, Promyelocytic, Acute; Oxides | 1999 |
[A study of tissue factor expression and hemostatic molecular markers in patients with acute promyelocytic leukemia].
Topics: Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Hemostasis; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; RNA, Messenger; Thromboplastin; Tretinoin | 2001 |
[Effects of arsenic trioxide on K562 cells stably expressing two promyelocytic leukemia-specific fusion proteins].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Differentiation; Cell Division; Gene Expression; Growth Inhibitors; Humans; K562 Cells; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Tretinoin | 2000 |
[Effects of all-trans retinoic acid and arsenic trioxide on tissue factor expression of acute promyelocytic leukemia cells].
Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blood Coagulation; Cells, Cultured; Female; Gene Expression; Humans; Leukemia, Promyelocytic, Acute; Leukocytes, Mononuclear; Male; Middle Aged; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; RNA, Messenger; Thromboplastin; Transcription, Genetic; Tretinoin; Tumor Cells, Cultured; U937 Cells | 2000 |
Synergic effects of arsenic trioxide and cAMP during acute promyelocytic leukemia cell maturation subtends a novel signaling cross-talk.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Division; Cyclic AMP; Drug Synergism; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Receptor Cross-Talk; Signal Transduction; Thionucleotides; Tumor Cells, Cultured | 2002 |
Arsenic trioxide newly joins treatment strategies for acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Remission Induction; Treatment Outcome | 2001 |
Successful unrelated bone marrow transplantation after arsenic trioxide treatment in a patient with relapsed acute promyelocytic leukemia.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Bone Marrow Transplantation; Combined Modality Therapy; Drug Resistance; Female; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Remission Induction; Salvage Therapy; Transplantation Conditioning; Transplantation, Homologous; Tretinoin | 2002 |
[Seven years' summary report on the treatment of acute promyelocytic leukemia with arsenic trioxide--an analysis of 242 cases].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Recurrence; Survival Rate | 2000 |
[Mechanism of tissue factor expression on NB4 cells down-regulated by all-trans retinoic acid and arsenic trioxide].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cycloheximide; Dactinomycin; Down-Regulation; Gene Expression Regulation; Humans; Leukemia, Promyelocytic, Acute; Oxides; Thromboplastin; Tretinoin; Tumor Cells, Cultured | 2000 |
Mechanism of action of all-trans retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Apoptosis; Arsenicals; Cell Differentiation; Chlorides; Humans; Leukemia, Promyelocytic, Acute; Tretinoin | 2002 |
Combined arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia recurring from previous relapses successfully treated using arsenic trioxide.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Recurrence; Remission Induction; Tretinoin | 2002 |
Arsenic trioxide therapy for relapsed or refractory Japanese patients with acute promyelocytic leukemia: need for careful electrocardiogram monitoring.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Drug Monitoring; Electrocardiography; Female; Heart; Heart Diseases; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Prospective Studies; Remission Induction; Tretinoin | 2002 |
Clinical usefulness of arsenic trioxide in the treatment of acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Salvage Therapy | 2002 |
The MRP1-mediated effluxes of arsenic and antimony do not require arsenic-glutathione and antimony-glutathione complex formation.
Topics: Antimony; Antimony Potassium Tartrate; Arsenic; Arsenic Trioxide; Arsenicals; Biological Transport, Active; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Glutathione; Humans; K562 Cells; Kinetics; Leukemia, Promyelocytic, Acute; Multidrug Resistance-Associated Proteins; Oxides; Spectrophotometry, Atomic; Tumor Cells, Cultured | 2002 |
Differentiation induction as a treatment for hematologic malignancies.
Topics: Arsenic Trioxide; Arsenicals; Cell Differentiation; Hematologic Neoplasms; Leukemia, Promyelocytic, Acute; Models, Biological; Oncogene Proteins, Fusion; Oxides; Signal Transduction; Transcription, Genetic | 2002 |
Adaptive immunity cooperates with liposomal all-trans-retinoic acid (ATRA) to facilitate long-term molecular remissions in mice with acute promyelocytic leukemia.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Immunocompetence; Leukemia, Promyelocytic, Acute; Liposomes; Mice; Mice, Inbred C3H; Mice, SCID; Mice, Transgenic; Neoplasm Proteins; Neoplasm Transplantation; Oncogene Proteins, Fusion; Oxides; Tretinoin | 2002 |
[Study on Herpes Zoster Reactivation Induced by Arsenic in Patients with Acute Promyelocytic Leukemia].
Topics: Arsenic; Herpes Zoster; Herpesvirus 3, Human; Humans; Leukemia, Promyelocytic, Acute; Retrospective Studies | 2022 |
Effects of arsenic on the topology and solubility of promyelocytic leukemia (PML)-nuclear bodies.
Topics: Arsenic; Cell Nucleus; HEK293 Cells; Humans; Leukemia, Promyelocytic, Acute; Nuclear Bodies; Promyelocytic Leukemia Protein; Solubility; Transcription Factors | 2022 |
The p97/VCP segregase is essential for arsenic-induced degradation of PML and PML-RARA.
Topics: Arsenic; Cytoplasm; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Proteasome Endopeptidase Complex; Sumoylation; Transcription Factors; Ubiquitin; Valosin Containing Protein | 2023 |
Optimizing Arsenic Therapy by Selectively Targeting Leukemia Cells.
Topics: Arsenic; Drug-Related Side Effects and Adverse Reactions; Humans; Leukemia, Promyelocytic, Acute; Research Design | 2023 |
Characteristics of arsenic species in cerebrospinal fluid (CSF) of acute promyelocytic leukaemia (APL) patients treated with arsenic trioxide plus mannitol.
Topics: Arsenic; Arsenic Trioxide; Chromatography, High Pressure Liquid; Humans; Leukemia, Promyelocytic, Acute; Mannitol; Neoplasm Recurrence, Local | 2021 |
A call to action for the treatment of acute promyelocytic leukemia in the modern era: It is no longer just about the ATRA and arsenic.
Topics: Arsenic; Arsenic Trioxide; Humans; Leukemia, Promyelocytic, Acute; Tretinoin | 2021 |
[Arsenic: The gold standard for acute promyelocytic leukaemia with FLT3-ITD mutation].
Topics: Antineoplastic Agents; Arsenic; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Mutation | 2021 |
Arsenic and all-
Topics: Arsenic; Arsenic Trioxide; Humans; Leukemia, Promyelocytic, Acute; Tretinoin | 2021 |
Oral arsenic and all-
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents; Arsenic; Cohort Studies; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Treatment Outcome; Tretinoin; Young Adult | 2018 |
Role of arsenic (+3 oxidation state) methyltransferase in arsenic mediated APL treatment: an in vitro investigation.
Topics: Antineoplastic Agents; Apoptosis; Arsenic; Arsenic Trioxide; Cell Differentiation; Cell Proliferation; Hep G2 Cells; Humans; In Vitro Techniques; Leukemia, Promyelocytic, Acute; Methyltransferases; Oncogene Proteins, Fusion; Tumor Cells, Cultured | 2018 |
Towards home-based treatment for acute promyelocytic leukaemia, with caution.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic; Humans; Leukemia, Promyelocytic, Acute; Tretinoin | 2018 |
Arsenic and old
Topics: Animals; Arsenic; fms-Like Tyrosine Kinase 3; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Mice; Tretinoin | 2019 |
A novel realgar-indigo naturalis formula more effectively induces apoptosis in NB4 cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Arsenic; Caspase 3; Caspase 9; Cell Line, Tumor; Cell Proliferation; DNA Fragmentation; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Humans; Leukemia, Promyelocytic, Acute | 2019 |
Uncoupling RARA transcriptional activation and degradation clarifies the bases for APL response to therapies.
Topics: Animals; Antineoplastic Agents; Arsenic; Cell Differentiation; Cell Line; Cell Transformation, Neoplastic; Gene Expression Regulation, Leukemic; Humans; Leukemia, Promyelocytic, Acute; Mice; Nuclear Proteins; Promyelocytic Leukemia Protein; Proteolysis; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Transcription Factors; Transcriptional Activation; Tretinoin; Tumor Suppressor Proteins | 2013 |
Outpatient oral treatment for acute promyelocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Tretinoin | 2015 |
Outpatient oral treatment for acute promyelocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Tretinoin | 2015 |
Transcriptional repression of microRNA genes by PML-RARA increases expression of key cancer proteins in acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Arsenic; Biomarkers, Tumor; Cell Adhesion Molecules; Cell Line, Tumor; Gene Expression Regulation, Leukemic; Homeodomain Proteins; Humans; Leukemia, Promyelocytic, Acute; MicroRNAs; Oncogene Proteins, Fusion; RNA, Neoplasm; Transcription, Genetic; Tretinoin | 2009 |
Acute promyelocytic leukemia--weapons of mass differentiation.
Topics: Animals; Antineoplastic Agents; Arsenic; Cell Differentiation; Cell Transformation, Neoplastic; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Promyelocytic, Acute; Mice; Oncogene Proteins, Fusion; Tretinoin | 2009 |
The cleavage product deltaPML-RARalpha contributes to all-trans retinoic acid-mediated differentiation in acute promyelocytic leukemia cells.
Topics: Acetamides; Antineoplastic Agents; Arsenic; Blotting, Western; Cell Differentiation; Cell Line; Cycloheximide; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Leukemia, Promyelocytic, Acute; Leupeptins; Luciferases; Multienzyme Complexes; Neoplasm Proteins; Oncogene Proteins, Fusion; Plasmids; Proteasome Endopeptidase Complex; Protein Synthesis Inhibitors; Transcriptional Activation; Transfection; Tretinoin; Tumor Cells, Cultured | 2003 |
The history of acute promyelocytic leukaemia.
Topics: Antineoplastic Agents; Arsenic; Chromosome Aberrations; History, 20th Century; Humans; Leukemia, Promyelocytic, Acute; Tretinoin | 2003 |
Effects of arsenic on telomerase and telomeres in relation to cell proliferation and apoptosis in human keratinocytes and leukemia cells in vitro.
Topics: Apoptosis; Arsenic; Cell Division; Cell Line; Cyclic N-Oxides; Humans; Keratinocytes; Leukemia, Promyelocytic, Acute; Spin Labels; Telomerase; Telomere | 2003 |
Trolox selectively enhances arsenic-mediated oxidative stress and apoptosis in APL and other malignant cell lines.
Topics: Annexin A5; Antioxidants; Apoptosis; Arsenic; Cell Division; Cell Line, Tumor; Chromans; Heme Oxygenase (Decyclizing); Heme Oxygenase-1; Humans; JNK Mitogen-Activated Protein Kinases; Leukemia, Promyelocytic, Acute; Membrane Proteins; Oxidative Stress | 2005 |
Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation.
Topics: Antineoplastic Agents; Arsenic; Blood Proteins; Cell Line, Tumor; Cytokines; DNA-Binding Proteins; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Glycosylation; Humans; Hydrogen Peroxide; In Vitro Techniques; Leukemia, Promyelocytic, Acute; Oxidants; Oxidation-Reduction; Promoter Regions, Genetic; Proto-Oncogene Proteins c-myc; Reactive Oxygen Species; Sp1 Transcription Factor; Telomerase | 2005 |
Chronic exposure to methylated arsenicals stimulates arsenic excretion pathways and induces arsenic tolerance in rat liver cells.
Topics: Animals; Arsenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Glutathione Transferase; Leukemia, Promyelocytic, Acute; Liver; Methylation; Rats; Rats, Inbred F344 | 2006 |
Arsenic patent keeps drug for rare cancer out of reach of many.
Topics: Antineoplastic Agents; Arsenic; Humans; Leukemia, Promyelocytic, Acute; Patents as Topic | 2007 |
RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation.
Topics: Amino Acid Sequence; Animals; Arsenic; Cell Line; Humans; Leukemia, Promyelocytic, Acute; Molecular Sequence Data; Neoplasm Proteins; Nuclear Proteins; Oncogene Proteins, Fusion; Promyelocytic Leukemia Protein; Proteasome Endopeptidase Complex; Rats; RNA, Small Interfering; Sequence Alignment; SUMO-1 Protein; Transcription Factors; Tumor Suppressor Proteins; Ubiquitin; Ubiquitin-Protein Ligases | 2008 |
Marked for death.
Topics: Arsenic; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Nuclear Proteins; Oncogene Proteins, Fusion; Promyelocytic Leukemia Protein; RING Finger Domains; SUMO-1 Protein; Transcription Factors; Tumor Suppressor Proteins | 2008 |
Toxic effects of arsenic (As3+) and other metal ions on acute promyelocytic leukemia cells.
Topics: Apoptosis; Arsenic; Cell Division; Humans; Leukemia, Promyelocytic, Acute; Poisons; Tumor Cells, Cultured | 1997 |
Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia.
Topics: Apoptosis; Arsenic; Biological Transport; Cell Nucleus; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Oncogene Proteins, Fusion | 1997 |
Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic; Cell Differentiation; Drug Screening Assays, Antitumor; Drug Synergism; Hematopoiesis; Humans; Leukemia, Promyelocytic, Acute; Liver; Lung; Mice; Mice, Transgenic; Neoplasm Proteins; Neoplasm Transplantation; Neoplastic Stem Cells; Oncogene Proteins, Fusion; Remission Induction; Spleen; Tretinoin; Tumor Cells, Cultured | 1999 |
Severe neurotoxicity following arsenic therapy for acute promyelocytic leukemia: potentiation by thiamine deficiency.
Topics: Arsenic; Diet, Vegetarian; Drug Synergism; Female; Humans; Leukemia, Promyelocytic, Acute; Middle Aged; Neurotoxicity Syndromes; Thiamine; Thiamine Deficiency | 2002 |